

### 1. 국외 DB

1. Abu-Rumeileh SB, S. Ladogana, A. Zenesini, C. Bartoletti-Stella, A. Poggi, A. Mammana, A. Polischi, B. Pocchiari, M. Capellari, S. Parchi, P. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. *Journal of neurology, neurosurgery, and psychiatry*. 2020;14. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
2. Abu-Rumeileh SH, S. Steinacker, P. Anderl-Straub, S. Polischi, B. Ludolph, A. C. Capellari, S. Parchi, P. Otto, M. CSF SerpinA1 in Creutzfeldt-Jakob disease and frontotemporal lobar degeneration. *Annals of Clinical and Translational Neurology*. 2020;7(2):191-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
3. Agnello LG, C. M. Lo Sasso, B. Bivona, G. Milano, S. Ciaccio, A. M. Piccoli, T. La Bella, V. Ciaccio, M. Neurogranin as a Novel Biomarker in Alzheimer's Disease. *Laboratory medicine*. 2020;14. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
4. Aquilani RC, A. Maestri, R. Ramusino, M. C. Pierobon, A. Dossena, M. Solerte, S. B. Condino, A. M. Torlaschi, V. Bini, P. Boselli, M. Ceroni, M. Buonocore, D. Boschi, F. Bruni, M. Verri, M. Mini nutritional assessment may identify a dual pattern of perturbed plasma amino acids in patients with alzheimer's disease: A window to metabolic and physical rehabilitation? *Nutrients*. 2020;12(6):1-18. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
5. Ashton NJH, A. Rajkumar, A. P. Leuzy, A. Snowden, S. Suarez-Calvet, M. Karikari, T. K. Scholl, M. La Joie, R. Rabinovici, G. D. Hoglund, K. Ballard, C. Hortobagyi, T. Svenningsson, P. Blennow, K. Zetterberg, H. Aarsland, D. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. *Nature Reviews Neurology*. 2020;16(5):265-84. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
6. Babic Leko MNP, M. Klepac, N. Strac, D. S. Borovecki, F. Pivac, N. Hof, P. R. Simic, G. IL-1beta, IL-6, IL-10, and TNFalpha Single Nucleotide Polymorphisms in Human Influence the Susceptibility to Alzheimer's Disease Pathology. *Journal of Alzheimer's Disease*. 2020;75(3):1029-47. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
7. Babic Leko MNP, M. Klepac, N. Svob Strac, D. Borovecki, F. Pivac, N. Hof, P. R. Simic, G. Relationships of Cerebrospinal Fluid Alzheimer's Disease Biomarkers and COMT, DBH, and MAOB Single Nucleotide Polymorphisms. *Journal of Alzheimer's Disease*. 2020;73(1):135-45. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

8. Bagnato SB, C. Moderate/severe traumatic brain injury as a trigger of chronic neurodegeneration in humans. *Neural Regeneration Research*. 2020;15(7):1247-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
9. Barthelemy NRB, R. J. Hirtz, C. Marin, P. Becher, F. Sato, C. Gabelle, A. Lehmann, S. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. *Alzheimer's Research and Therapy*. 2020;12 (1) (no pagination)(26). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
10. Barthelemy NRL, Y. Joseph-Mathurin, N. Gordon, B. A. Benzinger, T. L. S. Fagan, et al., A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nature Medicine*. 2020;26(3):398-407. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
11. Bateman RJB, N. R. Horie, K. Another step forward in blood-based diagnostics for Alzheimer's disease. *Nature Medicine*. 2020;26(3):314-6. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
12. Benussi AG, M. Palluzzi, F. Koch, G. Di Lazzaro, V. Nardone, R. Cantoni, V. Dell'Era, V. Premi, E. Martorana, A. di Lorenzo, F. Bonni, S. Ranieri, F. Capone, F. Musumeci, G. Cotelli, M. S. Padovani, A. Borroni, B. Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias. *Annals of Neurology*. 2020;87(3):394-404. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
13. Blennow KC, C. Cicognola, C. Wildsmith, K. R. Manser, P. T. Bohorquez, S. M. S. Zhang, Z. Xie, B. Peng, J. Hansson, O. Kvartsberg, H. Portelius, E. Zetterberg, H. Lashley, T. Brinkmalm, G. Kerchner, G. A. Weimer, R. M. Ye, K. Høglund, K. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. *Brain*. 2020;143(2):650-60. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
14. Carapelle EM, C. Cassano, T. Avolio, C. Interaction between cognitive reserve and biomarkers in alzheimer disease. *International Journal of Molecular Sciences*. 2020;21(17):1-12. 배제사유: 원저가 아닌 연구
15. Carraro MF, C. Latorraca, S. Mazzeo, S. Bessi, V. Lucidi, G. Vagaggini, A. Bagnoli, S. Nacmias, B. Sorbi, S. Cerebrospinal fluid biomarkers for dementia: A case of post-lumbar puncture epidural hematoma. *Clinical Neurology and Neurosurgery*. 2020;190 (no pagination)(105638). 배제사유: 사전에 정의한 연구설계가 아닌 문헌
16. Catalan-Garcia MG-G, F. J. Moreno-Lozano, P. J. Alcarraz-Vizan, G. Tort-Merino, A. Milisenda, J. C. Canto-Santos, J. Barcos-Rodriguez, T. Cardellach, F. Llado, A. Novials, A. Garrabou, G. Grau-Junyent, J. M. Mitochondrial dysfunction: A common hallmark underlying comorbidity between sIBM and other degenerative and age-related diseases. *Journal of Clinical Medicine*. 2020;9 (5) (no pagination)(1446). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
17. Cortes-Gomez ML-A, E. Alom, J. Del Ser, T. Avila, J. Saez-Valero, J. Garcia-Ayllon, M. S. Tau phosphorylation by glycogen synthase kinase 3beta modulates AChE expression.

Journal of neurochemistry. 2020;21. 배제사유: 동물연구 또는 전임상연구

18. de Almeida SMR, C. E. Tang, B. de Pereira, A. P. Rotta, I. Vaida, F. Letendre, S. Potter, M. Ellis, R. J. Neurocytoskeleton Proteins in Cerebrospinal Fluid of People With HIV-1 Subtypes B and C. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2020;84(5):514-21. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
19. Doecke JDW, L. Burnham, S. C. Villemagne, V. L. Li, Q. X. Collins, S. Fowler, C. J. Manuilova, E. Widmann, M. Rainey-Smith, S. R. Martins, R. N. Masters, C. L. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimer's Research and Therapy. 2020;12 (1) (no pagination)(36). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
20. Elibol BB, M. Terzioglu-Usak, S. Dalli, T. Kilic, U. Thymoquinone administration ameliorates Alzheimer's disease-like phenotype by promoting cell survival in the hippocampus of amyloid beta( $\beta$ 1-42) infused rat model. Phytomedicine. 2020;79 (no pagination)(153324). 배제사유: 동물연구 또는 전임상연구
21. Enache DP, J. B. Jelic, V. Winblad, B. Nilsson, P. Aarsland, D. Berezki, E. Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease. 2020;18:18. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
22. Forland MGT, O. B. Aarsland, D. Maple-Grodem, J. Pedersen, K. F. Alves, G. Lange, J. The value of cerebrospinal fluid alpha-synuclein and the tau/alpha-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. European Journal of Neurology. 2020;27(1):43-50. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
23. Foucault-Fruchard LD, J. B. Morange, V. Beaufils, E. Duwicquet, C. Quadrio, I. Balageas, A. C. Dufour-Rainfray, D. An automated alert system based on the p-Tau/Tau ratio to quickly inform health professionals upon a suspected case of sporadic Creutzfeldt-Jakob disease. Journal of the Neurological Sciences. 2020;415 (no pagination)(116971). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
24. Gmitterova KV, D. Schmitz, M. Zafar, S. Maass, F. Lingor, P. Zerr, I. Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders. Journal of Alzheimer's Disease. 2020;73(4):1355-61. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
25. Gonzalez-Sanchez MJ, J. Narvaez, A. Antequera, D. Llamas-Velasco, S. Martin, A. H. S. Arjona, J. A. M. Munain, A. L. Bisa, A. L. Marco, M. P. Rodriguez-Nunez, M. Perez-Martinez, D. A. Villarejo-Galende, A. Bartolome, F. Dominguez, E. Carro, E. Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients. Biomolecules. 2020;10 (4) (no pagination)(571). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
26. Gramkow MHG, L. Koikkalainen, J. Lotjonen, J. Law, I. Hasselbalch, S. G. Waldemar, G. Frederiksen, K. S. Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort. PeerJ. 2020;2020 (7) (no pagination)(e9498). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

27. Huang XH, K. Li, Z. Bai, D. Hao, Y. Wu, Q. Yi, W. Xu, N. Pan, Y. Zhang, L. Electroacupuncture improves cognitive deficits and insulin resistance in an OLETF rat model of Al/D-gal induced aging model via the PI3K/Akt signaling pathway. *Brain Research*. 2020;1740 (no pagination)(146834). 배제사유: 동물연구 또는 전임상연구
28. Iannuzzi FS, R. Canu, N. Maier, T. J. Annunziato, L. Matrone, C. Fyn tyrosine kinase elicits amyloid precursor protein Tyr682 phosphorylation in neurons from Alzheimer's disease patients. *Cells*. 2020;9(8):1-21. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
29. Irwin DJF, J. Coffey, C. S. Caspell-Garcia, C. Kang, J. H. Simuni, T. Foroud, T. Toga, A. W. Tanner, C. M. Kiebertz, K. Chahine, L. M. Reimer, A. Hutten, S. Weintraub, D. Mollenhauer, B. Galasko, D. R. Siderowf, A. Marek, K. Trojanowski, J. Q. Shaw, L. M. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. *Annals of Neurology*. 2020;88(3):574-87. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
30. Jack CR. The transformative potential of plasma phosphorylated tau. *The Lancet Neurology*. 2020;19(5):373-4. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
31. Jiao FY, F. Wang, Y. Zhang, S. Guo, Y. Du, W. Gao, Y. Ren, J. Zhang, H. Liu, L. Song, H. Wang, L. The Validation of Multifactor Model of Plasma Aβ<sub>42</sub> and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease. *Frontiers in Aging Neuroscience*. 2020;12 (no pagination)(212). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
32. Kaplow JV, M. Gray, J. Kanekiyo, M. Huyck, E. Traynham, C. J. Esquivel, R. Fagan, A. M. Luthman, J. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ<sub>42</sub> ratio with amyloid PET status. *Alzheimer's and Dementia*. 2020;16(1):144-52. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
33. Karikari TKP, T. A. Ashton, N. J. Janelidze, S. Benedet, A. L. Rodriguez, J. L. Chamoun, M. Savard, M. Kang, M. S. Therriault, J. Scholl, M. Massarweh, G. Soucy, J. P. Hoglund, K. Brinkmalm, G. Mattsson, N. Palmqvist, S. Gauthier, S. Stomrud, E. Zetterberg, H. Hansson, O. Rosa-Neto, P. Blennow, K. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurology*. 2020;19(5):422-33. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
34. Katayama TS, J. Kikuchi-Takeguchi, S. Kano, K. Takahashi, K. Saito, T. Okizaki, A. Hasebe, N. Cerebrospinal fluid levels of alpha-synuclein, amyloid beta, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings. *Neuroscience Letters*. 2020;715 (no pagination)(134564). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
35. Kawarabayashi TN, T. Miyashita, K. Fukamachi, I. Seino, Y. Shoji, M. Novel ELISAs to measure total and phosphorylated tau in cerebrospinal fluid. *Neuroscience Letters*. 2020;722:134826. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

36. Lantero Rodriguez JK, T. K. Suarez-Calvet, M. Troakes, C. King, A. Emersic, A. Aarsland, D. Hye, A. Zetterberg, H. Blennow, K. Ashton, N. J. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. *Acta Neuropathologica*. 2020;140(3):267-78. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
37. Lidon LU, L. Llorens, F. Gil, V. Alvarez, I. Diez-fairen, M. Aguilar, M. Pastor, P. Zerr, I. Alcolea, D. Lleo, A. Vidal, E. Gavin, R. Ferrer, I. Del Rio, J. A. Disease-specific changes in reelin protein and mRNA in neurodegenerative diseases. *Cells*. 2020;9 (5) (no pagination)(1252). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
38. Lim BS, S. B. Grontvedt, G. R. Brathen, G. Diamandis, E. P. Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study. *Neurobiology of Aging*. 2020;93:97. e1-. e7. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
39. Llorens FV-p, A. Hermann, P. Schmitz, M. Calero, O. Stehmann, C. Sarros, S. Moda, F. Ferrer, I. Poleggi, A. Pocchiari, M. Catania, M. Klotz, S. O'Regan, C. Brett, F. Heffernan, J. Ladogana, A. Collins, S. J. Calero, M. Kovacs, G. G. Zerr, I. Diagnostic accuracy of prion disease biomarkers in iatrogenic creutzfeldt-jakob disease. *Biomolecules*. 2020;10 (2) (no pagination)(290). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
40. Llorens FV-P, A. Hermann, P. Schmitz, M. Goebel, S. Waniek, K. Lachmann, I. Zerr, I. Cerebrospinal fluid non-phosphorylated tau in the differential diagnosis of Creutzfeldt-Jakob disease: a comparative prospective study with 14-3-3. *Journal of Neurology*. 2020;267(2):543-50. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
41. Lopez-Perez OB-M, M. Hernaiz, A. Llorens, F. Betancor, M. Otero, A. Toivonen, J. M. Zaragoza, P. Zerr, I. Badiola, J. J. Bolea, R. Martin-Burriel, I. BAMBI and CHGA in prion diseases: Neuropathological assessment and potential role as disease biomarkers. *Biomolecules*. 2020;10 (5) (no pagination)(706). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
42. Manniche CS, A. H. Hasselbalch, S. G. Andreasson, U. Zetterberg, H. Blennow, K. Hogh, P. Juhler, M. Hejl, A. M. Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. *Journal of Alzheimer's Disease*. 2020;75(3):937-47. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
43. Marelli CH, C. Gutierrez, L. A. Paquet, C. Menjot De Champfleury, N. De Verbizier, D. Jacob, M. Dubois, J. Maleska, A. M. Hirtz, C. Navucet, S. Bennys, K. Dumurgier, J. Cognat, E. Berr, C. Magnin, E. Lehmann, S. Gabelle, A. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. *Journal of Alzheimer's Disease*. 2020;74(3):903-11. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
44. Mila-Aloma MS, G. Gispert, J. D. Vilor-Tejedor, N. Grau-Rivera, O. Sala-Vila, A. Sanchez-Benavides, G. Arenaza-Urquijo, E. M. Crous-Bou, M. Gonzalez-de-Echavarri, J.

- M. Minguillon, C. Fauria, K. Simon, M. Kollmorgen, G. Zetterberg, H. Blennow, K. Suarez-Calvet, M. Molinuevo, J. L. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. *Alzheimer's and Dementia*. 2020. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
45. Mohapatra DJ, S. Prusty, S. K. Sahu, P. K. Biomarkers of alzheimer's disease: A review. *Systematic Reviews in Pharmacy*. 2020;11(6):151-7. 배제사유: 원저가 아닌 연구
46. Mok THM, S. Preclinical biomarkers of prion infection and neurodegeneration. *Current Opinion in Neurobiology*. 2020;61:82-8. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
47. Mouton-Liger FD, J. Cognat, E. Hourregue, C. Zetterberg, H. Vanderstichele, H. Vanmechelen, E. Bouaziz-Amar, E. Blennow, K. Hugon, J. Paquet, C. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. *Alzheimer's Research and Therapy*. 2020;12 (1) (no pagination)(88). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
48. Musaeus CSN, M. S. Musaeus, J. S. Hogg, P. Electroencephalographic Cross-Frequency Coupling as a Sign of Disease Progression in Patients With Mild Cognitive Impairment: A Pilot Study. *Frontiers in Neuroscience*. 2020;14 (no pagination)(790). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
49. Nam EL, Y. B. Moon, C. Chang, K. A. Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression. *International Journal of Molecular Sciences*. 2020;21(14):15. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
50. Nasiri ES, R. Dietrich, H. Oikonomidi, A. Huerta, P. T. Popp, J. Al-Abed, Y. Bacher, M. Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease. *Molecular Medicine*. 2020;26(1):34. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
51. Obrocki PK, A. Ness, D. Senkevich, K. Hanrieder, J. Capraro, F. Mattsson, N. Andreasson, U. Portelius, E. Ashton, N. J. Blennow, K. Scholl, M. Paterson, R. W. Schott, J. M. Zetterberg, H. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course - A joint PhD student course at University College London and University of Gothenburg. *Alzheimer's Research and Therapy*. 2020;12 (1) (no pagination)(20). 배제사유: 원저가 아닌 연구
52. Ono KT, M. Protofibrils of amyloid-beta are important targets of a disease-modifying approach for alzheimer's disease. *International Journal of Molecular Sciences*. 2020;21 (3) (no pagination)(952). 배제사유: 원저가 아닌 연구
53. Paraskevaidi MA, D. Karim, S. Martin, F. L. Crean, S. Diagnostic biomarkers for alzheimer's disease using non-invasive specimens. *Journal of Clinical Medicine*. 2020;9 (6) (no pagination)(1673). 배제사유: 원저가 아닌 연구
54. Rizzi LM, L. Schwartz, I. V. D. Roriz-Cruz, M. Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort. *SN Comprehensive Clinical Medicine*. 2020;2(9):1543-50. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

55. Shaw LMK, M. Figurski, M. Toledo, J. Irwin, D. Hee Kang, J. Trojanowski, J. Q. Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. *The Journal of Applied Laboratory Medicine*. 2020;5(1):183-93. 배제사유: 원저가 아닌 연구
56. Silva JCD, S. Mamaev, S. Worsfold, C. Moghekar, A. Wiederhold, T. Hamza, G. M. Wojchowski, D. M. Castaldi, M. P. Kapur, S. A. Bergo, V. B. Chien, A. Martin, R. Weis-Garcia, F. A Targeted Multiplexed MALDI MS Assay Platform using Affinity-Bead Assisted Mass Spectrometry (Affi-BAMS) for Monitoring Brain and CSF Biomarkers. *Journal of biomolecular techniques : JBT*. 2020;31(Supplement):S28. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
57. Subramanian MLV, V. Chung, J. Fiorello, M. G. Xia, W. Zetterberg, H. Blennow, K. Zetterberg, M. Shareef, F. Siegel, N. H. Ness, S. Jun, G. R. Stein, T. D. Neurofilament light chain in the vitreous humor of the eye. *Alzheimer's research & therapy*. 2020;12(1):111. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
58. Van Der Ende ELX, M. Xu, D. Poos, J. M. Panman, J. L. Jiskoot, L. C. Meeter, L. H. Dopfer, et al.. Neuronal pentraxin 2: A synapse-derived CSF biomarker in genetic frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*. 2020;91(6):612-21. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
59. Van Harten ACW, H. J. Weigand, S. D. Mielke, M. M. Kremers, W. K. Eichenlaub, U. Batrla-Utermann, R. Dyer, R. B. Algeciras-Schimmich, A. Knopman, D. S. Jack, C. R. , Jr. Petersen, R. C. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics. *Neurology*. 2020;95(3):e256-e67. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
60. Veerabhadrapa BD, C. Hirtz, C. Vialaret, J. Alcolea, D. Lleo, A. Fortea, J. Santosh, M. S. Choubey, S. Lehmann, S. Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand? *Critical Reviews in Clinical Laboratory Sciences*. 2020;57(2):99-113. 배제사유: 원저가 아닌 연구
61. Villa CL, M. Salvatore, E. Combi, R. Molecular and imaging biomarkers in Alzheimer's disease: A focus on recent insights. *Journal of Personalized Medicine*. 2020;10(3):1-32. 배제사유: 원저가 아닌 연구
62. Wang HD, K. K. Chen, P. C. Li, Y. Niu, M. Cho, J. H. Wang, X. Bai, B. Jiao, Y. Chepyala, S. R. Haroutunian, V. Zhang, B. Beach, T. G. Peng, J. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. *Molecular Neurodegeneration*. 2020;15(1):43. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
63. Wang HYP, Z. Lee, K. C. Lopez-Brignoni, E. Nikolov, B. Crowley, C. A. Marsman, M. R. Barbier, R. Friedmann, N. Burns, L. H. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients. *Journal of Prevention of Alzheimer's Disease*. 2020;7(4):256-64. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
64. Wang LZ, M. Wang, Q. Jiang, X. Li, K. Liu, J. APOE epsilon4 allele is associated with

- elevated levels of CSF VILIP-1 in preclinical alzheimer's disease. *Neuropsychiatric Disease and Treatment*. 2020;16:923-31. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
65. Woollacott IOCN, J. M. Heller, C. Foiani, M. S. Moore, K. M. Russell, L. L. Paterson, R. W. Keshavan, A. Schott, J. M. Warren, J. D. Heslegrave, A. Zetterberg, H. Rohrer, J. D. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. *Dementia & Geriatric Cognitive Disorders*. 2020;49(1):56-76. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
66. Zetterberg HB, K. Blood Biomarkers: Democratizing Alzheimer's Diagnostics. *Neuron*. 2020;106(6):881-3. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
67. Zhou MH, R. U. Dammer, E. B. Duong, D. M. Ping, L. Johnson, E. C. B. Lah, J. J. Levey, A. I. Seyfried, N. T. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease. *Clinical Proteomics*. 2020;17 (1) (no pagination)(19). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
68. Abu-Rumeileh SB, S. Polischi, B. Mammana, A. Franceschini, A. Green, A. Capellari, S. Parchi, P. Diagnostic value of surrogate CSF biomarkers for Creutzfeldt-Jakob disease in the era of RT-QuIC. *Journal of Neurology*. 2019;266(12):3136-43. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
69. Abu-Rumeileh SS, P. Polischi, B. Mammana, A. Bartoletti-Stella, A. Oeckl, P. Baiardi, S. Zenesini, C. Huss, A. Cortelli, P. Capellari, S. Otto, M. Parchi, P. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. *Alzheimer's Research & Therapy*. 2019;12(1):2. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
70. Ahman HBG, V. Cedervall, Y. Lennhed, B. Berglund, L. McKee, K. Kilander, L. Rosendahl, E. Ingelsson, M. Aberg, A. C. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers. *Journal of Alzheimer's Disease*. 2019;71(s1):S75-S83. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
71. Akhtar RSM, T. High serum neurofilament light chain predicts a worse fate in early parkinsonism. *Neurology*. 2019;92(13):595-6. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
72. Alcolea DP, J. Munoz, L. Camacho, V. Lopez-Mora, D. Fernandez-Leon, A. Le Bastard, N. Huyck, E. Nadal, A. Olmedo, V. Sampedro, F. Montal, V. Vilaplana, E. Clarimon, J. Blesa, R. Fortea, J. Lleo, A. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. *Annals of Clinical and Translational Neurology*. 2019;6(9):1815-24. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
73. Artuso VB, L. Ghidoni, R. Moradi-Bachiller, S. Fusco, F. Curtolo, S. Roiter, I. Forloni, G. Albani, D. Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia. *Current Alzheimer Research*. 2019;16(1):1-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구



74. Ashton NJI, M. Zetterberg, H. Blennow, K. Salivary Biomarkers for Alzheimer's Disease and Related Disorders. *Neurology and Therapy*. 2019;8(Supplement 2):83-94. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
75. Baiardi SA-R, S. Rossi, M. Zenesini, C. Bartoletti-Stella, A. Polischi, B. Capellari, S. Parchi, P. Antemortem CSF Abeta42/Abeta40 ratio predicts Alzheimer's disease pathology better than Abeta42 in rapidly progressive dementias. *Annals of Clinical and Translational Neurology*. 2019;6(2):263-73. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
76. Baldacci FD, S. Piccarducci, R. Giampietri, L. Pietrobono, D. Giorgi, F. S. Nicoletti, V. Frosini, D. Libertini, P. Lo Gerfo, A. Petrozzi, L. Donadio, E. Betti, L. Trincavelli, M. L. Siciliano, G. Ceravolo, R. Tognoni, G. Bonuccelli, U. Martini, C. Potential Diagnostic Value of Red Blood Cells alpha-Synuclein Heteroaggregates in Alzheimer's Disease. *Molecular Neurobiology*. 2019;56(9):6451-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
77. Barrero Hernandez FJ. Biomarkers for the diagnosis of alzheimer's disease. *Recent Advances in Alzheimer Research*. 2019;3:67-82. 배제사유: 원저가 아닌 연구
78. Bateman RJB, K. Doody, R. Hendrix, S. Lovestone, S. Salloway, S. Schindler, R. Weiner, M. Zetterberg, H. Aisen, P. Vellas, B. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. *Journal of Prevention of Alzheimer's Disease*. 2019;6(3):169-73. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
79. Bayart JLH, B. Ivanoiu, A. van Pesch, V. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Abeta<sub>42</sub> and T-Tau assays for Alzheimer's disease diagnosis. *Journal of Neurology*. 2019;266(9):2304-11. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
80. Berger MO, D. Olurinde, M. O. Whitson, H. E. Weinhold, K. J. Woldorff, M. G. Lipsitz, et al.,. The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction. *Journal of the American Geriatrics Society*. 2019;67(4):794-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
81. Biscetti LS, N. Farotti, L. Cataldi, S. Eusebi, P. Paciotti, S. Parnetti, L. The added value of Abeta42/Abeta40 in the CSF signature for routine diagnostics of Alzheimer's disease. *Clinica Chimica Acta*. 2019;494:71-3. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
82. Blennow KZ, H. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. *Progress in Molecular Biology and Translational Science*. 2019;168:3-23. 배제사유: 원저가 아닌 연구
83. Buckley RFM, E. C. Chhatwal, J. Schultz, A. P. Rabin, J. S. Rentz, D. M. Acar, D. Properzi, M. J. Dumurgier, J. Jacobs, H. Gomez-Isla, T. Johnson, K. A. Sperling, R. A. Hanseeuw, B. J. Alzheimer's Disease Neuroimaging, Initiative. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. *Neurobiology of Aging*. 2019;78:178-85. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

84. Casoli TP, S. Fabbietti, P. Fattoretti, P. Paciaroni, L. Fabi, K. Gobbi, B. Galeazzi, R. Rossi, R. Lattanzio, F. Pelliccioni, G. Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease. *Journal of International Medical Research*. 2019;47(10):4968-80. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
85. Catak CZ, M. Malik, R. Janowitz, D. Soric, V. Seegerer, A. Krebs, A. Doring, M. Opherk, C. Linn, J. Wollenweber, F. A. Decreased CSF levels of s-amyloid in patients with cortical superficial siderosis. *Frontiers in Neurology*. 2019;10 (APR) (no pagination)(439). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
86. Chan HNX, D. Ho, S. L. He, D. Wong, M. S. Li, H. W. Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplification. *Theranostics*. 2019;9(10):2939-49. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
87. Chen CH, C. Shi, Q. Zhou, W. Xiao, K. Wang, Y. Liu, L. Chen, J. Xia, Y. Dong, X. P. Profiles of 14-3-3 and Total Tau in CSF Samples of Chinese Patients of Different Genetic Prion Diseases. *Frontiers in Neuroscience*. 2019;13 (no pagination)(934). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
88. Chen ZM, D. Keshavan, A. Rissman, R. A. Billinton, A. Perkinson, M. Percival-Alwyn, J. Schultz, A. Properzi, M. Johnson, K. Selkoe, D. J. Sperling, R. A. Patel, P. Zetterberg, H. Galasko, D. Schott, J. M. Walsh, D. M. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. *Alzheimer's & Dementia*. 2019;15(3):487-96. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
89. Cicognola CB, G. Wahlgren, J. Portelius, E. Gobom, J. Cullen, N. C. Hansson, O. Parnetti, L. Constantinescu, R. Wildsmith, K. Chen, H. H. Beach, T. G. Lashley, T. Zetterberg, H. Blennow, K. Hoglund, K. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. *Acta Neuropathologica*. 2019;137(2):279-96. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
90. Clarke MTMB, A. Foiani, M. S. Woollacott, I. O. C. Heller, C. Heslegrave, A. Keshavan, A. Fox, N. C. Schott, J. M. Warren, J. D. Blennow, K. Zetterberg, H. Rohrer, J. D. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. *Alzheimer's Research and Therapy*. 2019;11 (1) (no pagination)(105). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
91. Cseh EKV, G. Danics, K. Szalardy, L. Nanasi, N. Klivenyi, P. Vecsei, L. Zadori, D. Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. *Ideggyogyaszati Szemle*. 2019;72(1-2):39-47. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
92. Cummings JB, K. Johnson, K. Keeley, M. Bateman, R. J. Molinuevo, J. L. Touchon, J. Aisen, P. Vellas, B. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. *Journal of Prevention of Alzheimer's Disease*. 2019;6(3):157-63. 배제사유: 원저가 아닌 연구
93. Deng FM, J. A review on protein markers of exosome from different bio-resources and

the antibodies used for characterization. *Journal of Histotechnology*. 2019;42(4):226-39. 배제사유: 원저가 아닌 연구

94. Efficacy and safety results of reverse-SD, phase-2b clinical study of the selective p38a kinase inhibitor neflamapimod in early-stage Alzheimer's disease (AD). *Journal of prevention of alzheimer's disease*. 2019;6:S9-S10. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
95. Eruysal ER, L. Kamel, H. Iadecola, C. Ishii, M. Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease. *Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring*. 2019;11:646-53. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
96. Foiani MSC, C. Ermann, N. Woollacott, I. O. C. Heller, C. Heslegrave, A. J. Keshavan, A. Paterson, R. W. Ye, K. Kornhuber, J. Fox, N. C. Schott, J. M. Warren, J. D. Lewczuk, P. Zetterberg, H. Blennow, K. Hoglund, K. Rohrer, J. D. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. *Journal of Neurology, Neurosurgery & Psychiatry*. 2019;90(7):740-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
97. Freund BP, J. C. Cervenka, M. C. Sutter, R. Kaplan, P. W. EEG Differences in Two Clinically Similar Rapid Dementias: Voltage-Gated Potassium Channel Complex-Associated Autoimmune Encephalitis and Creutzfeldt-Jakob Disease. *Clinical EEG and Neuroscience*. 2019;50(2):121-8. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
98. Glerup HSH, S. G. Simonsen, A. H. Biomarkers for Alzheimer's disease in saliva: A systematic review. *Disease Markers*. 2019;2019 (no pagination)(4761054). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
99. Goldhardt OW, I. Yakushev, I. Begcevic, I. Forstl, H. Magdolen, V. Soosaipillai, A. Diamandis, E. Alexopoulos, P. Grimmer, T. Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET. *Translational Neurodegeneration*. 2019;8 (1) (no pagination)(25). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
100. Grant MKOH, M. Rozga, M. Brinkmalm, G. Portelius, E. Blennow, K. Ashe, K. H. Zahs, K. R. Liu, P. Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. *PLoS ONE [Electronic Resource]*. 2019;14(2):e0212815. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
101. Hansson KD, R. Hansson, O. Pernevik, E. Paterson, R. Schott, J. M. Magdalinou, N. Zetterberg, H. Blennow, K. Gobom, J. Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. *Clinical Mass Spectrometry*. 2019;Part B. 14:74-82. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
102. Hansson OS, A. F. Meeter, L. H. Nilsson, K. Landqvist Waldo, M. Nilsson, C. Blennow, K. van Swieten, J. C. Janelidze, S. CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia. *Annals of Clinical and Translational Neurology*. 2019;6(5):863-72. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

103. Ishii MK, H. Iadecola, C. Retinol Binding Protein 4 Levels Are Not Altered in Preclinical Alzheimer's Disease and Not Associated with Cognitive Decline or Incident Dementia. *Journal of Alzheimer's Disease*. 2019;67(1):257-63. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
104. Jacobs KRL, C. K. Blennow, K. Zetterberg, H. Chatterjee, P. Martins, R. N. Brew, B. J. Guillemin, G. J. Lovejoy, D. B. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-beta and tau. *Neurobiology of Aging*. 2019;80:11-20. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
105. Kehoe PGAM, N. Zetterberg, H. Blennow, K. Miners, J. S. Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2019;72(2):525-35. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
106. Kern SS, J. A. Blennow, K. Zetterberg, H. Skoog, I. Waern, M. Hagen, C. E. van Harten, A. C. Knopman, D. S. Jack, C. R. , Jr. Petersen, R. C. Mielke, M. M. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. *JAMA Neurology*. 2019;76(2):187-93. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
107. Kevadiya BDO, B. M. Thomas, M. B. Mukadam, I. Nigam, S. McMillan, J. Gorantla, S. Bronich, T. K. Edagwa, B. Gendelman, H. E. Neurotheranostics as personalized medicines. *Advanced Drug Delivery Reviews*. 2019;148:252-89. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
108. Khoonsari PES, G. Herman, S. Remnestal, J. Giedraitis, V. Brundin, R. Degerman Gunnarsson, M. Kilander, L. Zetterberg, H. Nilsson, P. Lannfelt, L. Ingelsson, M. Kultima, K. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. *Journal of Alzheimer's Disease*. 2019;67(2):639-51. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
109. Kim HJL, T. S. Lee, S. M. Kim, T. S. Kim, Y. An, Y. S. Youn, Y. C. Park, S. A. Chang, J. Moon, S. Y. Cerebrospinal fluid levels of beta-amyloid 40 and beta-amyloid 42 are proportionately decreased in amyloid positron-emission tomography negative idiopathic normal-pressure hydrocephalus patients. *Journal of Clinical Neurology (Korea)*. 2019;15(3):353-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
110. Kim HL, J. U. Kim, S. Song, S. Sim, S. J. A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer's Disease Biomarker Using a Chaotropic Agent. *ACS Sensors*. 2019;4(3):595-602. 배제사유: 동물연구 또는 전임상연구
111. Kounnas MZD, M. S. Herz, J. Comer, W. T. NGP 555, a gamma-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*. 2019;5:458-67. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
112. Kvartsberg HL, T. Murray, C. E. Brinkmalm, G. Cullen, N. C. Hoglund, K. Zetterberg, H. Blennow, K. Portelius, E. The intact postsynaptic protein neurogranin is reduced in

- brain tissue from patients with familial and sporadic Alzheimer's disease. *Acta Neuropathologica*. 2019;137(1):89-102. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
113. Lapucci CR, N. Boffa, G. Saitta, L. Nobili, F. Mancardi, G. L. Mandich, P. Grandis, M. E200k familial creutzfeldt-jakob disease presenting with subacute multiple cranial neuropathy. *Open Neurology Journal*. 2019;13(1):72-5. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
114. Law LLS, K. E. Dougherty, R. J. Edwards, D. F. Kosciak, R. L. Gallagher, C. L. Carlsson, C. M. Zetterberg, H. Blennow, K. Asthana, S. Sager, M. A. Hermann, B. P. Johnson, S. C. Cook, D. B. Bendlin, B. B. Okonkwo, O. C. Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. *Journal of Alzheimer's Disease*. 2019;69(1):111-21. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
115. Lee SMH, J. W. Kim, S. J. Kim, H. Noh, R. Kim, S. Lee, Y. S. Kim, S. Y. Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach. *Prion*. 2019;13(1):141-50. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
116. Lehmann SP, C. Malaplate-Armand, C. Magnin, E. Schraen, S. Quillard-Muraine, M. Bousiges, O. Delaby, C. Dumurgier, J. Hugon, J. Sablonniere, B. Blanc, F. Wallon, D. Gabelle, A. Laplanche, J. L. Bouaziz-Amar, E. Peoc'h, K. e, P. L. M. Group. Diagnosis associated with Tau higher than 1200pg/mL: Insights from the clinical and laboratory practice. *Clinica Chimica Acta*. 2019;495:451-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
117. Li DM, M. M. An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform. *Neurology and Therapy*. 2019;8(Supplement 2):73-82. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
118. Lifke VK, G. Manuilova, E. Oelschlaegel, T. Hillringhaus, L. Widmann, M. von Arnim, C. A. F. Otto, M. Christenson, R. H. Powers, J. L. Shaw, L. M. Hansson, O. Doecke, J. D. Li, Q. X. Teunissen, C. Tumani, H. Blennow, K. Elecsys<sup>®</sup> Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. *Clinical Biochemistry*. 2019;72:30-8. 배제사유: 동물연구 또는 전임상연구
119. Lim BT, M. Soosaipillai, A. Brown, M. Zilakaki, M. Tagaraki, F. Fotiou, D. Koutsouraki, E. Grosi, E. Prassas, I. Diamandis, E. P. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. *Clinical Chemistry and Laboratory Medicine*. 2019. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
120. Liu WB, X. Zhang, A. Huang, J. Xu, S. Zhang, J. Role of Exosomes in Central Nervous System Diseases. *Frontiers in Molecular Neuroscience*. 2019;12 (no pagination)(240). 배제사유: 원저가 아닌 연구
121. Logmin KM, A. S. Elben, S. Schnitzler, A. Groiss, S. J. Intravenous immunoglobulins as

- first-line therapy for IgLON5 encephalopathy. *Journal of Neurology*. 2019;266(4):1031-3. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
122. Lue LFK, Y. M. Sabbagh, M. Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. *Neurology and Therapy*. 2019;8(Supplement 2):95-111. 배제사유: 원저가 아닌 연구
  123. Mielke MMS, J. A. Blennow, K. Zetterberg, H. Skoog, I. Vemuri, P. Machulda, M. M. Graff-Radford, J. Knopman, D. S. Jack, C. R. , Jr. Petersen, R. C. Kern, S. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. *Alzheimer's & Dementia*. 2019;15(11):1437-47. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
  124. Miners JSK, P. G. Love, S. Zetterberg, H. Blennow, K. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. *Alzheimer's Research & Therapy*. 2019;11(1):81. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
  125. Minta KP, E. Janelidze, S. Hansson, O. Zetterberg, H. Blennow, K. Andreasson, U. Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2019;69(4):1213-20. 배제사유: 알츠하이머 치매 의심 환자를 대상으로 수행되지 않은 연구
  126. Molinuevo JLK, A. Dhadda, S. Irizarry, M. C. Swanson, C. J. Zhang, Y. Kaplow, J. Bradley, H. Rabe, M. Totsuka, K. et al. . BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY. *Alzheimer's & dementia*. 2019;15(7):P1484. 배제사유: 회색문헌(초록만 발표된 문헌)
  127. Naveed MM, S. Khan, A. Ibrahim, S. Meer, B. Plasma Biomarkers: Potent Screeners of Alzheimer's Disease. *American Journal of Alzheimer's Disease and other Dementias*. 2019;34(5):290-301. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
  128. Nordengen KK, B. E. Henjum, K. Selnes, P. Gisladottir, B. Wettergreen, M. Torsetnes, S. B. Grontvedt, G. R. Waterloo, K. K. Aarsland, D. Nilsson, L. N. G. Fladby, T. Glial activation and inflammation along the Alzheimer's disease continuum. *Journal of Neuroinflammation*. 2019;16(1):46. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
  129. O'Bryant SE. Blood Biomarkers for Use in Alzheimer Disease - Moving from "if" to "how?". *JAMA Neurology*. 2019;76(9):1009-10. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
  130. Paciotti SS, F. N. Eusebi, P. Farotti, L. Cataldi, S. Gatticchi, L. Parnetti, L. Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis. *Clinica Chimica Acta*. 2019;494:74-8. 배제사유: 적절한 의료 결과를 하나 이상 보고하지 않은 연구
  131. Palmqvist SJ, S. Stomrud, E. Zetterberg, H. Karl, J. Zink, K. Bittner, T. Mattsson, N. Eichenlaub, U. Blennow, K. Hansson, O. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related beta-Amyloid Status. *JAMA Neurology*.

- 2019;24:24. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
132. Paraskevas GPB, A. Constantinides, V. C. Bourbouli, M. Petropoulou, O. Kapaki, E. In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies. *Dementia & Geriatric Cognitive Disorders*. 2019;47(4-6):289-96. 배제사유: 동물연구 또는 전임상연구
133. Paraskevas GPC, V. C. Pyrgelis, E. S. Kapaki, E. Mixed small vessel disease in a patient with dementia with lewy bodies. *Brain Sciences*. 2019;9 (7) (no pagination)(159). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
134. Picard CP, A. Belanger, S. Labonte, A. Auld, D. Poirier, J. Prevent-Ad Research Group. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study. *PLoS ONE [Electronic Resource]*. 2019;14(8):e0220254. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
135. Pillai AB, D. Nierenberg, J. Pandya, C. Feng, T. Reichert, C. Ramos-Cejudo, J. Osorio, R. Zetterberg, H. Blennow, K. Pomara, N. Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. *Biomarkers in Neuropsychiatry*. 2019;1. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
136. Radanovic MO, C. A. Freitas, T. Q. Talib, L. L. Forlenza, O. V. Correlation between CSF biomarkers of alzheimer's disease and global cognition in a psychogeriatric clinic cohort. *Brazilian Journal of Psychiatry*. 2019;41(6):479-84. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
137. Raha-Chowdhury RH, J. W. Raha, A. A. Vuono, R. Bickerton, A. Jones, E. Fincham, R. Allinson, K. Holland, A. Zaman, S. H. Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer's Disease and in Down Syndrome Dementia. *Journal of Alzheimer's Disease*. 2019;69(1):91-109. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
138. Rinne JOS, T. Rummukainen, J. Herukka, S. K. Nerg, O. Koivisto, A. M. Rauramaa, T. Nagren, K. Hiltunen, M. Alafuzoff, I. Rinne, J. Jaaskelainen, J. E. Soininen, H. Leinonen, V. [11C]PIB PET Is Associated with the Brain Biopsy Amyloid-beta Load in Subjects Examined for Normal Pressure Hydrocephalus. *Journal of Alzheimer's Disease*. 2019;67(4):1343-51. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
139. Rosenberg GAP, J. Knoefel, J. Adair, J. C. Thompson, J. Raja, R. Caprihan, A. A multimodal approach to stratification of patients with dementia: Selection of mixed dementia patients prior to autopsy. *Brain Sciences*. 2019;9 (8) (no pagination)(187). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
140. Salvado GM, J. L. Brugulat-Serrat, A. Falcon, C. Grau-Rivera, O. Suarez-Calvet, M. Pavia, J. Ninerola-Baizan, A. Perissinotti, A. Lomena, F. Minguillon, C. Fauria, K. Zetterberg, H. Blennow, K. Gispert, J. D. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. *Alzheimer's Research and Therapy*. 2019;11 (1) (no pagination)(27). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
141. Sandelius AP, E. Kallen, A. Zetterberg, H. Rot, U. Olsson, B. Toledo, J. B. Shaw, L. M.

- Lee, V. M. Y. Irwin, D. J. Grossman, M. Weintraub, D. Chen-Plotkin, A. Wolk, D. A. McCluskey, L. Elman, L. Kostanjevecki, V. Vandijck, M. McBride, J. Trojanowski, J. Q. Blennow, K. Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. *Alzheimer's & Dementia*. 2019;15(1):55-64. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
142. Santos JRFB, C. Schuchhardt, J. Wedekind, D. Waniek, K. Lachmann, I. Wiltfang, J. Vogelgsang, J. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. *Journal of Neural Transmission*. 2019;126(3):339-48. 배제사유: 동물연구 또는 전임상연구
143. Sarrafpour SO, C. Chiang, A. Arakaki, X. Harrington, M. Fonteh, A. Lipid Metabolism in Late-Onset Alzheimer's Disease Differs from Patients Presenting with Other Dementia Phenotypes. *International Journal of Environmental Research & Public Health [Electronic Resource]*. 2019;16(11):05. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
144. Scholl MM, A. Mattsson, N. Ashton, N. J. Blennow, K. Zetterberg, H. Jagust, W. Biomarkers for tau pathology. *Molecular and Cellular Neuroscience*. 2019;97:18-33. 배제사유: 원저가 아닌 연구
145. Schultz NJ, S. Byman, E. Minthon, L. Nagga, K. Hansson, O. Wennstrom, M. Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease. *PLoS ONE [Electronic Resource]*. 2019;14(6):e0218561. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
146. Shoji M. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy. *Advances in Experimental Medicine & Biology*. 2019;1184:393-405. 배제사유: 원저가 아닌 연구
147. Slot RERK, M. I. Van Harten, A. C. Jongbloed, W. Bouwman, F. H. Teunissen, C. E. Scheltens, P. van der Flier, W. M. Veerhuis, R. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Abeta42, levels in non-demented elderly. *Neurobiology of Aging*. 2019;79:101-9. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
148. Somers CL, P. Sieben, A. Van Broeckhoven, C. De Deyn, P. P. Kornhuber, J. Martin, J. J. Bjerke, M. Engelborghs, S. Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. *Journal of Alzheimer's Disease*. 2019;68(3):1151-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
149. Spallazzi MB, F. Michelini, G. Immovilli, P. Taga, A. Morelli, N. Ruffini, L. Caffarra, P. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. *Acta Neurologica Belgica*. 2019;119(3):445-52. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
150. Spitzer PW, J. Herrmann, M. Oberstein, T. J. Condic, M. Lewczuk, P. Kornhuber, J. Maler, J. M. Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease. *Journal of Geriatric Psychiatry and Neurology*. 2019;32(4):211-20. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구



151. Suarez-Calvet MM-R, E. Kleinberger, G. Schlepckow, K. Araque Caballero, M. A. Franzmeier, N. Capell, A. Fellerer, K. Nuscher, B. Eren, E. Levin, J. Deming, Y. Piccio, L. Karch, C. M. Cruchaga, C. Shaw, L. M. Trojanowski, J. Q. Weiner, M. Ewers, M. Haass, C. Alzheimer's Disease Neuroimaging, Initiative. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. *Molecular Neurodegeneration*. 2019;14(1):1. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
152. Sun RW, H. Shi, Y. Gao, D. Sun, Z. Chen, Z. Jiang, H. Zhang, J. A Pilot Study of Urinary Exosomes in Alzheimer's Disease. *Neurodegenerative Diseases*. 2019;19(5-6):184-91. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
153. Thompson AGBM, S. H. Review: Fluid biomarkers in the human prion diseases. *Molecular and Cellular Neuroscience*. 2019;97:81-92. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
154. van der Ende ELM, L. H. Stingl, C. van Rooij, J. G. J. Stoop, M. P. Nijholt, D. A. T. Sanchez-Valle, R. Graff, C. Oijerstedt, L. Grossman, M. McMillan, C. Pijnenburg, Y. A. L. Laforce, R. Binetti, G. Benussi, L. Ghidoni, R. Luiders, T. M. Seelaar, H. van Swieten, J. C. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. *Annals of Clinical and Translational Neurology*. 2019;6(4):698-707. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
155. van Steenoven IN, B. Cocco, C. Ferri, G. L. Oeckl, P. Otto, M. Koel-Simmelink, M. J. A. Bridel, C. van der Flier, W. M. Lemstra, A. W. Teunissen, C. E. VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. *International Journal of Molecular Sciences*. 2019;20(19):20. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
156. Vanderstichele HMT, C. E. Vanmechelen, E. Critical Steps to be Taken into Consideration Before Quantification of beta-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. *Neurology and Therapy*. 2019;8(Supplement 2):129-45. 배제사유: 원저가 아닌 연구
157. Vergallo AG, L. Pagni, C. Giorgi, F. S. Nicoletti, V. Miccoli, M. Libertini, P. Petrozzi, L. Bonuccelli, U. Tognoni, G. Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. *Journal of Geriatric Psychiatry and Neurology*. 2019;32(3):164-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
158. Viode AE, S. Benyounes, I. Verny, M. Dubois, B. Junot, C. Fenaille, F. Lamari, F. Becher, F. Simultaneous quantification of tau and alpha-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls. *Analyst*. 2019;144(21):6342-51. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
159. Vogelgsang JV, R. Wedekind, D. Wiltfang, J. Higher Level of Mismatch in APOEepsilon4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid. *ASN Neuro*. 2019;11:1759091419845524. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구

160. Wei KT, T. Chu, K. Borzage, M. T. Braskie, M. N. Harrington, M. G. King, K. S. White matter hypointensities and hyperintensities have equivalent correlations with age and CSF beta-amyloid in the nondemented elderly. *Brain and Behavior*. 2019;9 (12) (no pagination)(e01457). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
161. Whelan CDM, N. Nagle, M. W. Vijayaraghavan, S. Hyde, C. Janelidze, S. Stomrud, E. Lee, J. Fitz, L. Samad, T. A. Ramaswamy, G. Margolin, R. A. Malarstig, A. Hansson, O. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. *Acta Neuropathologica Communications*. 2019;7(1):169. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
162. Zerr IV-P, A. Schmitz, V. E. Poggi, A. Pocchiari, M. Sanchez-Valle, R. Calero, M. Calero, O. Baldeiras, I. Santana, I. Kovacs, G. G. Llorens, F. Schmitz, M. Evaluation of human cerebrospinal fluid malate dehydrogenase 1 as a marker in genetic prion disease patients. *Biomolecules*. 2019;9 (12) (no pagination)(800). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
163. Zhou MD, D. M. Johnson, E. C. B. Dai, J. Lah, J. J. Levey, A. I. Seyfried, N. T. Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard. *Journal of Proteome Research*. 2019;18(6):2422-32. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
164. Abu-Rumeileh SC, S. Stanzani-Maserati, M. Polischi, B. Martinelli, P. Caroppo, P. Ladogana, A. Parchi, P. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. *Alzheimer's Research and Therapy*. 2018;10 (1) (no pagination)(3). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
165. Agah ES, F. Sanjari Moghaddam, H. Saghadzadeh, A. Tafakhori, A. Rezaei, N. CSF and blood biomarkers in amyotrophic lateral sclerosis: Protocol for a systematic review and meta-analysis. *Systematic Reviews*. 2018;7 (1) (no pagination)(237). 배제사유: 원저가 아닌 연구
166. Alam JB, K. Prins, N. Scheltens, P. Reverse-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer's disease (AD). *Journal of prevention of alzheimer's disease*. 2018;5(1):S50-S1. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
167. Alexopoulos PS, C. Cerebrospinal fluid biomarkers of preclinical Alzheimer's disease. *Neuromethods*. 2018;137:93-106. 배제사유: 원저가 아닌 연구
168. Allali GK, I. Laidet, M. Armand, S. Assal, F. Parkinsonism is a Phenotypical Signature of Amyloidopathy in Patients with Gait Disorders. *Journal of Alzheimer's Disease*. 2018;63(4):1373-81. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
169. Alvarez IA, M. Gonzalez, J. M. Ysamat, M. Lorenzo-Bosquet, C. Alonso, A. Tartari, J. P. Romero, S. Diez-Fairen, M. Carcel, M. Pujalte, F. Pastor, P. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. *Journal of Alzheimer's Disease*. 2018;61(1):135-43. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

170. Araki WA, Y. M. Mizusawa, H. Potential value of soluble APP $\alpha$  and APP $\beta$  in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives. *Neurology and Clinical Neuroscience*. 2018;6(4):89-93. 배제사유: 인산화타우 단백질 [효소면역검사]를 수행하지 않은 연구
171. Ashton NJI, M. Scholl, M. Blennow, K. Lovestone, S. Hye, A. Zetterberg, H. No association of salivary total tau concentration with Alzheimer's disease. *Neurobiology of Aging*. 2018;70:125-7. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
172. Babic Leko MW, N. Nikolac Perkovic, M. Klepac, N. Borovecki, F. Hof, P. R. Sonicki, Z. Pivac, N. de Silva, R. Simic, G. Association of MAPT haplotype-tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: A preliminary study in a Croatian cohort. *Brain and Behavior*. 2018;8 (11) (no pagination)(e01128). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
173. Bartos AF, L. Svarcova, J. Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2018;64(3):751-60. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
174. Begcevic IT, M. Brinc, D. Brown, M. Martinez-Morillo, E. Lazarou, I. Kozori, M. Tagaraki, F. Nenopoulou, S. Gkioka, M. Lazarou, E. Lim, B. Batruch, I. Diamandis, E. P. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. *F1000Research*. 2018;7:1012. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
175. Benvenuto AG, B. Koric, L. Gueriot, C. Didic, M. Felician, O. Guye, M. Guedj, E. Ceccaldi, M. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism. *Journal of Alzheimer's Disease*. 2018;65(4):1147-57. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
176. Blennow KZ, H. Biomarkers for Alzheimer's disease: current status and prospects for the future. *Journal of Internal Medicine*. 2018;284(6):643-63. 배제사유: 원저가 아닌 연구
177. Blennow KZ, H. The Past and the Future of Alzheimer's Disease Fluid Biomarkers. *Journal of Alzheimer's Disease*. 2018;62(3):1125-40. 배제사유: 원저가 아닌 연구
178. Chatterjee MDC, M. Morrema, T. H. J. de Waal, M. van der Flier, W. M. Hoozemans, J. J. M. Teunissen, C. E. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. *Alzheimer's Research & Therapy*. 2018;10(1):52. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
179. Chiaravalloti AB, G. Ricci, M. Martorana, A. Ursini, F. Sannino, P. Karalis, G. Schillaci, O. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study. *Brain Research*. 2018;1678:116-22. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
180. Dayon LNG, A. Wojcik, J. Cominetti, O. Corthesy, J. Oikonomidi, A. Henry, H. Kussmann, M. Migliavacca, E. Severin, I. Bowman, G. L. Popp, J. Alzheimer disease

- pathology and the cerebrospinal fluid proteome. *Alzheimer's Research & Therapy*. 2018;10(1):66. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
181. de Almeida SMR, C. E. Rotta, I. Piovesan, M. Tang, B. Vaida, F. Raboni, S. M. Letendre, S. Potter, M. Batistela Fernandes, M. S. Ellis, R. J. H. I. V. Neurobehavioral Research Center Group. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. *Journal of Neurovirology*. 2018;24(1):28-40. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
182. de Leon MJP, E. Osorio, R. S. Glodzik, L. Saint-Louis, L. Kim, H. J. Fortea, J. Fossati, S. Laska, E. Siegel, C. Butler, T. Li, Y. Rusinek, H. Zetterberg, H. Blennow, K. The nonlinear relationship between cerebrospinal fluid  $A\beta_{42}$  and tau in preclinical Alzheimer's disease. *PLoS ONE*. 2018;13 (2) (no pagination)(e0191240). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
183. del Campo MG, D. Elias, N. Boonkamp, L. Pijnenburg, Y. A. van Swieten, J. C. Watts, K. Paciotti, S. Beccari, T. Hu, W. Teunissen, C. E. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. *Annals of Clinical and Translational Neurology*. 2018;5(10):1163-75. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
184. Doecke JDR, A. Villemagne, V. L. Varghese, S. Rainey-Smith, S. Sarros, S. Evered, L. A. Fowler, C. J. Pertile, K. K. Rumble, R. L. Trounson, B. Taddei, K. Laws, S. M. Macaulay, S. L. Bush, A. I. Ellis, K. A. Martins, R. Ames, D. Silbert, B. Vanderstichele, H. Masters, C. L. Darby, D. G. Li, Q. X. Collins, S. Aibl Research Group. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. *Journal of Alzheimer's Disease*. 2018;61(1):169-83. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
185. Duron EV, J. S. Grousselle, D. Gabelle, A. Lehmann, S. Pasquier, F. Buee, L. Allinquant, B. Schraen-Maschke, S. Baret, C. Rigaud, A. S. Hanon, O. Epelbaum, J. Somatostatin and neuropeptide Y in cerebrospinal fluid: Correlations with amyloid peptides  $A\beta_{1-42}$  and tau proteins in elderly patients with mild cognitive impairment. *Frontiers in Aging Neuroscience*. 2018;10 (OCT) (no pagination)(297). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
186. Exploratory analysis of results from the NILVAD trial suggest benefit in very mild AD subjects. *Journal of prevention of alzheimer's disease*. 2018;5(1):S186-. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
187. Falcon CT, A. Monte-Rubio, G. C. Cacciaglia, R. Operto, G. Rami, L. Gispert, J. D. Molinuevo, J. L. Alzheimer's Disease Neuroimaging, Initiative. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. *NeuroImage Clinical*. 2018;19:190-201. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
188. Fiorini MB, M. Benedetti, M. D. Monaco, S. Zanusso, G. Reappraisal of  $A\beta_{40}$  and  $A\beta_{42}$  Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2018;66(1):219-27. 배제사유: 인산화타우단백 [효소

면역검사를 수행하지 않은 연구

189. Gille BD, L. Stoops, E. Demeyer, L. Francois, C. Lefever, S. De Schaepdryver, M. Brix, B. Vandenberghe, R. Tournoy, J. Vanderstichele, H. Poesen, K. Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. *SLAS Technology*. 2018;23(2):188-97. 배제사유: 동물연구 또는 전임상연구
190. Guix FXC, G. T. Cha, D. J. Mustapic, M. Liu, W. Mengel, D. Chen, Z. Aikawa, E. Young-Pearse, T. Kapogiannis, D. Selkoe, D. J. Walsh, D. M. Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles. *International Journal of Molecular Sciences*. 2018;19(3):27. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
191. Hampel HOB, S. E. Molinuevo, J. L. Zetterberg, H. Masters, C. L. Lista, S. Kiddle, S. J. Batrla, R. Blennow, K. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nature Reviews Neurology*. 2018;14(11):639-52. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
192. Hansson OS, J. Stomrud, E. Zetterberg, H. Trojanowski, J. Q. Bittner, T. Lifke, V. Corradini, V. Eichenlaub, U. Batrla, R. Buck, K. Zink, K. Rabe, C. Blennow, K. Shaw, L. M. Swedish Bio, Finder study group Alzheimer's Disease Neuroimaging, Initiative. CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's & Dementia*. 2018;14(11):1470-81. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
193. Henjum KQ-P, E. Zetterberg, H. Blennow, K. Nilsson, L. N. G. Watne, L. O. CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Abeta42, t-tau and p-tau. *Journal of Neuroinflammation*. 2018;15(1):304. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
194. Janssens JV, Y. Fransen, E. Aerts, T. Van Dam, D. Engelborghs, S. De Deyn, P. P. Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. *Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring*. 2018;10:172-81. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
195. Keshavan AH, A. Zetterberg, H. Schott, J. M. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2018;10:448-51. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
196. Kidemet-Piskac SBL, M. Blazekovic, A. Langer Horvat, L. Klepac, N. Sonicki, Z. Kolenc, D. Hof, P. R. Boban, M. Mimica, N. Borovecki, F. Simic, G. Evaluation of cerebrospinal fluid phosphorylated tau<sup>231</sup> as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. *CNS Neuroscience and Therapeutics*. 2018;24(8):734-40. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
197. La Joie RB, A. Fagan, A. M. Ayakta, N. Baker, S. L. Bourakova, V. Boxer, A. L. Cha, J. Karydas, A. Jerome, G. Maass, A. Mensing, A. Miller, Z. A. O'Neil, J. P. Pham, J. Rosen,

- H. J. Tsai, R. Visani, A. V. Miller, B. L. Jagust, W. J. Rabinovici, G. D. Associations between  $^{18}\text{F}$ AV1451 tau PET and CSF measures of tau pathology in a clinical sample. *Neurology*. 2018;90(4):e282-e90. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
198. Lashley TS, J. M. Weston, P. Murray, C. E. Wellington, H. Keshavan, A. Foti, S. C. Foiani, M. Toombs, J. Rohrer, J. D. Heslegrave, A. Zetterberg, H. Molecular biomarkers of Alzheimer's disease: progress and prospects. *DMM Disease Models and Mechanisms*. 2018;11 (5) (no pagination)(dmm031781). 배제사유: 원저가 아닌 연구
199. Law LLR, R. N. Schultz, S. A. Dougherty, R. J. Edwards, D. F. Kosciak, R. L. Gallagher, C. L. Carlsson, C. M. Bendlin, B. B. Zetterberg, H. Blennow, K. Asthana, S. Sager, M. A. Hermann, B. P. Johnson, S. C. Cook, D. B. Okonkwo, O. C. Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2018;10:188-95. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
200. Lehmann SD, C. Boursier, G. Catteau, C. Ginestet, N. Tiers, L. Maceski, A. Navucet, S. Paquet, C. Dumurgier, J. Vanmechelen, E. Vanderstichele, H. Gabelle, A. Relevance of A $\beta$ 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM<sub>R</sub> Scale. *Frontiers in aging neuroscience*. 2018;10:138. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
201. Lewczuk PG, A. Kofanova, O. Ermann, N. Betsou, F. Brandner, S. Mroczko, B. Blennow, K. Strapagiel, D. Paciotti, S. Vogelgsang, J. Roehrl, M. H. Mendoza, S. Kornhuber, J. Teunissen, C. Interlaboratory proficiency processing scheme in CSF aliquoting: Implementation and assessment based on biomarkers of Alzheimer's disease. *Alzheimer's Research and Therapy*. 2018;10 (1) (no pagination)(87). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
202. Lim ASPG, C. Yu, L. Sohail, S. Swardfager, W. Tasaki, S. Schneider, J. A. Paquet, C. Stuss, D. T. Masellis, M. Black, S. E. Hugon, J. Buchman, A. S. Barnes, L. L. Bennett, D. A. De Jager, P. L. Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. *PLoS Medicine*. 2018;15 (9) (no pagination)(e1002647). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
203. Lin YTW, Y. C. Sun, G. C. Ho, C. Y. Wong, T. Y. Lin, C. H. Chen, H. H. Yeh, T. C. Li, C. J. Tseng, C. J. Cheng, P. W. Effect of resveratrol on reactive oxygen species-induced cognitive impairment in rats with angiotensin II-induced early alzheimer's disease. *Journal of Clinical Medicine*. 2018;7 (10) (no pagination)(329). 배제사유: 동물연구 또는 전임상연구
204. Ljubenkov PAS, A. M. Rojas, J. C. Allen, I. E. Wang, P. Heuer, H. Karydas, A. Kornak, J. Cobigo, Y. Seeley, W. W. Grinberg, L. T. Spina, S. Fagan, A. M. Jerome, G. Knopman, D. Boeve, B. F. Dickerson, B. C. Kramer, J. Miller, B. Boxer, A. L. Rosen, H. J. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. *Annals of Clinical and Translational Neurology*. 2018;5(10):1250-63. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

205. Lleo AI, D. J. Illan-Gala, I. McMillan, C. T. Wolk, D. A. Lee, E. B. Van Deerlin, V. M. Shaw, L. M. Trojanowski, J. Q. Grossman, M. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. *JAMA Neurology*. 2018;75(6):738-45. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
206. Mukaetova-Ladinska EBA-A, Z. Andrade, J. da Silva, J. A. Boksha, I. Burbaeva, G. Kalaria, R. N. O'Brien, J. T. Platelet tau protein as a potential peripheral biomarker in Alzheimer's disease: An explorative study. *Current Alzheimer Research*. 2018;15(9):800-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
207. Nagata YH, A. Ikeda, S. Shirahata, A. Shoji, F. Maruyama, M. Kayano, M. Bundo, M. Hattori, K. Yoshida, S. Goto, Y. I. Urakami, K. Soga, T. Ozaki, K. Niida, S. Comparative analysis of cerebrospinal fluid metabolites in Alzheimer's disease and idiopathic normal pressure hydrocephalus in a Japanese cohort. *Biomarker Research*. 2018;6 (1) (no pagination)(5). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
208. Neergaard JSD, K. Christiansen, C. Karsdal, M. A. Brix, S. Henriksen, K. Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: A prospective study. *PLoS ONE [Electronic Resource]*. 2018;13(4):e0194802. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
209. Nielsen MSS, A. H. Siersma, V. Hasselbalch, S. G. Hoegh, P. The Diagnostic and Prognostic Value of a Dual-Tasking Paradigm in a Memory Clinic. *Journal of Alzheimer's Disease*. 2018;61(3):1189-99. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
210. Oberstein TJT, L. Spitzer, P. Hellstern, J. Herrmann, M. Kornhuber, J. Maler, J. M. Imbalance of circulating T<sub>H</sub>17 and regulatory T cells in Alzheimer's disease: A case control study. *Frontiers in Immunology*. 2018;9 (JUN) (no pagination)(1213). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
211. Paquet CB-A, E. Cognat, E. Volpe-Gillot, L. Haddad, V. Mahieux, F. Dekimeche, S. Defontaines, B. Chabriat, H. Belin, C. Texeira, A. Goutagny, S. Questel, F. Azuar, J. Sellier, P. O. Laplanche, J. L. Hugon, J. Dumurgier, J. Distribution of cerebrospinal fluid biomarker profiles in patients explored for cognitive disorders. *Journal of Alzheimer's Disease*. 2018;64(3):889-97. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
212. Perez-Ruiz ED, D. Ven, K. Tripodi, L. Leirs, K. Rosseels, J. van de Wouwer, M. Geukens, N. De Vos, A. Vanmechelen, E. Winderickx, J. Lammertyn, J. Spasic, D. Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples. *Analytica Chimica Acta*. 2018;1015:74-81. 배제사유: 동물연구 또는 전임상연구
213. Perneczky RA, P. Soluble amyloid precursor proteins in blood: Methods and challenges. *Neuromethods*. 2018;137:179-87. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
214. Polanco JCL, C. Bodea, L. G. Martinez-Marmol, R. Meunier, F. A. Gotz, J. Amyloid-beta and tau complexity - Towards improved biomarkers and targeted therapies. *Nature Reviews Neurology*. 2018;14(1):22-40. 배제사유: 원저가 아닌 연구

215. Portelius EO, B. Hoglund, K. Cullen, N. C. Kvartsberg, H. Andreasson, U. Zetterberg, H. Sandelius, A. Shaw, L. M. Lee, V. M. Y. Irwin, D. J. Grossman, M. Weintraub, D. Chen-Plotkin, A. Wolk, D. A. McCluskey, L. Elman, L. McBride, J. Toledo, J. B. Trojanowski, J. Q. Blennow, K. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. *Acta Neuropathologica*. 2018;136(3):363-76. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
216. Reis TL, J. Panizzutti, R. Ferreira, S. T. Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer's disease and depression caroline madeira, charles vargas-lopes, I Carlos Otavio Brandao<sup>2</sup>,6. *Frontiers in Psychiatry*. 2018;9 (NOV) (no pagination)(561). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
217. Reus LMV, E. G. Tijms, B. M. Kate, M. T. Gossink, F. Krudop, W. A. Campo, M. D. Teunissen, C. E. Barkhof, F. van der Flier, W. M. Visser, P. J. Dols, A. Pijnenburg, Y. A. Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. *Journal of Psychiatric Research*. 2018;104:183-91. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
218. Rizzi LM, L. Roriz-Cruz, M. CSF Aβeta<sup>1-42</sup>, but not p-Tau<sup>181</sup>, Predicted Progression from Amnesic MCI to Alzheimer's Disease Dementia. *NeuroMolecular Medicine*. 2018;20(4):491-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
219. Rojas JCB, J. Lobach, I. V. Tsai, R. M. Rabinovici, G. D. Miller, B. L. Boxer, A. L. A. L. Investigators. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. *Neurology*. 2018;90(4):e273-e81. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
220. Rostgaard NR, P. Portelius, E. Blennow, K. Zetterberg, H. Simonsen, A. H. Nielsen, J. E. CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers. *Neurology*. 2018;90(2):e157-e63. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
221. Sanchez-Valle RH, A. Foiani, M. S. Bosch, B. Antonell, A. Balasa, M. Llado, A. Zetterberg, H. Fox, N. C. Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. *Alzheimer's Research & Therapy*. 2018;10(1):113. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
222. Schauer SPM, W. R. Yuan, M. Jenkins, R. G. Rodney Mathews, W. Honigberg, L. A. Wildsmith, K. R. Preanalytical approaches to improve recovery of amyloid-beta peptides from CSF as measured by immunological or mass spectrometry-based assays. *Alzheimer's Research and Therapy*. 2018;10 (1) (no pagination)(118). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
223. Schindler SEG, J. D. Gordon, B. A. Xiong, C. Batrla-Utermann, R. Quan, M. Wahl, S. Benzinger, T. L. S. Holtzman, D. M. Morris, J. C. Fagan, A. M. Cerebrospinal fluid



- biomarkers measured by Elecsys assays compared to amyloid imaging. *Alzheimer's & Dementia*. 2018;14(11):1460-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
224. Schindler SES, C. L. Teunissen, C. McCue, L. M. Morris, J. C. Holtzman, D. M. Mulder, S. D. Scheltens, P. Xiong, C. Fagan, A. M. Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years. *Alzheimer's & Dementia*. 2018;14(1):62-70. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
225. Schipke CGDV, A. Fuentes, M. Jacobs, D. Vanmechelen, E. Peters, O. Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. *Dementia and Geriatric Cognitive Disorders Extra*. 2018;8(2):277-89. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
226. Shahpasand-Kroner HK, H. W. Bauer, C. Schuchhardt, J. Huttenrauch, M. Stazi, M. Bouter, C. Wirths, O. Vogelgsang, J. Wiltfang, J. A two-step immunoassay for the simultaneous assessment of Abeta38, Abeta40 and Abeta42 in human blood plasma supports the Abeta42/Abeta40 ratio as a promising biomarker candidate of Alzheimer's disease. *Alzheimer's Research & Therapy*. 2018;10(1):121. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
227. Shaw LMW, T. Fields, L. Korecka, M. Figurski, M. Trojanowski, J. Q. Eichenlaub, U. Wahl, S. Quan, M. Pontecorvo, M. J. Lachno, D. R. Talbot, J. A. Andersen, S. W. Siemers, E. R. Dean, R. A. Derivation of cutoffs for the Elecsys<sup>®</sup> amyloid beta (1-42) assay in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2018;10:698-705. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
228. Sherbaf FGM, B. Ashraf-Ganjouei, A. Zadeh, M. M. Javinani, A. Moghaddam, H. S. Shandiz, M. S. Aarabi, M. H. Serum insulin-like growth factor-1 in Parkinson's disease; study of cerebrospinal fluid biomarkers and white matter microstructure. *Frontiers in Endocrinology*. 2018;9 (no pagination)(608). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
229. Sogorb-Esteve AG-A, M. S. Gobom, J. Alom, J. Zetterberg, H. Blennow, K. Saez-Valero, J. Levels of ADAM10 are reduced in Alzheimer's disease CSF. *Journal of Neuroinflammation*. 2018;15(1):213. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
230. Sutphen CLM, L. Herries, E. M. Xiong, C. Ladenson, J. H. Holtzman, D. M. Fagan, A. M. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. *Alzheimer's and Dementia*. 2018;14(7):869-79. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
231. Trombetta BAC, B. C. Koenig, A. M. Shaw, L. M. Trojanowski, J. Q. Wolk, D. A. Locascio, J. J. Arnold, S. E. The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. *PLoS ONE [Electronic Resource]*. 2018;13(3):e0193707. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

232. Trotta TP, M. A. Cianciulli, A. Mori, G. Di Benedetto, A. Porro, C. Microglia-derived extracellular vesicles in Alzheimer's Disease: A double-edged sword. *Biochemical Pharmacology*. 2018;148:184-92. 배제사유: 원저가 아닌 연구
233. van Steenoven IM, N. K. Vaikath, N. N. Berendse, H. W. van der Flier, W. M. van de Berg, W. D. J. Teunissen, C. E. Lemstra, A. W. El-Agnaf, O. M. A. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. *Movement Disorders*. 2018;33(11):1724-33. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
234. Vogelgsang JS-K, H. Vogelgsang, R. Streit, F. Vukovich, R. Wiltfang, J. Multiplex immunoassay measurement of amyloid-beta<sub>42</sub> to amyloid-beta<sub>40</sub> ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease. *Experimental Brain Research*. 2018;236(5):1241-50. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
235. Vojdani AV, E. Saidara, E. Kharrazian, D. Reaction of Amyloid-beta Peptide Antibody with Different Infectious Agents Involved in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2018;63(2):847-60. 배제사유: 동물연구 또는 전임상연구
236. Voyle NA-S, D. Klein, G. Hofmann, C. Delmar, P. Pross, N. Andjelkovic, M. Milosavljevic-Ristic, S. Martenyi, F. Fontoura, P. et al. .. THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY. *Alzheimer's & dementia*. 2018;14(7):P240. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
237. Wei TYF, Y. Chang, K. H. Lin, K. J. Lu, Y. J. Cheng, C. M. Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders. *Trends in Biotechnology*. 2018;36(3):290-303. 배제사유: 원저가 아닌 연구
238. Wellington HP, R. W. Suarez-Gonzalez, A. Poole, T. Frost, C. Sjobom, U. Slattery, C. F. Magdalinou, N. K. Lehmann, M. Portelius, E. Fox, N. C. Blennow, K. Zetterberg, H. Schott, J. M. CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. *Annals of Clinical & Translational Neurology*. 2018;5(2):162-71. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
239. Westwood SB, A. L. Hye, A. Ashton, N. J. Nevado-Holgado, A. J. Anand, S. N. Liu, B. Newby, D. Bazenet, C. Kiddle, S. J. Ward, M. Newton, B. Desai, K. Tan Hehir, C. Zanette, M. Galimberti, D. Parnetti, L. Lleo, A. Baker, S. Narayan, V. A. van der Flier, W. M. Scheltens, P. Teunissen, C. E. Visser, P. J. Lovestone, S. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [<sup>18</sup>F]-Flutemetamol PET Scan Result. *Frontiers in aging neuroscience*. 2018;10:409. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
240. Willemse EAJvM, I. S. Tijms, B. M. Bouwman, F. H. Franke, A. Hubeek, I. Boelaarts, L. Claus, J. J. Korf, E. S. C. van Marum, R. J. Roks, G. Schoonenboom, N. Verwey, N. Zwan, M. D. Wahl, S. van der Flier, W. M. Teunissen, C. E. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. *Alzheimer's and Dementia*:

- Diagnosis, Assessment and Disease Monitoring. 2018;10:563-72. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
241. Woollacott IOCN, J. M. Heslegrave, A. Heller, C. Foiani, M. S. Dick, K. M. Russell, L. L. Paterson, R. W. Keshavan, A. Fox, N. C. Warren, J. D. Schott, J. M. Zetterberg, H. Rohrer, J. D. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. *Alzheimer's Research & Therapy*. 2018;10(1):79. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
242. Wu ZZ, M. Zhang, Z. Dong, W. Wang, Q. Ren, J. Ratio of beta-amyloid protein (Abeta) and tau predicts the postoperative cognitive dysfunction on patients undergoing total hip/knee replacement surgery. *Experimental and Therapeutic Medicine*. 2018;15(1):878-84. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
243. Zetterberg H. Chitotriosidase: Shucking the role of microglia in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*. 2018;89(3):228-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
244. Zetterberg HB, K. Chronic traumatic encephalopathy: fluid biomarkers. *Handbook of Clinical Neurology*. 2018;158:323-33. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
245. Abe YK, N. Takahashi, R. Gotou, M. Mizukami, K. Uchida, H. Matsubara, E. Relationship between cytokine levels in the cerebrospinal fluid and 11C-Pittsburgh compound B retention in patients with mild cognitive impairment. *Geriatrics & gerontology international*. 2017;17(11):1907-13. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
246. Abuyaman OC, M. Smith, A. D. Nexo, E. The soluble transcobalamin receptor (sCD320) in relation to Alzheimer's disease and cognitive scores. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2017;77(5):332-7. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
247. Almdahl ISL, C. Selnes, P. Kalheim, L. F. Coello, C. Gajdzik, B. Moller, I. Wettergreen, M. Grambaite, R. Bjornerud, A. Brathen, G. Sando, S. B. White, L. R. Fladby, T. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease. *Frontiers in aging neuroscience*. 2017;9:9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
248. Blennow K. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. *Neurology and Therapy*. 2017;6(Supplement 1):15-24. 배제사유: 원자가 아닌 연구
249. Blokhuis CD, S. Cohen, S. Demirkaya, N. Scherpbier, H. J. Kootstra, N. A. Kuhle, J. Teunissen, C. E. Verbraak, F. D. Pajkrt, D. Inflammatory and neuronal biomarkers associated with retinal thinning in pediatric HIV. *Investigative Ophthalmology and Visual Science*. 2017;58(13):5985-92. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
250. Bourbouli MR, M. Bougea, A. Zouvelou, V. Constantinides, V. C. Zaganas, I. Evdokimidis, I. Kapaki, E. Paraskevas, G. P. Cerebrospinal Fluid TAR DNA-Binding

Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. *Dementia and Geriatric Cognitive Disorders*. 2017;44(3-4):144-52. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구

251. Calcagno AR, A. Atzori, C. Ghisetti, V. Cardellino, C. Audagnotto, S. Scarvaglieri, E. Lipani, F. Imperiale, D. Di Perri, G. Bonora, S. Blood Brain Barrier Impairment in HIV-Positive Naive and Effectively Treated Patients: Immune Activation Versus Astrocytosis. *Journal of Neuroimmune Pharmacology*. 2017;12(1):187-93. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
252. Casaletto KBE, F. M. Bettcher, B. M. Neuhaus, J. Bendlin, B. B. Asthana, S. Johnson, S. C. Yaffe, K. Carlsson, C. Blennow, K. Zetterberg, H. Kramer, J. H. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. *Neurology*. 2017;89(17):1782-8. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
253. Cherry JDS, T. D. Tripodis, Y. Alvarez, V. E. Huber, B. R. Au, R. Kiernan, P. T. Daneshvar, D. H. Mez, J. Solomon, T. M. Alosco, M. L. McKee, A. C. CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease. *PLoS ONE*. 2017;12 (9) (no pagination)(e0185541). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
254. Clement AM, C. Andersson, D. R. Asuni, A. A. Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models. *Neuroscience*. 2017;354:101-9. 배제사유: 동물연구 또는 전임상연구
255. D'Anna LA-R, S. Fabris, M. Pistis, C. Baldi, A. Sanvilli, N. Curcio, F. Gigli, G. L. D'Anna, S. Valente, M. Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. *Neurodegenerative Diseases*. 2017;17(4-5):227-34. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
256. Dayon LW, J. Nunez Galindo, A. Corthesy, J. Cominetti, O. Oikonomidi, A. Henry, H. Migliavacca, E. Bowman, G. L. Popp, J. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. *Journal of Alzheimer's Disease*. 2017;60(4):1641-52. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
257. Demirtas MF, C. Tucholka, A. Gispert, J. D. Molinuevo, J. L. Deco, G. A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. *NeuroImage: Clinical*. 2017;16:343-54. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
258. Eliassen CFR, I. Selnes, P. Grambaite, R. Fladby, T. Hessen, E. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. *Brain and Behavior*. 2017;7 (9) (no pagination)(e00776). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
259. Euctr ES. A study to test a new Alzheimer's disease vaccine in people with suspected or very mild Alzheimer's disease. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-004352-30-ES>. 2017. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구

260. Fania CA, B. Capitanio, D. Torretta, E. Gussago, C. Ferri, E. Mari, D. Gelfi, C. Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms. PLoS ONE [Electronic Resource]. 2017;12(6):e0179280. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
261. Fereshtehnejad SMZ, Y. Dagher, A. Postuma, R. B. Clinical criteria for subtyping Parkinson's disease: Biomarkers and longitudinal progression. Brain. 2017;140(7):1959-76. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
262. Gawinecka JS, M. Zerr, I. Biomarkers in cerebrospinal fluid. Neuromethods. 2017;129:229-52. 배제사유: 원저가 아닌 연구
263. Hayashi YY, M. Kimura, A. Asano, T. Satoh, K. Kitamoto, T. Yoneda, M. Inuzuka, T. Clinical findings of a probable case of MM2-cortical-type sporadic Creutzfeldt-Jakob disease with antibodies to anti-N-terminus of alpha-enolase. Prion. 2017;11(6):454-64. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
264. He BC, Y. Tan, E. L. Li, P. The application of aptasensors for the aging diseases diagnosis. Current Immunology Reviews. 2017;13(2):144-52. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
265. Hov KRB, N. Idland, A. V. Zetterberg, H. Blennow, K. Chaudhry, F. A. Frihagen, F. Raeder, J. Wyller, T. B. Watne, L. O. Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. Dementia and Geriatric Cognitive Disorders Extra. 2017;7(3):374-85. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
266. Humpel CB, T. Cerebrospinal Fluid Levels of 14-3-3 Gamma: What Does It Tell Us About Sporadic Creutzfeldt-Jakob Disease? Pharmacology. 2017;100(5-6):243-5. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
267. Janelidze SP, J. Mikulskis, A. Chiao, P. Zetterberg, H. Blennow, K. Hansson, O. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurology. 2017;74(12):1492-501. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
268. Johansson VJ, J. Fortgang, R. G. Zetterberg, H. Blennow, K. Cannon, T. D. Hultman, C. M. Wetterberg, L. Landen, M. Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. European Archives of Psychiatry & Clinical Neuroscience. 2017;267(5):391-402. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
269. Kasai TT, H. Kondo, M. Ishii, R. Ohmichi, T. Yeung, W. T. E. Morimoto, M. Chiyonobu, T. Terada, N. Allsop, D. Nakagawa, M. Mizuno, T. Tokuda, T. Increased levels of plasma total tau in adult Down syndrome. PLoS ONE [Electronic Resource]. 2017;12(11):e0188802. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
270. Kolarova MS, U. Bartos, A. Ricny, J. Kayed, R. Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. Journal of Alzheimer's Disease. 2017;58(2):471-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구

271. Kovacs GGA, U. Liman, V. Regelsberger, G. Lutz, M. I. Danics, K. Keller, E. Zetterberg, H. Blennow, K. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. *European Journal of Neurology*. 2017;24(11):1326-e77. 배제사유: 동물연구 또는 전임상연구
272. Kuiperij HBV, A. A. Beenes, M. Verwey, N. A. Benussi, L. Paterlini, A. Binetti, G. Teunissen, C. E. Raaphorst, J. Schelhaas, H. J. Kusters, B. Pijnenburg, Y. A. Ghidoni, R. Verbeek, M. M. Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. *Journal of Alzheimer's Disease*. 2017;55(2):585-95. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
273. Lanoiselee HMN, G. Wallon, D. Rovelet-Lecrux, A. Lacour, M. Rousseau, S. Richard, A. C. Pasquier, F. Rollin-Sillaire, A. Martinaud, O. Quillard-Muraine, M. de la Sayette, V. Boutoleau-Bretonniere, C. Etcharry-Bouyx, F. Chauvire, V. Sarazin, M. le Ber, I. Epelbaum, S. Jonveaux, T. Rouaud, O. Ceccaldi, M. Felician, O. Godefroy, O. Formaglio, M. Croisile, B. Auriacombe, S. Chamard, L. Vincent, J. L. Sauvee, M. Marelli-Tosi, C. Gabelle, A. Ozsancak, C. Pariente, J. Paquet, C. Hannequin, D. Campion, D. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. *PLoS Medicine*. 2017;14 (3) (no pagination)(e1002270). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
274. Lauridsen CS, S. B. Moller, I. Berge, G. Pomary, P. K. Grontvedt, G. R. Salvesen, O. Brathen, G. White, L. R. Cerebrospinal fluid Abeta43 is reduced in early-onset compared to late-onset Alzheimer's disease, but has similar diagnostic accuracy to Abeta42. *Frontiers in Aging Neuroscience*. 2017;9 (JUN) (no pagination)(210). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
275. Lewczuk PL, N. Lachmann, I. Holzer, M. Flach, K. Brandner, S. Engelborghs, S. Teunissen, C. E. Zetterberg, H. Molinuevo, J. L. Mroczko, B. Blennow, K. Popp, J. Parnetti, L. Chiasserini, D. Perret-Liaudet, A. Spitzer, P. Maler, J. M. Kornhuber, J. Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. *Journal of Alzheimer's Disease*. 2017;55(1):159-70. 배제사유: 동물연구 또는 전임상연구
276. Liguori CO, E. Pierantozzi, M. Cerroni, R. Galati, S. Saviozzi, V. Mercuri, N. B. Stefani, A. Cerebrospinal-fluid Alzheimer's disease biomarkers and blood-brain barrier integrity in a natural population of cognitive intact Parkinson's disease patients. *CNS and Neurological Disorders - Drug Targets*. 2017;16(3):339-45. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
277. Lindberg OM, G. Stomrud, E. Palmqvist, S. Wahlund, L. O. Westman, E. Hansson, O. Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and Abeta Pathology in Non-demented Individuals. *Frontiers in aging neuroscience*. 2017;9:306. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
278. Llorens FS, M. Zerr, I. Progress in CSF biomarker discovery in sCJD. *Oncotarget*. 2017;8(4):5666-7. 배제사유: 원저가 아닌 연구

279. Lopez-Font IB, C. P. Zetterberg, H. Blennow, K. Saez-Valero, J. Alterations in the Balance of Amyloid-beta Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. *Journal of Alzheimer's Disease*. 2017;57(4):1281-91. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
280. Lue LFG, A. Walker, D. G. Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies. *Neurology and Therapy*. 2017;6(Supplement 1):25-36. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
281. Mo YS, J. Wilson, K. Holder, D. Sur, C. Laterza, O. Savage, M. J. Struyk, A. Scheltens, P. Teunissen, C. E. Burke, J. Macaulay, S. L. Brathen, G. Sando, S. B. White, L. R. Weiss, C. Cowes, A. Bush, M. M. DeSilva, G. Darby, D. G. Rainey-Smith, S. R. Surls, J. Sagini, E. Tanen, M. Altman, A. Luthman, J. Egan, M. F. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Abeta42 cutoff with concordance to amyloid positron emission tomography imaging. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2017;6:201-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
282. Modreanu RC, S. C. Marti, M. J. Rios, J. Sanchez-Gomez, A. Camara, A. Fernandez, M. Compta, Y. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal tau and Abeta as well as dementia-risk in Parkinson's disease. *Journal of the Neurological Sciences*. 2017;373:223-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
283. Muszynski PG, M. Kulczynska-Przybik, A. Kulakowska, A. Mroczko, B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer's disease. *Current Neuropharmacology*. 2017;15(6):906-17. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
284. Muszynski PK-P, A. Borawska, R. Litman-Zawadzka, A. Slowik, A. Klimkowicz-Mrowiec, A. Pera, J. Dziedzic, T. Mroczko, B. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2017;59(3):903-12. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
285. Niemela VL, A. M. Blennow, K. Sundblom, J. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease? *PLoS ONE [Electronic Resource]*. 2017;12(2):e0172762. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
286. Oboudiyat CG, T. Varelas, E. Weintraub, S. Rogalski, E. Bigio, E. H. Mesulam, M. M. Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia. *Alzheimer's and Dementia*. 2017;13(5):598-601. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
287. Oudart JBZ, L. Maquart, F. X. Dubernard, X. Labrousse, M. Fiabane, G. Quedreux, A. Litre, F. Ramont, L. Tau protein as a possible marker of cerebrospinal fluid leakage in cerebrospinal fluid rhinorrhoea: A pilot study. *Biochemia Medica*. 2017;27(3):030703. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

288. Portelius EB, G. Pannee, J. Zetterberg, H. Blennow, K. Dahlen, R. Brinkmalm, A. Gobom, J. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. *Expert Review of Proteomics*. 2017;14(11):1007-20. 배제사유: 원저가 아닌 연구
289. Pottiez GY, L. Stewart, T. Song, N. Aro, P. Galasko, D. R. Quinn, J. F. Peskind, E. R. Shi, M. Zhang, J. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid beta 1-42 in CSF for the Diagnosis of Alzheimer's Disease. *Journal of Proteome Research*. 2017;16(3):1228-38. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
290. Rabelo AGBT, C. V. L. Magalhaes, T. N. C. Carletti-Cassani, A. F. M. K. Amato Filho, A. C. S. Joaquim, H. P. G. Talib, L. L. Forlenza, O. Ribeiro, P. A. O. Secolin, R. Lopes-Cendes, I. Cendes, F. Balthazar, M. L. F. Is cerebral microbleed prevalence relevant as a biomarker in amnesic mild cognitive impairment and mild Alzheimer's disease? *Neuroradiology Journal*. 2017;30(5):477-85. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
291. Reijs BLRV, S. J. B. Soininen, H. Lotjonen, J. Koikkalainen, J. Pikkarainen, M. Hall, A. Vanninen, R. Liu, Y. Herukka, S. K. Freund-Levi, Y. Frisoni, G. B. Frolich, L. Nobili, F. Rikkert, M. O. Spuru, L. Tsolaki, M. Wallin, A. K. Scheltens, P. Verhey, F. Visser, P. J. Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. *Journal of Alzheimer's Disease*. 2017;60(4):1387-95. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
292. Robinson RAA, B. Guest, P. C. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. *Advances in Experimental Medicine & Biology*. 2017;974:21-48. 배제사유: 원저가 아닌 연구
293. Russell CLM, V. Hansson, K. Blennow, K. Gobom, J. Zetterberg, H. Hiltunen, M. Ward, M. Pike, I. Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. *Journal of Alzheimer's Disease*. 2017;55(1):303-13. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
294. Sabbagh MN. Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer's Disease and Related Disorders. *Neurology and Therapy*. 2017;6(Supplement 1). 배제사유: 원저가 아닌 연구
295. Schartner JN, A. Budde, B. Lange, J. Hoeck, N. Wiltfang, J. Kotting, C. Gerwert, K. An ATR-FTIR Sensor Unraveling the Drug Intervention of Methylene Blue, Congo Red, and Berberine on Human Tau and Abeta. *ACS Medicinal Chemistry Letters*. 2017;8(7):710-4. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
296. Schelle JH, L. M. Gopfert, J. C. Joos, T. O. Vanderstichele, H. Stoops, E. Mandelkow, E. M. Neumann, U. Shimshek, D. R. Staufenbiel, M. Jucker, M. Kaeser, S. A. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. *Alzheimer's & Dementia*. 2017;13(6):701-9. 배제사유: 동물연구 또는 전임상연구



297. Schultz SAB, E. A. Darst, B. F. Zetterberg, H. Blennow, K. Edwards, D. F. Kosciak, R. L. Carlsson, C. M. Gallagher, C. L. Bendlin, B. B. Asthana, S. Sager, M. A. Hogan, K. J. Hermann, B. P. Cook, D. B. Johnson, S. C. Engelman, C. D. Okonkwo, O. C. Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. *Neurology*. 2017;88(17):1650-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
298. Schwarz AJS, K. L. Lachno, D. R. Case, M. G. Suhy, J. Pontecorvo, M. J. Dean, R. A. Siemers, E. R. Effect of solanezumab on biomarkers of neurodegeneration in the expedition3 trial in mild Alzheimer disease. *Alzheimer's & dementia*. 2017;13(7):P605-. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
299. Seibyl JS, L. M. Blennow, K. Widmann, M. Corradini, V. Wahl, S. Zink, K. Buck, K. Eichenlaub, U. Hansson, O. Amyloid-PET concordance of elecsys& CSF biomarker immunoassays for Alzheimer's disease. *Alzheimer's & dementia*. 2017;13(7):P199-P200. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
300. Sengupta UP, E. Hansson, O. Farmer, K. Castillo-Carranza, D. Woltjer, R. Zetterberg, H. Galasko, D. Blennow, K. Kaye, R. Tau oligomers in cerebrospinal fluid in Alzheimer's disease. *Annals of Clinical & Translational Neurology*. 2017;4(4):226-35. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
301. Tatebe HK, T. Ohmichi, T. Kishi, Y. Kakeya, T. Waragai, M. Kondo, M. Allsop, D. Tokuda, T. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. *Molecular Neurodegeneration*. 2017;12(1):63. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
302. Toro JC-G, D. Duque, A. Minota, K. Patino, J. Garcia, M. Seronegative Paraneoplastic Limbic Encephalitis Associated with Thymoma. *Cognitive and Behavioral Neurology*. 2017;30(3):125-8. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
303. van Maurik ISZ, M. D. Tijms, B. M. Bouwman, F. H. Teunissen, C. E. Scheltens, P. Wattjes, M. P. Barkhof, F. Berkhof, J. van der Flier, W. M. Alzheimer's Disease Neuroimaging, Initiative. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. *JAMA Neurology*. 2017;74(12):1481-91. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
304. Vanderstichele HD, L. Janelidze, S. Coart, E. Stoops, E. Mauroo, K. Herbst, V. Francois, C. Hansson, O. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, alpha-synuclein, and total tau in combination with Abeta(1-42)/Abeta(1-40). *Alzheimer's Research and Therapy*. 2017;9 (1) (no pagination)(40). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
305. Velickaite VG, V. Strom, K. Alafuzoff, I. Zetterberg, H. Lannfelt, L. Kilander, L. Larsson, E. M. Ingelsson, M. Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease. *BMC Geriatrics*. 2017;17(1):208. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

306. Vishnu VYM, M. Gairolla, J. Kumar, A. Mohanty, M. Goyal, M. K. Lal, V. Mittal, B. R. Prabhakar, S. Clinical, molecular imaging and biomarker concordance in the diagnosis of Alzheimer's disease and vascular dementia. *Australasian Medical Journal*. 2017;10(4):262-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
307. Wang MJY, S. Han, J. Y. Park, S. Y. Jang, J. W. Chun, I. K. Kim, S. E. Lee, B. S. Kim, G. J. Yu, J. S. Lim, K. Kang, S. M. Park, Y. H. Youn, Y. C. An, S. S. A. Kim, S. Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer's disease. *Alzheimer's Research & Therapy*. 2017;9(1):98. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
308. Wang YB, V. Kaniyappan, S. Kruger, L. Irsen, S. Tepper, K. Chandupatla, R. Maetzler, W. Schneider, A. Mandelkow, E. Mandelkow, E. M. The release and trans-synaptic transmission of Tau via exosomes. *Molecular Neurodegeneration*. 2017;12(1):5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
309. Wang ZX, L. Wan, W. Duan, L. Bai, X. Zu, H. Intranasal BMP9 ameliorates alzheimer disease-like pathology and cognitive deficits in APP/PS1 transgenic mice. *Frontiers in Molecular Neuroscience*. 2017;10 (no pagination)(32). 배제사유: 동물연구 또는 전임상연구
310. Weiner MWV, D. P. Aisen, P. S. Beckett, L. A. Cairns, N. J. Green, R. C. Harvey, D. Jack, C. R. , Jr. Jagust, W. Morris, J. C. Petersen, R. C. Salazar, J. Saykin, A. J. Shaw, L. M. Toga, A. W. Trojanowski, J. Q. Alzheimer's Disease Neuroimaging, Initiative. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. *Alzheimer's & Dementia*. 2017;13(5):561-71. 배제사유: 원저가 아닌 연구
311. Westwood SL, B. Baird, A. L. Anand, S. Nevado-Holgado, A. J. Newby, D. Pikkarainen, M. Hallikainen, M. Kuusisto, J. Streffer, J. R. Novak, G. Blennow, K. Andreasson, U. Zetterberg, H. Smith, U. Laakso, M. Soininen, H. Lovestone, S. The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. *Alzheimer's Research & Therapy*. 2017;9(1):31. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
312. Abner ELJ, G. A. Shaw, L. M. Trojanowski, J. Q. Goetzl, E. J. Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. *Annals of Clinical and Translational Neurology*. 2016;3(5):399-403. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
313. Andreasson UB, K. Zetterberg, H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2016;3:98-102. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
314. Barthelemy NRG, A. Hirtz, C. Fenaille, F. Sergeant, N. Schraen-Maschke, S. Vialaret, J. Buee, L. Junot, C. Becher, F. Lehmann, S. Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. *Journal of Alzheimer's Disease*. 2016;51(4):1033-43. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

315. Berge GS, S. B. Albrektsen, G. Lauridsen, C. Moller, I. Grontvedt, G. R. Brathen, G. White, L. R. Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. *BMC Neurology*. 2016;16(1):180. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
316. Blennow KB, L. Eusebi, P. Parnetti, L. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. *Movement Disorders*. 2016;31(6):836-47. 배제사유: 원저가 아닌 연구
317. Blennow KN, T. Lasser, R. A. Dukart, J. Rabe, C. Volz, D. Scheltens, P. Gantenerumab treatment reduces biomarkers of neuronal and synaptic degeneration in Alzheimer's disease. *Alzheimer's & dementia*. 2016;12(7):P198. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
318. Brai EAR, N. Alberi, L. Notch1 hallmarks fibrillary depositions in sporadic Alzheimer's disease. *Acta Neuropathologica Communications*. 2016;4(1):64. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
319. Calcagno AA, C. Romito, A. Vai, D. Audagnotto, S. Stella, M. L. Montrucchio, C. Imperiale, D. Di Perri, G. Bonora, S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. *Journal of NeuroVirology*. 2016;22(1):88-92. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
320. Carmona PM, M. Toledano, A. Blood-based biomarkers of alzheimer's disease: Diagnostic algorithms and new technologies. *Current Alzheimer Research*. 2016;13(4):450-64. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
321. Celebi OU, A. Oguz, K. K. Has, A. C. Dolgun, A. Cakmakli, G. Y. Akbiyik, F. Elibol, B. Saka, E. Default mode network connectivity is linked to cognitive functioning and CSF Aβ<sub>1-42</sub> levels in Alzheimer's disease. *Archives of Gerontology and Geriatrics*. 2016;62:125-32. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
322. Chen CZ, W. Lv, Y. Shi, Q. Wang, J. Xiao, K. Chen, L. N. Zhang, B. Y. Dong, X. P. The Levels of Tau Isoforms Containing Exon-2 and Exon-10 Segments Increased in the Cerebrospinal Fluids of the Patients with Sporadic Creutzfeldt-Jakob Disease. *Molecular Neurobiology*. 2016;53(6):3999-4009. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
323. Chen JW, A. Liu, L. Blood-based amyloid and tau biomarker tests for alzheimer's disease. *Neuroscience and Biomedical Engineering*. 2016;4(1):4-13. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
324. Cicognola CC, D. Eusebi, P. Andreasson, U. Vanderstichele, H. Zetterberg, H. Parnetti, L. Blennow, K. No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. *Molecular Neurodegeneration*. 2016;11(1):65. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

325. Compta YB, M. Bargallo, N. Valldeoriola, F. Munoz, E. Tolosa, E. Rios, J. Camara, A. Fernandez, M. Marti, M. J. White matter hyperintensities, cerebrospinal amyloid-beta and dementia in Parkinson's disease. *Journal of the Neurological Sciences*. 2016;367:284-90. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
326. Counts SEH, B. Prout, J. G. Michalski, B. Farotti, L. Fahnstock, M. Mufson, E. J. Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. *Current Alzheimer Research*. 2016;13(7):800-8. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
327. De Vos AS, H. Jacobs, D. Franssen, E. Klewansky, T. De Roeck, E. Robberecht, C. Van Broeckhoven, C. Duyckaerts, C. Engelborghs, S. Vanmechelen, E. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2016;53(4):1523-38. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
328. Di Domenico FP, G. Giraldo, E. Badia, M. C. Monllor, P. Lloret, A. Eugenia Schinina, M. Giorgi, A. Cini, C. Tramutola, A. Butterfield, D. A. Vina, J. Perluigi, M. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. *Free Radical Biology and Medicine*. 2016;91:1-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
329. Di Domenico FP, G. Giraldo, E. Lloret, A. Badia, M. C. Schinina, M. E. Giorgi, A. Butterfield, D. A. Vina, J. Perluigi, M. Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage. *Current Alzheimer Research*. 2016;13(2):112-22. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
330. D'Onofrio GY, Z. Forlenza, O. V. Alzheimer's Disease and Cognitive Frailty: Novel Therapeutic Technologies. *BioMed Research International*. 2016;2016 (no pagination)(7242651). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
331. Evered LS, B. Scott, D. A. Ames, D. Maruff, P. Blennow, K. Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction. *Anesthesiology*. 2016;124(2):353-61. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
332. Gabelle AJ, I. Hirtz, C. Navucet, S. Grasselli, C. Lehmann, S. Dauvilliers, Y. CSF orexin-a/hypocretin-1 changes in the alzheimer disease process. *Alzheimer's and dementia Conference: alzheimer's association international conference 2016 Canada Conference start: 20160722 Conference end: 20160728*. 2016;12(7 Supplement):P476. 배제사유: 회색문헌(초록만 발표된 문헌)
333. Henjum KA, I. S. Arskog, V. Minthon, L. Hansson, O. Fladby, T. Nilsson, L. N. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. *Alzheimer's Research & Therapy*. 2016;8(1):17. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
334. Heslegrave AH, W. Paterson, R. Magdalinos, N. Svensson, J. Johansson, P. Ohrfelt, A. Blennow, K. Hardy, J. Schott, J. Mills, K. Zetterberg, H. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. *Molecular Neurodegeneration*.

2016;11:3. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구

335. Horvath IJ, X. Johansson, P. Wang, C. Moskalenko, R. Steinau, A. Forsgren, L. Wagberg, T. Svensson, J. Zetterberg, H. Morozova-Roche, L. A. Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. *Acs Chemical Neuroscience*. 2016;7(1):34-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
336. Junttila AK, M. Hartikainen, P. Siloaho, M. Helisalmi, S. Moilanen, V. Kiviharju, A. Jansson, L. Tienari, P. J. Remes, A. M. Herukka, S. K. Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. *Dementia and Geriatric Cognitive Disorders Extra*. 2016;6(1):142-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
337. Kaushik AJ, R. D. Tiwari, S. Vashist, A. Nair, M. Nano-biosensors to detect beta-amyloid for Alzheimer's disease management. *Biosensors and Bioelectronics*. 2016;80:273-87. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
338. Krebs SJS, B. M. Sithinamsuwan, P. Allen, I. E. Chalermchai, T. Tipsuk, S. Phanuphak, N. Jagodzinski, L. Kim, J. H. Ananworanich, J. Marovich, M. A. Valcour, V. G. Search study team. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals. *AIDS*. 2016;30(10):1533-42. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
339. Kruse NS, M. G. Schulz-Schaeffer, W. J. Vanmechelen, E. Vanderstichele, H. El-Agnaf, O. M. Mollenhauer, B. A First Tetraplex Assay for the Simultaneous Quantification of Total alpha-Synuclein, Tau, beta-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. *PLoS ONE [Electronic Resource]*. 2016;11(4):e0153564. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
340. Lasser RS, P. Dubois, B. Nikolcheva, T. Retout, S. Volz, D. Csoboth, C. Boada, M. Efficacy, safety and biomarker data from scarlet road-a global phase 3 study of gantenerumab in patients with prodromal ad. *American journal of geriatric psychiatry*. 2016;24(3):S161-S2. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
341. Lauridsen CS, S. B. Shabnam, A. Moller, I. Berge, G. Grontvedt, G. R. Bakken, I. J. Salvesen, O. Brathen, G. White, L. R. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnesic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. *Frontiers in aging neuroscience*. 2016;8:30. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
342. Lehmann ST, C. E. Editorial: Biomarkers of Alzheimer's disease: The present and the future. *Frontiers in Neurology*. 2016;7 (SEP) (no pagination)(158). 배제사유: 원지가 아닌 연구
343. Leitao MJB, I. Almeida, M. R. Ribeiro, M. H. Santos, A. C. Ribeiro, M. Tomas, J. Rocha, S. Santana, I. Oliveira, C. R. CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result. *Journal of Neurology*. 2016;263(9):1847-61. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

연구

344. Leitaó MJB, I. Almeida, M. R. Ribeiro, M. H. Santos, A. C. Ribeiro, M. Tomas, J. Rocha, S. Santana, I. Oliveira, C. R. Sporadic Creutzfeldt-Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3gamma assay. *Neuroscience*. 2016;322:398-407. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
345. Lelental NB, S. Kofanova, O. Blennow, K. Zetterberg, H. Andreasson, U. Engelborghs, S. Mroczko, B. Gabryelewicz, T. Teunissen, C. Mollenhauer, B. Parnetti, L. Chiasserini, D. Molinuevo, J. L. Perret-Liaudet, A. Verbeek, M. M. Andreasen, N. Brosseron, F. Bahl, J. M. Herukka, S. K. Hausner, L. Frolich, L. Labonte, A. Poirier, J. Miller, A. M. Zilka, N. Kovacech, B. Urbani, A. Suardi, S. Oliveira, C. Baldeiras, I. Dubois, B. Rot, U. Lehmann, S. Skinningsrud, A. Betsou, F. Wiltfang, J. Gkatzima, O. Winblad, B. Buchfelder, M. Kornhuber, J. Lewczuk, P. Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. *Journal of Alzheimer's Disease*. 2016;52(1):51-64. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
346. Lewczuk PK, J. Do we still need positron emission tomography for early Alzheimer's disease diagnosis? *Brain*. 2016;139(11):e60. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
347. Llorens FS, M. Varges, D. Kruse, N. Gotzmann, N. Gmitterova, K. Mollenhauer, B. Zerr, I. Cerebrospinal alpha-synuclein in alpha-synuclein aggregation disorders: tau/alpha-synuclein ratio as potential biomarker for dementia with Lewy bodies. *Journal of Neurology*. 2016;263(11):2271-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
348. Majbour NKV, N. N. van Dijk, K. D. Ardah, M. T. Varghese, S. Vesterager, L. B. Montezinho, L. P. Poole, S. Safieh-Garabedian, B. Tokuda, T. Teunissen, C. E. Berendse, H. W. van de Berg, W. D. El-Agnaf, O. M. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. *Molecular Neurodegeneration*. 2016;11:7. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
349. Meeter LHD, E. G. Jiskoot, L. C. Sanchez-Valle, R. Graff, C. Benussi, L. Ghidoni, R. Pijnenburg, Y. A. Borroni, B. Galimberti, D. Laforce, R. J. Masellis, M. Vandenberghe, R. Ber, I. L. Otto, M. van Minkelen, R. Papma, J. M. Rombouts, S. A. Balasa, M. Oijerstedt, L. Jelic, V. Dick, K. M. Cash, D. M. Harding, S. R. Jorge Cardoso, M. Ourselin, S. Rossor, M. N. Padovani, A. Scarpini, E. Fenoglio, C. Tartaglia, M. C. Lamari, F. Barro, C. Kuhle, J. Rohrer, J. D. Teunissen, C. E. van Swieten, J. C. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. *Annals of Clinical and Translational Neurology*. 2016;3(8):623-36. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
350. Mehta SHA, C. H. Advances in Biomarker Research in Parkinson's Disease. *Current Neurology and Neuroscience Reports*. 2016;16(1):1-8. 배제사유: 원저가 아닌 연구
351. Mollenhauer BP, L. Rektorova, I. Kramberger, M. G. Pikkarainen, M. Schulz-Schaeffer, W. J. Aarsland, D. Svenningsson, P. Farotti, L. Verbeek, M. M. Schlossmacher, M. G. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. *Journal of Neurochemistry*. 2016;290-317. 배제사유: 원저가 아닌 연구

352. Monge-Argiles JAG-B, R. Gutierrez-Agullo, M. Munoz-Ruiz, C. Sanchez-Paya, J. Leiva-Santana, C. Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population. *BioMed Research International*. 2016;2016:1390620. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
353. Niemantsverdriet EG, J. Struyfs, H. Martin, J. J. Goeman, J. De Deyn, P. P. Vanderstichele, H. Engelborghs, S. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2016;51(1):97-106. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
354. Nikolcheva TL, R. Ostrowitzki, S. Scheltens, P. Boada, M. Dubois, B. Dorflinger, E. Volz, D. Eichenlaub, U. Rabe, C. et al. . CSF and amyloid pet biomarker data from scarlet road-a global phase 3 study of gantenerumab in patients with prodromal AD. *Neurobiology of aging*. 2016;39:S28-S9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
355. Oeckl PM, F. Nagl, M. von Arnim, C. A. Halbgebauer, S. Steinacker, P. Ludolph, A. C. Otto, M. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. *Molecular & Cellular Proteomics*. 2016;15(10):3126-38. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
356. Paterson RWH, W. E. Heslegrave, A. J. Magdalinou, N. K. Andreasson, U. Sirka, E. Bliss, E. Slattery, C. F. Toombs, J. Svensson, J. Johansson, P. Fox, N. C. Zetterberg, H. Mills, K. Schott, J. M. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. *Translational Psychiatry*. 2016;6 (11) (no pagination)(e952). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
357. Paterson RWS, C. F. Magdalinou, N. K. Toombs, J. Chapman, M. D. Lunn, M. Blennow, K. Fox, N. C. Zetterberg, H. Schott, J. M. Csf in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. *Alzheimer's and dementia Conference: alzheimer's association international conference 2016 Canada Conference start: 20160722 Conference end: 20160728*. 2016;12(7 Supplement):P203-P4. 배제사유: 회색문헌(초록만 발표된 문헌)
358. Richens JLS, H. L. Butler, M. Cantlay, F. Vere, K. A. Bajaj, N. Morgan, K. O'Shea, P. Rationalising the role of Keratin 9 as a biomarker for Alzheimer's disease. *Scientific Reports*. 2016;6:22962. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
359. Rodrigues FBB, L. McColgan, P. Robertson, N. Tabrizi, S. J. Leavitt, B. R. Zetterberg, H. Wild, E. J. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. *Journal of Neurochemistry*. 2016;139(1):22-5. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
360. Sanfilippo CF, O. Zetterberg, H. Blennow, K. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. *Journal of Neural Transmission*. 2016;123(12):1443-7. 배제사유: 적절한 의료결과를 하나 이상

보고하지 않은 연구

361. Schmitz ME, E. Stoeck, K. Karch, A. Collins, S. Calero, M. Sklaviadis, T. Laplanche, J. L. Golanska, E. Baldeiras, I. Satoh, K. Sanchez-Valle, R. Ladogana, A. Skinningsrud, A. Hammarin, A. L. Mitrova, E. Llorens, F. Kim, Y. S. Green, A. Zerr, I. Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. *Molecular Neurobiology*. 2016;53(4):2189-99. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
362. Schmitz ML, F. Pracht, A. Thom, T. Correia, A. Zafar, S. Ferrer, I. Zerr, I. Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients. *Aging*. 2016;8(11):2927-35. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
363. Schuster JF, S. A. Methods for the Specific Detection and Quantitation of Amyloid-beta Oligomers in Cerebrospinal Fluid. *Journal of Alzheimer's Disease*. 2016;53(1):53-67. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
364. Sharma NS, A. N. Exploring biomarkers for Alzheimer's disease. *Journal of Clinical and Diagnostic Research*. 2016;10(7):KE01-KE6. 배제사유: 원저가 아닌 연구
365. Shi MK, A. Korff, A. Cook, T. J. Gingham, C. Bullock, K. M. Yang, L. Stewart, T. Zheng, D. Aro, P. Atik, A. Kerr, K. F. Zabetian, C. P. Peskind, E. R. Hu, S. C. Quinn, J. F. Galasko, D. R. Montine, T. J. Banks, W. A. Zhang, J. CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. *Alzheimer's and Dementia*. 2016;12(11):1125-31. 배제사유: 동물연구 또는 전임상연구
366. Simonsen AHK, B. El-Agnaf, O. M. A. Engelborghs, S. Herukka, S. K. Parnetti, L. Rektorova, I. Vanmechelen, E. Kapaki, E. Verbeek, M. Mollenhauer, B. The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. *Biomarkers in Medicine*. 2016;10(1):19-34. 배제사유: 원저가 아닌 연구
367. Somers CS, H. Goossens, J. Niemantsverdriet, E. Luyckx, J. De Roeck, N. De Roeck, E. De Vil, B. Cras, P. Martin, J. J. De Deyn, P. P. Bjerke, M. Engelborghs, S. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. *Journal of Alzheimer's Disease*. 2016;54(1):383-95. 배제사유: 원저가 아닌 연구
368. Soomro SM, C. Biomarkers for sporadic Creutzfeldt-Jakob disease. *Annals of Clinical and Translational Neurology*. 2016;3(6):465-72. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
369. Teunissen CEE, N. Koel-Simmelink, M. J. Durieux-Lu, S. Malekzadeh, A. Pham, T. V. Piersma, S. R. Beccari, T. Meeter, L. H. Dopfer, E. G. van Swieten, J. C. Jimenez, C. R. Pijnenburg, Y. A. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. *Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring*. 2016;2:86-94. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
370. Vishnu VYM, M. Garg, V. K. Mohanty, M. Goyal, M. K. Khurana, D. Mittal, B. R. Lal, V. Prabhakar, S. Hemostatic biomarkers succeed while inflammatory biomarkers fail to



differentiate vascular dementia from Alzheimer's disease. Stroke Conference: american heart association/american stroke association 2016 international stroke conference and state-of-the-science stroke nursing symposium los angeles, CA united states Conference start: 20160216 conference end: 20160219 Conference publication: (varpagings). 2016;47(no pagination). 배제사유: 회색문헌(초록만 발표된 문헌)

371. Vishnu VYM, M. Sharma, S. Mohanty, M. Goyal, M. K. Lal, V. Khandelwal, N. Mittal, B. R. Prabhakar, S. Role of plasma clusterin in Alzheimer's disease-a pilot study in a tertiary hospital in Northern India. PLoS ONE. 2016;11 (11) (no pagination)(e0166369). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
372. Vlassenko AGM, L. Jasielc, M. S. Su, Y. Gordon, B. A. Xiong, C. Holtzman, D. M. Benzinger, T. L. S. Morris, J. C. Fagan, A. M. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology. 2016;80(3):379-87. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
373. Wang HW, T. Qian, S. Ba, L. Lin, Z. Xiao, S. A Pilot Longitudinal Study on Cerebrospinal Fluid (CSF) Tau Protein in Alzheimer's Disease and Vascular Dementia. Shanghai Jingshen Yixue. 2016;28(5):271-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
374. Waragai MA, A. Trinh, I. Sekiyama, K. Takamatsu, Y. Une, K. Masliah, E. Hashimoto, M. Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease. Journal of Alzheimer's Disease. 2016;52(4):1453-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
375. Wauters MW, R. Ris, L. Internalization of the extracellular full-length tau inside Neuro2A and cortical cells is enhanced by phosphorylation. Biomolecules. 2016;6 (3) (no pagination)(36). 배제사유: 동물연구 또는 전임상연구
376. Wellington HP, R. W. Portelius, E. Tornqvist, U. Magdalinou, N. Fox, N. C. Blennow, K. Schott, J. M. Zetterberg, H. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829-35. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
377. Weston PSJP, R. W. Dickson, J. Barnes, A. Bomanji, J. B. Kayani, I. Lunn, M. P. Mummery, C. J. Warren, J. D. Rossor, M. N. Fox, N. C. Zetterberg, H. Schott, J. M. Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value over Cerebrospinal Fluid? Journal of Alzheimer's Disease. 2016;54(4):1297-302. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
378. Zimetti FC, P. Ronda, N. Favari, E. Adorni, M. P. Zanotti, I. Bernini, F. Barocco, F. Spallazzi, M. Galimberti, D. Ricci, C. Ruscica, M. Corsini, A. Ferri, N. Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer's disease. Journal of Alzheimer's Disease. 2016;55(1):315-20. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
379. Abuyaman ON, E. The soluble transcobalamin receptor (sCD320) is present in cerebrospinal fluid and correlates to dementia-related biomarkers tau proteins and amyloid-beta. Scandinavian Journal of Clinical & Laboratory Investigation. 2015;75(6):514-8. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구

380. Almeida RPS, S. A. Austin, B. P. Boots, E. A. Dowling, N. M. Gleason, C. E. Bendlin, B. B. Sager, M. A. Hermann, B. P. Zetterberg, H. Carlsson, C. M. Johnson, S. C. Asthana, S. Okonkwo, O. C. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. *JAMA Neurology*. 2015;72(6):699-706. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
381. Aschenbrenner AJB, D. A. Fagan, A. M. Duchek, J. M. Benzinger, T. L. Morris, J. C. Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. *Journal of the International Neuropsychological Society*. 2015;21(8):573-83. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
382. Barkovits KH, S. Marcus, K. MS-based methods for biomarkers of Parkinson's disease: What is the future? *Bioanalysis*. 2015;7(2):149-51. 배제사유: 원저가 아닌 연구
383. Berge GL, C. Sando, S. B. Holder, D. J. Moller, I. Aasly, J. O. Brathen, G. Savage, M. J. White, L. R. Effect of tween-20 on core biomarkers measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy control individuals. *Journal of Alzheimer's Disease*. 2015;49(2):493-502. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
384. Beriault DRD, E. P. Portelius, E. Perret-Liaudet, A. Salloway, S. Biomarkers, assays, and therapies for Alzheimer disease. *Clinical Chemistry*. 2015;61(7):903-8. 배제사유: 원저가 아닌 연구
385. Blennow KD, B. Fagan, A. M. Lewczuk, P. de Leon, M. J. Hampel, H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. *Alzheimer's & Dementia*. 2015;11(1):58-69. 배제사유: 원저가 아닌 연구
386. Blennow KZ, H. Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. *Nature Medicine*. 2015;21(3):217-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
387. Borger MF, S. Bahr, M. Grus, F. Lingor, P. Biomarker sources for Parkinson's disease: Time to shed tears? *Basal Ganglia*. 2015;5(2-3):63-9. 배제사유: 원저가 아닌 연구
388. Borroni BB, A. Archetti, S. Galimberti, D. Parnetti, L. Nacmias, B. Sorbi, S. Scarpini, E. Padovani, A. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. *Amyotrophic Lateral sclerosis & Frontotemporal Degeneration*. 2015;16(1-2):86-91. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
389. Canuet LP, S. Lopez, M. E. Bajo, R. Pineda-Pardo, J. A. Cuesta, P. Galvez, G. Gaztelu, J. M. Lourido, D. Garcia-Ribas, G. Maestu, F. Network disruption and cerebrospinal fluid amyloid-beta and phospho-tau levels in mild cognitive impairment. *Journal of Neuroscience*. 2015;35(28):10325-30. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
390. Coart EB, L. G. Duits, F. H. Scheltens, P. Van Der Flier, W. M. Teunissen, C. E. Van Der Vies, S. M. Burzykowski, T. Correcting for the Absence of a Gold Standard Improves

- Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2015;46(4):889-99. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
391. Cuchillo-Ibanez IL-F, I. Boix-Amoros, A. Brinkmalm, G. Blennow, K. Molinuevo, J. L. Saez-Valero, J. Heteromers of amyloid precursor protein in cerebrospinal fluid. *Molecular Neurodegeneration*. 2015;10:2. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
392. Cysique LAH, T. Croitoru-Lamoury, J. Taddei, K. Martins, R. N. Chew, C. S. Davies, N. N. Price, P. Brew, B. J. APOE epsilon4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. *BMC Neurology*. 2015;15:51. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
393. De Vos AJ, D. Struyfs, H. Fransen, E. Andersson, K. Portelius, E. Andreasson, U. De Sargeloose, D. Hernalsteen, D. Slegers, K. Robberecht, C. Van Broeckhoven, C. Zetterberg, H. Blennow, K. Engelborghs, S. Vanmechelen, E. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. *Alzheimer's & Dementia*. 2015;11(12):1461-9. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
394. Del Campo Milan MZ, L. Jimenez, C. R. Scheltens, P. Teunissen, C. E. Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease? *Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring*. 2015;1(1):75-80. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
395. Delaby CG, A. Blum, D. Schraen-Maschke, S. Moulinier, A. Boulanghien, J. Severac, D. Buee, L. Reme, T. Lehmann, S. Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. *Frontiers in neurology* [electronic resource]. 2015;6:181. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
396. Demeritte TN, B. P. Kanchanapally, R. Sinha, S. S. Pramanik, A. Chavva, S. R. Ray, P. C. Hybrid Graphene Oxide Based Plasmonic-Magnetic Multifunctional Nanoplatform for Selective Separation and Label-Free Identification of Alzheimer's Disease Biomarkers. *Acs Applied Materials & Interfaces*. 2015;7(24):13693-700. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
397. Diehl-Wiesenecker EvA, C. A. Dupuis, L. Muller, H. P. Ludolph, A. C. Kassubek, J. Adipose Tissue Distribution in Patients with Alzheimer's Disease: A Whole Body MRI Case-Control Study. *Journal of Alzheimer's Disease*. 2015;48(3):825-32. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
398. Duits FHH-G, M. Montaner, J. Goos, J. D. Montanola, A. Wattjes, M. P. Barkhof, F. Scheltens, P. Teunissen, C. E. van der Flier, W. M. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. *Journal of Alzheimer's Disease*. 2015;48(3):711-20. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
399. Elobeid AL, K. Cesarini, K. G. Alafuzoff, I. Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain

- biopsies of patients with normal-pressure hydrocephalus. *Journal of Neuropathology & Experimental Neurology*. 2015;74(5):470-9. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
400. Forlenza OVD, B. S. Teixeira, A. L. Radanovic, M. Talib, L. L. Rocha, N. P. Gattaz, W. F. Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease. *NeuroMolecular Medicine*. 2015;17(3):326-32. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
401. Fourier AP, E. Zetterberg, H. Blennow, K. Quadrio, I. Perret-Liaudet, A. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. *Clinica Chimica Acta*. 2015;449:9-15. 배제사유: 원저가 아닌 연구
402. Galasko D. Expanding the repertoire of biomarkers for Alzheimer's disease: Targeted and non-targeted approaches. *Frontiers in Neurology*. 2015;6 (DEC) (no pagination)(256). 배제사유: 원저가 아닌 연구
403. Galozzi SM, K. Barkovits, K. Amyloid-beta as a biomarker for Alzheimer's disease: quantification methods in body fluids. *Expert Review of Proteomics*. 2015;12(4):343-54. 배제사유: 원저가 아닌 연구
404. Giil LMK, E. K. Vedeler, C. A. Aarsland, D. Nordrehaug, J. E. Winblad, B. Cedazo-Minguez, A. Lund, A. Reksen, T. R. Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2015;47(2):523-9. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
405. Gourmaud SP, C. Dumurgier, J. Pace, C. Bouras, C. Gray, F. Laplanche, J. L. Meurs, E. F. Mouton-Liger, F. Hugon, J. Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: Links to cognitive decline. *Journal of Psychiatry and Neuroscience*. 2015;40(3):151-61. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
406. Hall AM, J. Koikkalainen, J. Lotjonen, J. Wolz, R. Scheltens, P. Frisoni, G. Tsolaki, M. Nobili, F. Freund-Levi, Y. Minthon, L. Frolich, L. Hampel, H. Visser, P. J. Soininen, H. Predicting progression from cognitive impairment to alzheimer's disease with the disease state index. *Current Alzheimer Research*. 2015;12(1):69-79. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
407. Halliday G. Progressive supranuclear palsy finally has a clinically measureable tau abnormality. *Journal of Neurology, Neurosurgery and Psychiatry*. 2015;86(3):241. 배제사유: 원저가 아닌 연구
408. Helbok RS, A. Delazer, M. Beer, R. Bodner, T. Pfäusler, B. Benke, T. Lackner, P. Fischer, M. Sohm, F. Hackl, W. Stover, J. F. Thome, C. Humpel, C. Schmutzhard, E. Cerebral tau is elevated after aneurysmal subarachnoid haemorrhage and associated with brain metabolic distress and poor functional and cognitive long-term outcome. *Journal of Neurology, Neurosurgery and Psychiatry*. 2015;86(1):79-86. 배제사유: 알츠하이머 치매의 심환자를 대상으로 수행되지 않은 연구

409. Heywood WEG, D. Bliss, E. Sirka, E. Paterson, R. W. Magdalinou, N. K. Carecchio, M. Reid, E. Heslegrave, A. Fenoglio, C. Scarpini, E. Schott, J. M. Fox, N. C. Hardy, J. Bhatia, K. Heales, S. Sebire, N. J. Zetterberg, H. Mills, K. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Molecular Neurodegeneration*. 2015;10:64. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
410. Hyeon JWK, S. Y. Lee, J. Park, J. S. Hwang, K. J. Lee, S. M. An, S. A. Lee, M. K. Ju, Y. R. Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory. *Scientific Reports*. 2015;5:15283. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
411. Inekci DH, K. Linemann, T. Karsdal, M. A. Habib, A. Bisgaard, C. Eriksen, F. B. Vilholm, O. J. Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease. *Current Alzheimer Research*. 2015;12(9):829-36. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
412. Jongbloed WvD, K. D. Mulder, S. D. van de Berg, W. D. Blankenstein, M. A. van der Flier, W. Veerhuis, R. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2015;46(4):1103-10. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
413. Kamalainen AH, S. K. Hartikainen, P. Helisalml, S. Moilanen, V. Knuuttila, A. Jansson, L. Tienari, P. J. Remes, A. M. Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion. *Dementia & Geriatric Cognitive Disorders*. 2015;39(5-6):287-93. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
414. Kang JHK, M. Figurski, M. J. Toledo, J. B. Blennow, K. Zetterberg, H. Waligorska, T. Brylska, M. Fields, L. Shah, N. Soares, H. Dean, R. A. Vanderstichele, H. Petersen, R. C. Aisen, P. S. Saykin, A. J. Weiner, M. W. Trojanowski, J. Q. Shaw, L. M. Alzheimer's Disease Neuroimaging, Initiative. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. *Alzheimer's & Dementia*. 2015;11(7):772-91. 배제사유: 원저가 아닌 연구
415. Khatoon SC, S. Bolognin, S. Puolivali, J. Iqbal, K. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. *Journal of Alzheimer's Disease*. 2015;47(3):557-64. 배제사유: 동물연구 또는 전임상연구
416. Koper OMK, J. Kemon, H. Dymicka-Piekarska, V. Application of the Bead-Based Technique in Neurodegeneration: A Literature Review. *Neurodegenerative Diseases*. 2015;15(5):281-93. 배제사유: 원저가 아닌 연구
417. Kristofikova ZR, J. Vyhnalek, M. Hort, J. Lacz, J. Sirova, J. Klaschka, J. Ripova, D. Levels of 17beta-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias. *Journal of Alzheimer's Disease*. 2015;48(1):105-14. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
418. Kvartsberg HD, F. H. Ingelsson, M. Andreasen, N. Ohrfelt, A. Andersson, K. Brinkmalm,

- G. Lannfelt, L. Minthon, L. Hansson, O. Andreasson, U. Teunissen, C. E. Scheltens, P. Van Der Flier, W. M. Zetterberg, H. Portelius, E. Blennow, K. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. *Alzheimer's and Dementia*. 2015;11(10):1180-90. 배제사유: 인산화타우 단백질 [효소면역검사]를 수행하지 않은 연구
419. Le Bastard NDD, P. P. Engelborghs, S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. *Clinical Chemistry*. 2015;61(5):734-43. 배제사유: 동물연구 또는 전임상연구
420. Lehmann SD, C. Paquet, C. Gabelle, A. Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. *Clinical Chemistry & Laboratory Medicine*. 2015;53(8):e175-7. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
421. Li NW, J. Ma, J. Gu, Z. Jiang, C. Yu, L. Fu, X. Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer's Disease. *Evidence-based Complementary and Alternative Medicine*. 2015;2015 (no pagination)(103985). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
422. Li QXV, V. L. Doecke, J. D. Rembach, A. Sarros, S. Varghese, S. McGlade, A. Laughton, K. M. Pertile, K. K. Fowler, C. J. Rumble, R. L. Trounson, B. O. Taddei, K. Rainey-Smith, S. R. Laws, S. M. Robertson, J. S. Evered, L. A. Silbert, B. Ellis, K. A. Rowe, C. C. Macaulay, S. L. Darby, D. Martins, R. N. Ames, D. Masters, C. L. Collins, S. Aibl Research Group. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-beta Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. *Journal of Alzheimer's Disease*. 2015;48(1):175-87. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
423. Llorens FK, N. Schmitz, M. Shafiq, M. da Cunha, J. E. Gotzman, N. Zafar, S. Thune, K. de Oliveira, J. R. Mollenhauer, B. Zerr, I. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD. *Journal of Neurology*. 2015;262(10):2305-11. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
424. Lovestone SB, M. Dubois, B. Hull, M. Rinne, J. O. Huppertz, H. J. Calero, M. Andres, M. V. Gomez-Carrillo, B. Leon, T. del Ser, T. Argo investigators. A phase II trial of tideglusib in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2015;45(1):75-88. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
425. Luo XS, H. Hou, L. Zhong, X. Chen, X. Zhang, Y. Zheng, D. Tan, Y. Hu, G. Mu, N. Chen, J. Fang, Y. He, H. Ning, Y. Different cerebrospinal fluid levels of Alzheimer-type biomarker Abeta42 between general paresis and asymptomatic neurosyphilis. *European Journal of Neurology*. 2015;22(5):853-8. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
426. Mroczko BG, M. Zboch, M. Muszynski, P. Zajkowska, A. Borawska, R. Szmikowski, M. Kornhuber, J. Lewczuk, P. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker

- of Alzheimer's disease. *Journal of Alzheimer's Disease*. 2015;43(3):1031-7. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
427. Mukaetova-Ladinska EBL, M. Kalaria, R. N. Tau protein, ischemic injury and vascular dementia. *Future Neurology*. 2015;10(6):559-75. 배제사유: 적절한 의료결과를 하나 이상 보고 하지 않은 연구
428. Muller MC, J. A. Kuiperij, H. B. Verbeek, M. M. Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study. *Journal of Alzheimer's Disease*. 2015;46(3):605-9. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
429. Olah ZK, J. Toth, M. E. Zvara, A. Santha, M. Ivitz, E. Janka, Z. Pakaski, M. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive. *Journal of Alzheimer's Disease*. 2015;44(4):1303-12. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행 되지 않은 연구
430. Paquet CD, J. Hugon, J. Pro-apoptotic kinase levels in cerebrospinal fluid as potential future biomarkers in Alzheimer's disease. *Frontiers in Neurology*. 2015;6 (Aug) (no pagination)(168). 배제사유: 원저가 아닌 연구
431. Ritter AC, J. Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics. *Frontiers in Neurology*. 2015;6 (Aug) (no pagination)(186). 배제사유: 원저가 아닌 연구
432. Rogeberg MA, I. S. Wettergreen, M. Nilsson, L. N. Fladby, T. Isobaric Quantification of Cerebrospinal Fluid Amyloid-beta Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. *Journal of Proteome Research*. 2015;14(11):4834-43. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
433. Rohan ZS, M. Kukal, J. Rusina, R. Matej, R. Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases. *BMC Neurology*. 2015;15:50. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
434. Rosseels JVdB, J. Violet, M. Jacobs, D. Grognet, P. Lopez, J. Huvent, I. Caldara, M. Swinnen, E. Papegaey, A. Caillierez, R. Buee-Scherrer, V. Engelborghs, S. Lippens, G. Colin, M. Buee, L. Galas, M. C. Vanmechelen, E. Winderickx, J. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. *Journal of Biological Chemistry*. 2015;290(7):4059-74. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
435. Rubenstein RC, B. Davies, P. Wagner, A. K. Robertson, C. S. Wang, K. K. A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids. *Journal of Neurotrauma*. 2015;32(5):342-52. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
436. Sarlus HE, H. Eriksdotter, M. Oprica, M. Schultzberg, M. Influence of Allergy on Immunoglobulins and Amyloid-beta in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2015;48(2):495-505. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구

437. Savage MJH, D. J. Wu, G. Kaplow, J. Siuciak, J. A. Potter, W. Z. Foundation for National Institutes of Health Biomarkers Consortium, C. S. F. Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative. Soluble BACE-1 Activity and sAbetaPPbeta Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort. *Journal of Alzheimer's Disease*. 2015;46(2):431-40. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
438. Schaffer CS, N. DeCrumpe, A. Goswami, D. Herrmann, S. Morales, J. Patel, P. Osborne, J. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease. *Journal of Laboratory Automation*. 2015;20(5):589-600. 배제사유: 원저가 아닌 연구
439. Scheltens PN, T. Lasser, R. Ostrowitzki, S. Boada, M. Dubois, B. Dorflinger, E. Volz, D. Eichenlaub, U. Rabe, C. et al. . Biomarker data from scarlet road: a global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. *Alzheimer's & dementia*. 2015;11(7 SUPPL. 1):P331. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
440. Schmitz MH, P. Oikonomou, P. Stoeck, K. Ebert, E. Poliakova, T. Schmidt, C. Llorens, F. Zafar, S. Zerr, I. Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy. *Neurobiology of Aging*. 2015;36(9):2597-606. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
441. Sjodin SA, K. K. A. Mercken, M. Zetterberg, H. Borghys, H. Blennow, K. Portelius, E. APLP1 as a cerebrospinal fluid biomarker for  $\gamma$ -secretase modulator treatment. *Alzheimer's research & therapy*. 2015;7(1). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
442. Skillback TF, B. Y. Rosen, C. Mattsson, N. Nagga, K. Kilander, L. Religa, D. Wimo, A. Winblad, B. Schott, J. M. Blennow, K. Eriksdotter, M. Zetterberg, H. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. *Brain*. 2015;138(Pt 9):2716-31. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
443. Slemmon JRS, A. Mercken, M. Streffer, J. Romano, G. Andreasen, N. Zetterberg, H. Blennow, K. Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with A $\beta$ 42 and influence of disease on the total-A $\beta$ 42/A $\beta$ 40 ratio. *Journal of Neurochemistry*. 2015;135(5):1049-58. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
444. Song LL, S. X. Ouyang, X. Melchor, J. Lee, J. Terracina, G. Wang, X. Hyde, L. Hess, J. F. Parker, E. M. Zhang, L. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. *Molecular Neurodegeneration*. 2015;10:14. 배제사유: 동물 연구 또는 전임상연구
445. Spiegel JP, E. Osorio, R. S. Glodzik, L. Li, Y. Tsui, W. Saint Louis, L. A. Randall, C. Butler, T. Xu, J. Zinkowski, R. P. Zetterberg, H. Fortea, J. Fossati, S. Wisniewski, T. Davies, P. Blennow, K. De Leon, M. J. Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2015;49(1):93-100. 배제사유: 알츠하이머 치매 의심 환자를 대상으로 수행되지 않은 연구



446. Sutphen CLJ, M. S. Shah, A. R. Macy, E. M. Xiong, C. Vlassenko, A. G. Benzinger, T. L. S. Stoops, E. E. J. Vanderstichele, H. M. J. Brix, B. Darby, H. D. Vandijck, M. L. J. Ladenson, J. H. Morris, J. C. Holtzman, D. M. Fagan, A. M. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. *JAMA Neurology*. 2015;72(9):1029-42. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
447. Tiepolt SP, M. Hoffmann, K. T. Schroeter, M. L. Sabri, O. Barthel, H. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject. *Journal of Alzheimer's Disease*. 2015;47(3):539-43. 배제사유: 사전에 정의한 연구설계가 아닌 문헌
448. Tiraboschi JMM-M, J. A. Puertas, M. C. Alonso-Villaverde, C. Prats, A. Ferrer, E. Rozas, N. Maso, M. Ouchi, D. Martinez-Picado, J. Podzamczar, D. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. *HIV Medicine*. 2015;16(6):388-92. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
449. Toledo JBZ, H. Van Harten, A. C. Glodzik, L. Martinez-Lage, P. Bocchio-Chiavetto, L. Rami, L. Hansson, O. Sperling, R. Engelborghs, S. Osorio, R. S. Vanderstichele, H. Vandijck, M. Hampel, H. Teipl, S. Moghekar, A. Albert, M. Hu, W. T. Monge Argiles, J. A. Gorostidi, A. Teunissen, C. E. De Deyn, P. P. Hyman, B. T. Molinuevo, J. L. Frisoni, G. B. Linazasoro, G. De Leon, M. J. Van Der Flier, W. M. Scheltens, P. Blennow, K. Shaw, L. M. Trojanowski, J. Q. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. *Brain*. 2015;138(9):2701-15. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
450. Travassos MS, I. Baldeiras, I. Tsolaki, M. Gkatzima, O. Sermin, G. Yener, G. G. Simonsen, A. Hasselbalch, S. G. Kapaki, E. Mara, B. Cunha, R. A. Agostinho, P. Blennow, K. Zetterberg, H. Mendes, V. M. Manadas, B. de Mendon, A. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-beta Levels in Patients with Alzheimer's Disease? *Journal of Alzheimer's Disease*. 2015;47(4):1069-78. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
451. Wang XZ, M. Hjorth, E. Cortes-Toro, V. Eyjolfsdottir, H. Graff, C. Nennesmo, I. Palmblad, J. Eriksdotter, M. Sambamurti, K. Fitzgerald, J. M. Serhan, C. N. Granholm, A. C. Schultzberg, M. Resolution of inflammation is altered in Alzheimer's disease. *Alzheimer's & Dementia*. 2015;11(1):40-50. e1-2. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
452. Wennstrom MH, S. Nagga, K. Londos, E. Minthon, L. Hansson, O. Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. *Alzheimer's Research & Therapy*. 2015;7(1):63. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
453. Wennstrom MS, Y. Hall, S. Nilsson, C. Minthon, L. Hansson, O. Nielsen, H. M. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies. *PLoS ONE*.

- 2015;10 (8) (no pagination)(e0135458). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
454. Weston PSJP, R. W. Modat, M. Burgos, N. Cardoso, M. J. Magdalinou, N. Lehmann, M. Dickson, J. C. Barnes, A. Bomanji, J. B. Kayani, I. Cash, D. M. Ourselin, S. Toombs, J. Lunn, M. P. Mummery, C. J. Warren, J. D. Rossor, M. N. Fox, N. C. Zetterberg, H. Schott, J. M. Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2015;1(4):440-6. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
455. Wild EJB, R. Langbehn, D. Robertson, N. Haider, S. Miller, J. R. Zetterberg, H. Leavitt, B. R. Kuhn, R. Tabrizi, S. J. Macdonald, D. Weiss, A. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. *Journal of Clinical Investigation*. 2015;125(5):1979-86. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
456. Wilke CD, C. Rattay, T. W. Maetzler, W. Synofzik, M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. *Neurobiology of Aging*. 2015;36(2):1072-4. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
457. Xu WY, Y. Yuan, G. Zhu, W. Ma, D. Hu, S. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. *Journal of Investigative Medicine*. 2015;63(2):267-72. 배제사유: 동물연구 또는 전임상연구
458. Yamada KP, T. K. Hochgrafe, K. Mahan, T. E. Jiang, H. Stewart, F. R. Mandelkow, E. M. Holtzman, D. M. Analysis of in vivo turnover of tau in a mouse model of tauopathy. *Molecular Neurodegeneration*. 2015;10 (1) (no pagination)(55). 배제사유: 동물연구 또는 전임상연구
459. Zhang WIA, G. Rabano, A. Bayer, T. A. Schneider, A. Rizzoli, S. O. Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool for Alzheimer's Disease Diagnostics. *Journal of Alzheimer's Disease*. 2015;46(4):1007-20. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
460. Zhou YZ, Y. Xie, H. Wang, Y. Liu, L. Yan, X. Alteration in amyloid beta42, phosphorylated tau protein, interleukin 6, and acetylcholine during diabetes-accelerated memory dysfunction in diabetic rats: correlation of amyloid beta42 with changes in glucose metabolism. *Behavioral & Brain Functions [Electronic Resource]: BBF*. 2015;11:24. 배제사유: 동물연구 또는 전임상연구
461. Alves GL, J. Blennow, K. Zetterberg, H. Andreasson, U. Forland, M. G. Tysnes, O. B. Larsen, J. P. Pedersen, K. F. CSF Abeta42 predicts early-onset dementia in Parkinson disease. *Neurology*. 2014;82(20):1784-90. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
462. Amadoro GC, V. Sancesario, G. M. Lubrano, A. Melchiorri, G. Bernardini, S. Calissano, P. Sancesario, G. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.

- Journal of Alzheimer's Disease. 2014;42(1):211-26. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
463. Antonell AM, A. Rami, L. Llado, A. Iranzo, A. Olives, J. Balasa, M. Sanchez-Valle, R. Molinuevo, J. L. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. Journal of Alzheimer's Disease. 2014;42(3):901-8. 배제사유: 인산화타우 단백질 [효소면역검사]를 수행하지 않은 연구
464. Babic MS, D. S. Muck-Seler, D. Pivac, N. Stanic, G. Hof, P. R. Simic, G. Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croatian Medical Journal. 2014;55(4):347-65. 배제사유: 원저가 아닌 연구
465. Bagyinszky EY, Y. C. An, S. S. A. Kim, S. Diagnostic methods and biomarkers for alzheimer's disease. Toxicology and Environmental Health Sciences. 2014;6(3):133-47. 배제사유: 원저가 아닌 연구
466. Berenguer RGMA, J. A. Ruiz, C. M. Paya, J. S. Blanco Canto, M. A. Santana, C. L. Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years. Alzheimer Disease & Associated Disorders. 2014;28(3):234-8. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
467. Blanc FP, N. Cretin, B. Kleitz, C. Berly, L. Jung, B. Kremer, S. Namer, I. J. Sellal, F. Jaulhac, B. De Seze, J. Lyme neuroborreliosis and dementia. Journal of Alzheimer's Disease. 2014;41(4):1087-93. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
468. Blennow KH, H. Zetterberg, H. Biomarkers in amyloid-beta immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology. 2014;39(1):189-201. 배제사유: 인산화타우 단백질 [효소면역검사]를 수행하지 않은 연구
469. Borroni BB, A. Cosseddu, M. Archetti, S. Padovani, A. Cerebrospinal fluid tau levels predict prognosis in non-inherited frontotemporal dementia. Neurodegenerative Diseases. 2014;13(4):224-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
470. Chen-Plotkin AS. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron. 2014;84(3):594-607. 배제사유: 원저가 아닌 연구
471. Coppi EF, L. Santangelo, R. Caso, F. Pinto, P. Passerini, G. Comi, G. Magnani, G. Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy. Neurological Sciences. 2014;35(5):785-7. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
472. Coulthart MBJ, G. H. Cashman, N. R. Interpretation of cerebrospinal fluid protein tests in the diagnosis of sporadic Creutzfeldt-Jakob disease: An evidence-based approach. Cmaj. 2014;186(9):E333-E9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
473. De Riva VG, E. Marcon, M. Di Dionisio, L. Deluca, C. Meligrana, L. Bolner, A. Perini, F. Analysis of combined CSF biomarkers in AD diagnosis. Clinical Laboratory. 2014;60(4):629-34. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
474. Dumurgier JL, J. L. Mouton-Liger, F. Lapalus, P. Indart, S. Prevot, M. Peoc'h, K. Hugon, J. Paquet, C. The screening of Alzheimer's patients with CSF biomarkers, modulates the

- distribution of APOE genotype: impact on clinical trials. *Journal of Neurology*. 2014;261(6):1187-95. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
475. Endres KF, F. Lotz, J. Hiemke, C. Teipel, S. Lieb, K. Tuscher, O. Fellgiebel, A. Increased CSF APPs-a levels in patients with Alzheimer disease treated with acitretin. *Neurology*. 2014;83(21):1930-5. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
476. Fagan AMX, C. Jasielec, M. S. Bateman, R. J. Goate, A. M. Benzinger, T. L. Ghetti, B. Martins, R. N. Masters, C. L. Mayeux, R. Ringman, J. M. Rossor, M. N. Salloway, S. Schofield, P. R. Sperling, R. A. Marcus, D. Cairns, N. J. Buckles, V. D. Ladenson, J. H. Morris, J. C. Holtzman, D. M. Dominantly Inherited Alzheimer, Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Science Translational Medicine*. 2014;6(226):226ra30. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
477. Gil-Gregorio PY-P, R. Preclinical Alzheimer's disease. *Reviews in Clinical Gerontology*. 2014;24(2):117-21. 배제사유: 원저가 아닌 연구
478. Hanzel CEI, M. F. Eyjolfsdottir, H. Hjorth, E. Schultzberg, M. Eriksdotter, M. Cuello, A. C. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. *Journal of Alzheimer's Disease*. 2014;40(3):667-78. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
479. Harari OC, C. Kauwe, J. S. Ainscough, B. J. Bales, K. Pickering, E. H. Bertelsen, S. Fagan, A. M. Holtzman, D. M. Morris, J. C. Goate, A. M. Alzheimer's Disease Neuroimaging, Initiative. Phosphorylated tau-Abeta42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. *Biological Psychiatry*. 2014;75(9):723-31. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
480. Heegaard NHHT, J. T. Bech, S. Salvesen, L. Jensen, P. L. Montezinho, L. C. P. Winge, K. Cerebrospinal fluid alpha-synuclein in the differential diagnosis of parkinsonian syndromes. *Future Neurology*. 2014;9(5):525-32. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
481. Herbert MKA, M. B. Kuiperij, H. B. Claassen, J. A. H. R. Spies, P. E. Esselink, R. A. J. Bloem, B. R. Verbeek, M. M. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. *Alzheimer's and Dementia*. 2014;10(4):448-55. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
482. Hertze JN, K. Minthon, L. Hansson, O. Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. *BMC Neurology*. 2014;14:64. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
483. Iulita MFA, S. Richter, L. Munter, L. M. Ducatenzeiler, A. Weise, C. Do Carmo, S. Klein, W. L. Multhaup, G. Cuello, A. C. Intracellular Abeta pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. *Acta Neuropathologica Communications*. 2014;2:61. 배제사유: 동물연구 또는 전임상연구

484. Kaerst LK, A. Wedekind, D. Stoeck, K. Lange, P. Zerr, I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. *Journal of Alzheimer's Disease*. 2014;38(1):63-73. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
485. Kalm MA, E. Wasling, P. Nyman, J. Hietala, M. A. Bremell, D. Hagberg, L. Elam, M. Blennow, K. Bjork-Eriksson, T. Zetterberg, H. Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. *International Journal of Radiation Oncology Biology Physics*. 2014;89(3):607-14. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
486. Kang JHK, M. Toledo, J. B. Trojanowski, J. Q. Shaw, L. M. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta1-42 and tau proteins as Alzheimer disease biomarkers. [Italian]. *Biochimica Clinica*. 2014;38(3):255-67. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
487. Kasai TT, T. Ishii, R. Ishigami, N. Tsuboi, Y. Nakagawa, M. Mizuno, T. El-Agnaf, O. M. Increased alpha-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. *Journal of Neurology*. 2014;261(6):1203-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
488. Klener JH, K. Bartos, A. Ricny, J. Ripova, D. Kopecky, V. Instability of cerebrospinal fluid after delayed storage and repeated freezing: a holistic study by drop coating deposition Raman spectroscopy. *Clinical Chemistry & Laboratory Medicine*. 2014;52(5):657-64. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
489. Kristofikova ZR, J. Kolarova, M. Vyhnaek, M. Hort, J. Laczko, J. Sirova, J. Ripova, D. Interactions between amyloid-beta and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease. *Journal of Alzheimer's Disease*. 2014;42 Suppl 3:S91-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
490. Lim TSC, J. Y. Park, S. A. Youn, Y. C. Lee, H. Y. Kim, B. G. Joo, I. S. Huh, K. Moon, S. Y. Evaluation of coexistence of Alzheimer's disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers. *BMC Neurology*. 2014;14:66. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
491. Magdalino NL, A. J. Zetterberg, H. Cerebrospinal fluid biomarkers in parkinsonian conditions: An update and future directions. *Journal of Neurology, Neurosurgery and Psychiatry*. 2014;85(10):1065-75. 배제사유: 원저가 아닌 연구
492. McAvoy TL, M. E. Spellman, D. S. Ke, Z. Howell, B. J. Wong, O. Zhu, L. Tanen, M. Struyk, A. Laterza, O. F. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. *Clinical Chemistry*. 2014;60(4):683-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
493. Mizoi MY, M. Saiki, R. Waragai, M. Uemura, K. Akatsu, H. Kashiwagi, K. Igarashi, K. Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid beta40 and beta42, and protein-conjugated acrolein. *Clinica Chimica Acta*. 2014;430:150-5. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구

494. Monacelli FB, R. Pacini, D. Serrati, C. Traverso, N. Odetti, P. Pentosidine determination in CSF: A potential biomarker of Alzheimer's disease? *Clinical Chemistry and Laboratory Medicine*. 2014;52(1):117-20. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
495. Monge Argiles JABC, M. A. Leiva Salinas, C. Flors, L. Munoz Ruiz, C. Sanchez Paya, J. Gasparini Berenguer, R. Leiva Santana, C. A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid. *Neurologia*. 2014;29(7):397-401. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
496. Mroczko BG, M. Zboch, M. Kulczynska, A. Koper, O. M. Szmitkowski, M. Kornhuber, J. Lewczuk, P. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. *Journal of Alzheimer's Disease*. 2014;40(2):351-7. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
497. Namiki CH, A. Siemers, E. Carlson, C. Sundell, K. Henley, D. Eads, J. Sexton, C. Liu-Seifert, H. Sethuraman, G. et al. . Effects of solanezumab on biomarkers in patients with Alzheimer's disease. *Clinical neurology*. 2014;Conference: 55th Annual Meeting of the Japanese Society of Neurology. Japan. 54(pp S223). 배제사유: 회색문헌(초록만 발표된 문헌)
498. Nishida H. Biomarkers for neural injury and infection in small animals. *Veterinary Clinics of North America - Small Animal Practice*. 2014;44(6):1187-99. 배제사유: 동물연구 또는 전임상연구
499. Nishida NN, N. Toda, H. Jingami, N. Uemura, K. Ozaki, A. Mase, M. Urade, Y. Matsumoto, S. Iwasaki, K. Ishikawa, M. Association of lipocalin-type prostaglandin D synthase with disproportionately enlarged subarachnoid-space in idiopathic normal pressure hydrocephalus. *Fluids and Barriers of the CNS*. 2014;11 (1) (no pagination)(9). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
500. Ouwens DMvD, E. Schoonenboom, S. N. Herzfeld de Wiza, D. Klein, M. van Golen, L. Pouwels, P. J. Barkhof, F. Moll, A. C. Snoek, F. J. Teunissen, C. E. Scheltens, P. Diamant, M. Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. *Diabetologia*. 2014;57(10):2208-14. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
501. Palmqvist SZ, H. Blennow, K. Vestberg, S. Andreasson, U. Brooks, D. J. Owenius, R. Hagerstrom, D. Wollmer, P. Minthon, L. Hansson, O. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. *JAMA Neurology*. 2014;71(10):1282-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
502. Portelius ES, H. Andreasson, U. Zetterberg, H. Persson, R. Karlsson, G. Blennow, K. Herukka, S. K. Mattsson, N. Exploring alzheimer molecular pathology in down's syndrome cerebrospinal fluid. *Neurodegenerative Diseases*. 2014;14(2):98-106. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
503. Richens JLV, K. A. Light, R. A. Soria, D. Garibaldi, J. Smith, A. D. Warden, D. Wilcock, G. Bajaj, N. Morgan, K. O'Shea, P. Practical detection of a definitive biomarker panel

- for Alzheimer's disease: comparisons between matched plasma and cerebrospinal fluid. *International Journal of Molecular Epidemiology and Genetics*. 2014;5(2):53-70. 배제사유: 동물연구 또는 전임상연구
504. Schmidt FMM, R. Stach, B. Jahn, I. Gertz, H. J. Schonknecht, P. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease. *Neuroscience Letters*. 2014;570:81-5. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
505. Seppala TTL, U. M. Appelberg, B. Herukka, S. K. Juva, K. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS). *American Journal of Geriatric Psychiatry*. 2014;22(9):908-16. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
506. Shea YFC, L. W. Mok, M. Y. M. Lam, M. F. Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease. *Journal of Nephrology*. 2014;27(2):217-20. 배제사유: 사전에 정의한 연구설계가 아닌 문헌
507. Stegurova LD, E. Bartos, A. Draber, P. Ripova, D. Draber, P. Gold nanoparticle-based immuno-PCR for detection of tau protein in cerebrospinal fluid. *Journal of Immunological Methods*. 2014;406:137-42. 배제사유: 동물연구 또는 전임상연구
508. Stoeck KS, M. Ebert, E. Schmidt, C. Zerr, I. Immune responses in rapidly progressive dementia: A comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis. *Journal of Neuroinflammation*. 2014;11 (1) (no pagination)(170). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
509. Struyfs HM, J. L. Martin, J. J. De Deyn, P. P. Engelborghs, S. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. *Journal of Alzheimer's Disease*. 2014;41(3):903-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
510. Sun QH, H. Blennow, K. Lista, S. Levey, A. Tang, B. Li, R. Shen, Y. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. *Journal of Alzheimer's Disease*. 2014;41(3):877-86. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
511. Toledo JBK, A. Shaw, L. M. Trojanowski, J. Q. Zhang, J. Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. *Alzheimer's Research and Therapy*. 2014;6 (3) (no pagination)(36). 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
512. Vos SJV, P. J. Verhey, F. Aalten, P. Knol, D. Ramakers, I. Scheltens, P. Rikkert, M. G. Verbeek, M. M. Teunissen, C. E. Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. *PLoS ONE [Electronic Resource]*. 2014;9(6):e100784. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
513. Vranova HPH, E. Kaiserova, M. Mensikova, K. Vastik, M. Mares, J. Hlustik, P. Zapletalova, J. Strnad, M. Stejskal, D. Kanovsky, P. Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. *Journal of the Neurological Sciences*. 2014;343(1-2):120-4. 배제사유: 인산화타우

단백 [효소면역검사]를 수행하지 않은 연구

514. Xie JG, A. Dorey, A. Garnier-Crussard, A. Perret-Liaudet, A. Delphin-Combe, F. Bathsavanis, A. Dauphinot, V. Lehmann, S. Mercier, B. Desestret, V. Rouillet-Solignac, I. Vighetto, A. Krolak-Salmon, P. Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature. *Journal of Alzheimer's Disease*. 2014;41(4):1109-16. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
515. Xie ZS, C. A. Ward, S. A. P. Zheng, H. Dong, Y. Sunder, N. Burke, D. W. Escobar, D. Zhang, Y. Marcantonio, E. R. Preoperative cerebrospinal fluid beta-Amyloid/Tau ratio and postoperative delirium. *Annals of Clinical and Translational Neurology*. 2014;1(5):319-28. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
516. Yue FL, C. Ai, Y. Chan, P. Zhang, Z. Age-associated changes of cerebrospinal fluid amyloid-beta and tau incynomolgus monkeys. *Neurobiology of Aging*. 2014;35(7):1656-9. 배제사유: 동물연구 또는 전임상연구
517. Arenaza-Urquijo EMM, J. L. Sala-Llonch, R. Sole-Padullés, C. Balasa, M. Bosch, B. Olives, J. Antonell, A. Llado, A. Sanchez-Valle, R. Rami, L. Bartres-Faz, D. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-beta levels. *Journal of Alzheimer's Disease*. 2013;35(4):715-26. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
518. Babic MV, Z. Diana, A. Klepac, N. Borovecki, F. Hof, P. R. Simic, G. Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid beta<sup>1-42</sup> and total tau. *Translational Neuroscience*. 2013;4(2):234-40. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
519. Barao SZ, L. Adamczuk, K. Vanhoutvin, T. van Leuven, F. Demedts, D. Vijverman, A. C. Bossuyt, X. Vandenberghe, R. De Strooper, B. BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. *Current Alzheimer Research*. 2013;10(7):671-8. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
520. Berger MM, D. Mathew, J. Newman, M. James, M. The effect of propofol versus isoflurane anesthesia on human csf markers of alzheimer's disease-preliminary results of a randomized controlled trial. *Anesthesia and analgesia*. 2013;116. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
521. Brinkmalm GB, A. Bourgeois, P. Persson, R. Hansson, O. Portelius, E. Mercken, M. Andreasson, U. Parent, S. Lipari, F. Ohrfelt, A. Bjerke, M. Minthon, L. Zetterberg, H. Blennow, K. Nutu, M. Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease. *Brain Research*. 2013;1513:117-26. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
522. Carrillo MCB, K. Soares, H. Lewczuk, P. Mattsson, N. Oberoi, P. Umek, R. Vandijck, M. Salamone, S. Bittner, T. Shaw, L. M. Stephenson, D. Bain, L. Zetterberg, H. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. *Alzheimer's and Dementia*. 2013;9(2):137-40. 배제사유: 원저가 아닌 연구



523. d'Abramo CA, C. M. Jimenez, H. T. Davies, P. Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. PLoS ONE. 2013;8 (4) (no pagination)(e62402). 배제사유: 동물연구 또는 전임상연구
524. Dasararaju RA, R. A. Primary adrenal lymphoma with paraneoplastic syndrome. North American Journal of Medical Sciences. 2013;5(12):721-3. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
525. Dean RS, E. Carlson, C. Estergard, W. Sundell, K. Henley, D. Hake, A. Eads, J. Sexton, C. Liu-Seifert, H. et al. . Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: results from two phase III clinical trials. Alzheimer's & dementia. 2013;9(4 SUPPL. 1):P283. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
526. Dehdashti SJZ, W. Gevertz, J. R. Wilhelm, R. Nguyen, D. T. Sittampalam, G. McKew, J. C. Austin, C. P. Prusiner, S. B. A high-throughput screening assay for determining cellular levels of total tau protein. Current Alzheimer Research. 2013;10(7):679-87. 배제사유: 동물연구 또는 전임상연구
527. Dehlin MB, J. Erlandsson, M. Andreassen, N. Zetterberg, H. Mannerkorpi, K. Bokarewa, M. Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjogren's syndrome. Scandinavian Journal of Rheumatology. 2013;42(5):394-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
528. Du Pasquier RAJ, S. Kalubi, M. Yerly, S. Fux, C. A. Gutmann, C. Cusini, A. Gunthard, H. F. Cavassini, M. Vernazza, P. L. Swiss, H. I. V. Cohort Study. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS. 2013;27(2):203-10. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
529. Forlenza OVD, B. S. Teixeira, A. L. Stella, F. Gattaz, W. Mild cognitive impairment (part 2): Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. Revista Brasileira de Psiquiatria. 2013;35(3):284-94. 배제사유: 원저가 아닌 연구
530. Frigerio CSL, P. Salta, E. Tournoy, J. Bossers, K. Vandenberghe, R. Wallin, A. Bjerke, M. Zetterberg, H. Blennow, K. De Strooper, B. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology. 2013;81(24):2103-6. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
531. Gil-Navarro SL, A. Rami, L. Castellvi, M. Bosch, B. Bargallo, N. Lomena, F. Rene, R. Montagut, N. Antonell, A. Molinuevo, J. L. Sanchez-Valle, R. Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. Dementia and Geriatric Cognitive Disorders. 2013;35(1-2):106-17. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
532. Herskovits AZL, J. J. Peskind, E. R. Li, G. Hyman, B. T. A Luminex assay detects amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. PLoS ONE [Electronic Resource]. 2013;8(7):e67898. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구

533. Hu SHJ, T. Yang, S. S. Yang, Y. Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. *Experimental and Clinical Endocrinology and Diabetes*. 2013;121(4):220-4. 배제사유: 동물연구 또는 전임상연구
534. Ikeda MY, K. Kakuda, S. Tashiro, Y. Fujita, Y. Takai, E. Hashimoto, Y. Makioka, K. Furuta, N. Ishiguro, K. Maruki, R. Yoshida, J. Miyaguchi, O. Tsukie, T. Kuwano, R. Yamazaki, T. Yamaguchi, H. Amari, M. Takatama, M. Harigaya, Y. Okamoto, K. Cerebrospinal fluid levels of phosphorylated tau and Abeta1-38/Abeta1-40/Abeta1-42 in Alzheimer's disease with PS1 mutations. *Amyloid*. 2013;20(2):107-12. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
535. Jantaratnotai NL, A. Cheng, J. Schwab, C. McGeer, P. L. McLarnon, J. G. Upregulation and expression patterns of the angiogenic transcription factor ets-1 in Alzheimer's disease brain. *Journal of Alzheimer's Disease*. 2013;37(2):367-77. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
536. Kang JHK, M. Toledo, J. B. Trojanowski, J. Q. Shaw, L. M. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers. *Clinical Chemistry*. 2013;59(6):903-16. 배제사유: 원저가 아닌 연구
537. Kouzuki MA, F. Taniguchi, M. Musha, T. Urakami, K. The relationship between the diagnosis method of neuronal dysfunction (DIMENSION) and brain pathology in the early stages of Alzheimer's disease. *Psychogeriatrics: The Official Journal of the Japanese Psychogeriatric Society*. 2013;13(2):63-70. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
538. Kristofikova ZR, D. Bartos, A. Bockova, M. Hegnerova, K. Ricny, J. Cechova, L. Vrajova, M. Homola, J. Neuroinflammation and complexes of 17beta-hydroxysteroid dehydrogenase type 10--amyloid beta in Alzheimer's disease. *Current Alzheimer Research*. 2013;10(2):165-73. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
539. Krut JJZ, H. Blennow, K. Cinque, P. Hagberg, L. Price, R. W. Studahl, M. Gisslen, M. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. *Journal of Neurology*. 2013;260(2):620-6. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
540. Liu ZC, H. H. Li, T. L. Xu, L. Du, H. Q. A cross-sectional study on cerebrospinal fluid biomarker levels in cognitively normal elderly subjects with or without a family history of Alzheimer's disease. *CNS Neuroscience & Therapeutics*. 2013;19(1):38-42. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
541. Luo XH, L. Shi, H. Zhong, X. Zhang, Y. Zheng, D. Tan, Y. Hu, G. Mu, N. Chan, J. Chen, X. Fang, Y. Wu, F. He, H. Ning, Y. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. *Journal of Neurochemistry*. 2013;127(5):681-90. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
542. Maarouf CLB, T. G. Adler, C. H. Malek-Ahmadi, M. Kokjohn, T. A. Dugger, B. N.

- Walker, D. G. Shill, H. A. Jacobson, S. A. Sabbagh, M. N. Roher, A. E. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. *Biomarker Insights*. 2013;8:19-28. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
543. Maftai MT, F. Schnack, C. Tumani, H. Otto, M. Elbert, T. Kolassa, I. T. Przybylski, M. Manea, M. von Arnim, C. A. F. Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients. *PLoS ONE*. 2013;8 (7) (no pagination)(e68996). 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
544. Mattsson NA, U. Persson, S. Carrillo, M. C. Collins, S. Chalbot, S. Cutler, N. Dufour-Rainfray, D. Fagan, A. M. Heegaard, N. H. Robin Hsiung, G. Y. Hyman, B. Iqbal, K. Kaeser, S. A. Lachno, D. R. Lleo, A. Lewczuk, P. Molinuevo, J. L. Parchi, P. Regeniter, A. Rissman, R. A. Rosenmann, H. Sancesario, G. Schroder, J. Shaw, L. M. Teunissen, C. E. Trojanowski, J. Q. Vanderstichele, H. Vandijck, M. Verbeek, M. M. Zetterberg, H. Blennow, K. Alzheimer's Association, Q. C. Program Work Group. CSF biomarker variability in the Alzheimer's Association quality control program. *Alzheimer's & Dementia*. 2013;9(3):251-61. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
545. Meredith JE, Jr. Sankaranarayanan, S. Guss, V. Lanzetti, A. J. Berisha, F. Neely, R. J. Slemmon, J. R. Portelius, E. Zetterberg, H. Blennow, K. Soares, H. Ahljanian, M. Albright, C. F. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. *PLoS ONE [Electronic Resource]*. 2013;8(10):e76523. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
546. Mertens JS, K. Wunderlich, P. Ladewig, J. Kesavan, J. C. Vandenberghe, R. Vandenbulcke, M. Van Damme, P. Walter, J. Brustle, O. Koch, P. APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based gamma-secretase modulation. *Stem Cell Reports*. 2013;1(6):491-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
547. Miyajima MN, M. Ogino, I. Miyata, H. Motoi, Y. Arai, H. Soluble amyloid precursor protein alpha in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus. *European Journal of Neurology*. 2013;20(2):236-42. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
548. Motsinger-Reif AAZ, H. Kling, M. A. Matson, W. Sharma, S. Fiehn, O. Reif, D. M. Appleby, D. H. Doraiswamy, P. M. Trojanowski, J. Q. Kaddurah-Daouk, R. Arnold, S. E. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. *Acta Neuropathologica Communications*. 2013;1:28. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
549. Nakayama YM, S. Yoneda, M. Kuzuhara, S. Kokubo, Y. Cerebrospinal fluid biomarkers for kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. *Journal of Neurodegenerative Diseases*. 2013;(no pagination)(679089). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
550. O'Dowd STA, M. T. Johansson, P. Lomakin, A. Benedek, G. B. Roberts, K. A. Cummins,

- G. El Agnaf, O. M. Svensson, J. Zetterberg, H. Lynch, T. Walsh, D. M. The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. *Journal of Alzheimer's Disease*. 2013;33(4):923-8. 배제 사유: 동물연구 또는 전임상연구
551. Prestia AC, A. Herholz, K. Reiman, E. Chen, K. Jagust, W. J. Frisoni, G. B. Amicucci, G. Archetti, S. Benussi, L. Binetti, G. Bocchio-Chiavetto, L. Bonetti, M. Canu, E. Caobelli, F. Cavedo, E. Chitto, E. Costardi, D. Cotelli, M. Galluzzi, S. Gennarelli, M. Geroldi, C. Ghidoni, R. Giubbini, R. Guerra, U. P. Kuffenschin, G. Lussignoli, G. Moretti, D. Orlandini, A. Paghera, B. Parapini, M. Paternico, D. Porteri, C. Romano, M. Rosini, S. Scarpazza, C. Villa, I. Zanardini, R. Zanetti, O. Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. *Alzheimer's and Dementia*. 2013;9(6):677-86. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
552. Ramakers IHV, F. R. Scheltens, P. Hampel, H. Soininen, H. Aalten, P. Rikkert, M. O. Verbeek, M. M. Spuru, L. Blennow, K. Trojanowski, J. Q. Shaw, L. M. Visser, P. J. Alzheimer's Disease Neuroimaging, InitiativeDescrip Investigators. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. *Psychological Medicine*. 2013;43(5):911-20. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
553. Ranaldi SC, C. Prome, S. Rubrecht, L. Cobo, S. Salvetat, N. du Paty, E. Galea, P. Aldrian, G. Le Nguyen, D. Krolak-Salmon, P. Molina, F. Laune, D. Checler, F. Fareh, J. Abraham, J. D. N-truncated Abeta peptides in complex fluids unraveled by new specific immunoassays. *Neurobiology of Aging*. 2013;34(2):523-39. 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
554. Rosa-Neto PH, G. Y. R. Masellis, M. Fluid biomarkers for diagnosing dementia: Rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. *Alzheimer's Research and Therapy*. 2013;5 (SUPPL. 1) (no pagination)(S8). 배제사유: 인산화타우단백 [효소면역검사를 수행하지 않은 연구
555. Rosen CH, O. Blennow, K. Zetterberg, H. Fluid biomarkers in Alzheimer's disease - Current concepts. *Molecular Neurodegeneration*. 2013;8 (1) (no pagination)(20). 배제사유: 원저가 아닌 연구
556. Sabbagh JJK, J. W. Cummings, J. L. Alzheimer's disease biomarkers in animal models: Closing the translational gap. *American Journal of Neurodegenerative Diseases*. 2013;2(2):108-20. 배제사유: 동물연구 또는 전임상연구
557. Sano KS, K. Atarashi, R. Takashima, H. Iwasaki, Y. Yoshida, M. Sanjo, N. Murai, H. Mizusawa, H. Schmitz, M. Zerr, I. Kim, Y. S. Nishida, N. Early Detection of Abnormal Prion Protein in Genetic Human Prion Diseases Now Possible Using Real-Time QUIC Assay. *PLoS ONE*. 2013;8 (1) (no pagination)(e54915). 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
558. Schmidt FMK, J. Gertz, H. J. Tittmann, M. Jahn, I. Pietsch, U. C. Kaisers, U. X. Thiery, J. Hegerl, U. Schonknecht, P. Cerebrospinal fluid melanin-concentrating hormone (MCH)

- and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. PLoS ONE [Electronic Resource]. 2013;8(5):e63136. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
559. Slaets SLB, N. Martin, J. J. Sleegers, K. Van Broeckhoven, C. De Deyn, P. P. Engelborghs, S. Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. *Journal of Alzheimer's Disease*. 2013;36(4):759-67. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
560. Sorensen KCS, A. H. Holmetoft, U. B. Hasselbalch, S. G. Heegaard, N. H. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease. *Journal of Alzheimer's Disease*. 2013;37(2):379-87. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
561. Souslova TM, T. C. Spiekerman, A. M. Mohammad, A. A. Personalized medicine in Alzheimer's disease and depression. *Contemporary Clinical Trials*. 2013;36(2):616-23. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
562. Stefani AO, E. Bassi, M. S. Pisani, V. Imbriani, P. Pisani, A. Pierantozzi, M. Strength and weaknesses of cerebrospinal fluid biomarkers in alzheimer's disease and possible detection of overlaps with frailty process. *CNS and Neurological Disorders - Drug Targets*. 2013;12(4):538-46. 배제사유: 원저가 아닌 연구
563. Taverna MS, T. Hampel, H. Rujescu, D. Lichtenthaler, S. F. A new sandwich immunoassay for detection of the alpha-secretase cleaved, soluble amyloid-beta protein precursor in cerebrospinal fluid and serum. *Journal of Alzheimer's Disease*. 2013;37(4):667-78. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
564. Teipel SJS, O. Grothe, M. Barthel, H. Prvulovic, D. Buerger, K. Bokde, A. L. W. Ewers, M. Hoffmann, W. Hampel, H. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2013;33(SUPPL. 1):S329-S47. 배제사유: 원저가 아닌 연구
565. Toledo JBX, S. X. Trojanowski, J. Q. Shaw, L. M. Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. *Acta Neuropathologica*. 2013;126(5):659-70. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
566. Vos SjrR, I. A. Verhey, F. Knol, D. L. Soininen, H. Wahlund, L. O. Hampel, H. Tsolaki, M. Minthon, L. Frisoni, G. B. Froelich, L. Nobili, F. van der Flier, W. Blennow, K. Wolz, R. Scheltens, P. Visser, P. J. Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. *Neurology*. 2013;80(12):1124-32. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
567. Weiner MWV, D. P. Aisen, P. S. Beckett, L. A. Cairns, N. J. Green, R. C. Harvey, D. Jack, C. R. Jagust, W. Liu, E. Morris, J. C. Petersen, R. C. Saykin, A. J. Schmidt, M. E. Shaw, L. Shen, L. Siuciak, J. A. Soares, H. Toga, A. W. Trojanowski, J. Q. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. *Alzheimer's and Dementia*. 2013;9(5):e111-e94. 배제사유: 원저가 아닌 연구
568. Wennstrom MS, Y. Hall, S. Nilsson, C. Minthon, L. Bostrom, F. Hansson, O. Nielsen, H. M. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme

- neurosin in patients with synucleinopathy. PLoS ONE [Electronic Resource]. 2013;8(1):e53250. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
569. Xie ZM, S. Swain, C. A. Ward, S. A. Crosby, C. A. Zheng, H. Sherman, J. Dong, Y. Zhang, Y. Sunder, N. Burke, D. Washicosky, K. J. Tanzi, R. E. Marcantonio, E. R. Cerebrospinal fluid abeta to tau ratio and postoperative cognitive change. *Annals of Surgery*. 2013;258(2):364-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
570. Yang TH, S. O'Malley, T. Sperling, R. A. Walsh, D. M. Selkoe, D. J. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. *Alzheimer's & Dementia*. 2013;9(2):99-112. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
571. Alexopoulos PG, L. H. Tsolakidou, A. Kratzer, M. Grimmer, T. Westerteicher, C. Jiang, M. Bujo, H. Diehl-Schmid, J. Kurz, A. Perneczky, R. Interrelations between CSF soluble AbetaPPbeta, amyloid-beta 1-42, SORL1, and tau levels in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2012;28(3):543-52. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
572. Andreasson UV, E. Shaw, L. M. Zetterberg, H. Vanderstichele, H. Analytical aspects of molecular Alzheimer's disease biomarkers. *Biomarkers in Medicine*. 2012;6(4):377-89. 배제사유: 원저가 아닌 연구
573. Bartos AC, L. Svarcova, J. Ricny, J. Ripova, D. Cerebrospinal fluid triplet in the diagnosis of Alzheimer-Fischer disease. [Czech]. *Ceska a Slovenska Neurologie a Neurochirurgie*. 2012;75(5):587-94. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
574. Bartos AF, L. Svarcova, J. Ripova, D. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. *Journal of Neuroimmunology*. 2012;252(1-2):100-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
575. Bibl ME, H. Wiltfang, J. Neurochemical biomarkers in Alzheimer's disease and related disorders. *Therapeutic Advances in Neurological Disorders*. 2012;5(6):335-48. 배제사유: 원저가 아닌 연구
576. Blennow KZ, H. Rinne, J. O. Salloway, S. Wei, J. Black, R. Grundman, M. Liu, E. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease. *Archives of Neurology*. 2012;69(8):1002-10. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
577. Compta YI-B, N. Pereira, J. B. Junque, C. Bargallo, N. Tolosa, E. Valldeoriola, F. Munoz, E. Camara, A. Buongiorno, M. Marti, M. J. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. *Parkinsonism & Related Disorders*. 2012;18(8):941-7. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
578. Craft SB, L. D. Montine, T. J. Minoshima, S. Watson, G. S. Claxton, A. Arbuckle, M. Callaghan, M. Tsai, E. Plymate, S. R. Green, P. S. Leverenz, J. Cross, D. Gerton, B. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. *Archives of Neurology*. 2012;69(1):29-38. 배제사유: 인산화타우단백 [효

소면역검사를 수행하지 않은 연구

579. Del Campo MM, B. Bertolotto, A. Engelborghs, S. Hampel, H. Simonsen, A. H. Kapaki, E. Kruse, N. Le Bastard, N. Lehmann, S. Molinuevo, J. L. Parnetti, L. Perret-Liaudet, A. Saez-Valero, J. Saka, E. Urbani, A. Vanmechelen, E. Verbeek, M. Visser, P. J. Teunissen, C. Recommendations to standardize preanalytical confounding factors in Alzheimers and Parkinsons disease cerebrospinal fluid biomarkers: An update. *Biomarkers in Medicine*. 2012;6(4):419-30. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
580. Dorothee GB, M. Moukari, E. De Souza, L. C. Maroy, R. Corlier, F. Colliot, O. Chupin, M. Lamari, F. Lehericy, S. Dubois, B. Sarazin, M. Aucouturier, P. Distinct patterns of anti-amyloid-beta antibodies in typical and atypical Alzheimer disease. *Archives of Neurology*. 2012;69(9):1181-5. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
581. Engelborghs SLB, N. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. *Journal of the Neurological Sciences*. 2012;322(1-2):197-9. 배제사유: 원저가 아닌 연구
582. Figurski MJW, T. Toledo, J. Vanderstichele, H. Korecka, M. Lee, V. M. Trojanowski, J. Q. Shaw, L. M. Alzheimer's Disease Neuroimaging, Initiative. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. *Alzheimer's & Dementia*. 2012;8(4):250-60. 배제사유: 원저가 아닌 연구
583. Hamlin CP, G. Berri, S. Sting, E. Harris, C. Cohen, M. Spear, C. Bizzi, A. Debanne, S. M. Rowland, D. Y. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. *Neurology*. 2012;79(6):547-52. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
584. Hardy J. CSF biomarking for diagnosis and treatment assessment in neurodegeneration. *Journal of Neurochemistry*. 2012;123(3):339-41. 배제사유: 원저가 아닌 연구
585. Herbert MKK, H. B. Verbeek, M. M. Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. *Journal of Immunological Methods*. 2012;381(1-2):1-8. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
586. Higuchi MI, N. Matsuba, Y. Takano, J. Suemoto, T. Maeda, J. Ji, B. Ono, M. Staufenbiel, M. Suhara, T. Saido, T. C. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. *FASEB Journal*. 2012;26(3):1204-17. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
587. Jack CR, Jr. Vemuri, P. Wiste, H. J. Weigand, S. D. Lesnick, T. G. Lowe, V. Kantarci, K. Bernstein, M. A. Senjem, M. L. Gunter, J. L. Boeve, B. F. Trojanowski, J. Q. Shaw, L. M. Aisen, P. S. Weiner, M. W. Petersen, R. C. Knopman, D. S. Alzheimer's Disease Neuroimaging, Initiative. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. *Archives of Neurology*. 2012;69(7):856-67. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
588. Jonsson MZ, H. Rolstad, S. Edman, A. Gouw, A. A. Bjerke, M. Lind, K. Blennow, K.

- Pantoni, L. Inzitari, D. Wallin, A. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions - The LADIS study. *Dementia and Geriatric Cognitive Disorders*. 2012;34(1):61-7. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
589. Kang JHV, H. Trojanowski, J. Q. Shaw, L. M. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. *Methods (Duluth)*. 2012;56(4):484-93. 배제사유: 원저가 아닌 연구
590. Kim WR, M. Visnick, Y. Miro, S. Saman, S. Jackson, B. McKee, A. C. Alvarez, V. E. Lee, N. C. Y. Hall, G. F. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. *Journal of Biological Chemistry*. 2012;287(6):3842-9. 배제사유: 동물연구 또는 전임상연구
591. Laske C. Alzheimer disease: Blood-based biomarkers in AD-a silver lining on the horizon. *Nature Reviews Neurology*. 2012;8(10):541-2. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
592. Luk CC, Y. Magdalinou, N. Marti, M. J. Hondhamuni, G. Zetterberg, H. Blennow, K. Constantinescu, R. Pijnenburg, Y. Mollenhauer, B. Trenkwalder, C. Van Swieten, J. Chiu, W. Z. Borroni, B. Camara, A. Cheshire, P. Williams, D. R. Lees, A. J. de Silva, R. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. *Journal of Neurochemistry*. 2012;123(3):396-405. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
593. Machaczka MA, M. P. Rucinska, M. Yoshitake, T. Kehr, J. Jurczak, W. Skotnicki, A. B. Mansson, J. E. Tytki-Szymanska, A. Svenningsson, P. A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease. *Jimd Reports*. 2012;3:53-7. 배제사유: 사전에 정의한 연구설계가 아닌 문헌
594. Malnar MK, M. Bene, R. Tarnik, I. P. Pavelin, S. Babic, I. Brajenovic-Milic, B. Hecimovic, H. Titlic, M. Trkanjec, Z. Demarin, I. Hecimovic, S. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting. *Acta Neurobiologiae Experimentalis*. 2012;72(3):264-71. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
595. Martone RLS, R. Xu, A. S. L. Reams, R. Y. The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration. *Current Translational Geriatrics and Gerontology Reports*. 2012;1(2):94-103. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
596. Mattsson NA, U. Carrillo, M. C. Persson, S. Shaw, L. M. Zegers, I. Zetterberg, H. Blennow, K. Proficiency testing programs for Alzheimers disease cerebrospinal fluid biomarkers. *Biomarkers in Medicine*. 2012;6(4):401-7. 배제사유: 원저가 아닌 연구
597. Mattsson NZ, I. Andreasson, U. Bjerke, M. Blankenstein, M. A. Bowser, R. Carrillo, M. C. Gobom, J. Heath, T. Jenkins, R. Jeromin, A. Kaplow, J. Kidd, D. Laterza, O. F. Lockhart, A. Lunn, M. P. Martone, R. L. Mills, K. Pannee, J. Ratcliffe, M. Shaw, L. M. Simon, A. J. Soares, H. Teunissen, C. E. Verbeek, M. M. Umek, R. M. Vanderstichele, H. Zetterberg, H. Blennow, K. Portelius, E. Reference measurement procedures for Alzheimer's disease



- cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42. *Biomarkers in Medicine*. 2012;6(4):409-17. 배제사유: 원저가 아닌 연구
598. Molina MF, R. Stereotypic movements in case of sporadic creutzfeldt-jakob disease: Possible role of Anti-NMDA receptor antibodies. *Case Reports in Neurology*. 2012;4(3):244-7. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
599. Monge-Argiles JAS-P, J. Munoz-Ruiz, C. Pampliega-Perez, A. Gomez-Lopez, M. J. Rodriguez Borja, E. Montoya-Gutierrez, J. Leiva-Santana, C. [Patients with mild cognitive impairment and a reduced CSF Abeta1-42 protein progress rapidly to Alzheimer's disease]. *Neurologia*. 2012;27(1):28-33. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
600. Monge-Argiles JAS-P, J. Munoz-Ruiz, C. Pampliega-Perez, A. Gomez-Lopez, M. J. Rodriguez Borja, E. Montoya-Gutierrez, J. Leiva-Santana, C. Patients with mild cognitive impairment and a reduced CSF Abeta<sup>1-42</sup> protein progress rapidly to Alzheimer's disease. [Spanish]. *Neurologia*. 2012 Jan;27(1):28-33. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
601. Mouton-Liger FP, C. Dumurgier, J. Lapalus, P. Gray, F. Laplanche, J. L. Hugon, J. Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. *Biol Psychiatry*. 2012 May 1;71(9):829-35. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
602. Mukaetova-Ladinska EBA-A, Z. Dodds, S. Andrade, J. Alves da Silva, J. Kalaria, R. N. O'Brien, J. T. Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer's disease: findings from a pilot study. *Age & Ageing*. 2012;41(3):408-12. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
603. O'Dowd SL, T. Does secretion of aberrant tau underlie lesion spread in tauopathies? *Movement Disorders*. 2012;27(2):201-. 배제사유: 원저가 아닌 연구
604. Ozerlat I. Alzheimer disease: CSF biomarkers could be used in Abeta immunotherapy trials for AD. *Nature Reviews Neurology*. 2012;8(6):297. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
605. Paternico DG, S. Drago, V. Bocchio-Chiavetto, L. Zanardini, R. Pedrini, L. Baronio, M. Amicucci, G. Frisoni, G. B. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. *Alzheimer's & Dementia*. 2012;8(6):520-7. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
606. Perret-Liaudet AP, M. Tholance, Y. Dumont, B. Vanderstichele, H. Zorzi, W. ElMoualij, B. Schraen, S. Moreaud, O. Gabelle, A. Thouvenot, E. Thomas-Anterion, C. Touchon, J. Krolak-Salmon, P. Kovacs, G. G. Coudreuse, A. Quadrio, I. Lehmann, S. Cerebrospinal fluid collection tubes: A critical issue for alzheimer disease diagnosis. *Clinical Chemistry*. 2012;58(4):787-9. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
607. Perret-Liaudet AP, M. Tholance, Y. Dumont, B. Vanderstichele, H. Zorzi, W. ElMoualij, B. Schraen, S. Moreaud, O. Gabelle, A. Thouvenot, E. Thomas-Anterion, C. Touchon, J. Krolak-Salmon, P. Kovacs, G. G. Coudreuse, A. Quadrio, I. Lehmann, S. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes.

- Journal of Alzheimer's Disease. 2012;31(1):13-20. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
608. Quinn JF. Biomarkers for Alzheimer's disease: Showing the way or leading us astray? Alzheimer's Disease: Advances For A New Century. 2012;Advances in Alzheimer's Disease. 3:371-6. 배제사유: 원저가 아닌 연구
609. Regeniter AK, J. Baumann, T. Sollberger, M. Herdener, M. Kunze, U. Camuso, M. C. Monsch, A. U. Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods (Duluth). 2012;56(4):494-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
610. Reis TB, C. O. Freire Coutinho, E. S. Engelhardt, E. Laks, J. Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil. CNS Neuroscience & Therapeutics. 2012;18(7):524-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
611. Roubaud-Baudron CK-S, P. Quadrio, I. Megraud, F. Salles, N. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiology of Aging. 2012;33(5):1009. e11-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
612. Roubaud-Baudron CK-S, P. Quadrio, I. Megraud, F. Salles, N. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiology of Aging. Neurobiol Aging. 2012 May;33(5):1009. e11-9. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
613. Santos ANE, M. Minthon, L. Simm, A. Silber, R. E. Blennow, K. Prvulovic, D. Hansson, O. Hampel, H. Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. Journal of Alzheimer's Disease. 2012;29(1):171-6. 배제사유: 사전에 정의한 대조군에 해당하지 않은 연구
614. Schonrock NM, M. Ittner, L. M. Gotz, J. MicroRNA networks surrounding APP and amyloid-beta metabolism - Implications for Alzheimer's disease. Experimental Neurology. 2012;235(2):447-54. 배제사유: 원저가 아닌 연구
615. Schoonenboom NSR, F. E. Verwey, N. A. Kester, M. I. Teunissen, C. E. van de Ven, P. M. Pijnenburg, Y. A. Blankenstein, M. A. Rozemuller, A. J. Scheltens, P. van der Flier, W. M. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78(1):47-54. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
616. Senanarong VS, N. Washirutmangkur, L. Pongvarin, N. Ratanabunakit, C. Aoonkaew, N. Udomphantharak, S. Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience. International journal of Alzheimer's disease. 2012;2012:212063. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
617. Seppala TTN, O. Koivisto, A. M. Rummukainen, J. Puli, L. Zetterberg, H. Pyykko, O. T. Helisalmi, S. Alafuzoff, I. Hiltunen, M. Jaaskelainen, J. E. Rinne, J. Soininen, H. Leinonen,

- V. Herukka, S. K. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. *Neurology*. 2012;78(20):1568-75. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
618. Slats DC, J. A. Spies, P. E. Borm, G. Besse, K. T. van Aalst, W. Tseng, J. Sjogren, M. J. Olde Rikkert, M. G. Verbeek, M. M. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. *Neurobiology of Aging*. 2012;33(4):831. e1-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
619. Slemmon JRM, J. Guss, V. Andreasson, U. Andreassen, N. Zetterberg, H. Blennow, K. Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. *Journal of Neurochemistry*. 2012;120(2):325-33. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
620. Tabaraud FL, J. P. Milor, A. M. Roussie, J. M. Barriere, G. Tartary, M. Boutros-Toni, F. Rigaud, M. Alzheimer CSF biomarkers in routine clinical setting. *Acta Neurologica Scandinavica*. 2012;125(6):416-23. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
621. Toledo JBB, J. Grossman, M. Arnold, S. E. Hu, W. T. Xie, S. X. Lee, V. M. Shaw, L. M. Trojanowski, J. Q. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. *Acta Neuropathologica*. 2012;124(1):23-35. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
622. Vafadar-Isfahani BB, G. Coveney, C. Lemetre, C. Boocock, D. Minthon, L. Hansson, O. Miles, A. K. Janciauskiene, S. M. Warden, D. Smith, A. D. Wilcock, G. Kalsheker, N. Rees, R. Matharoo-Ball, B. Morgan, K. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. *Journal of Alzheimer's Disease*. 2012;28(3):625-36. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
623. Vlachos GSP, G. P. Naoumis, D. Kapaki, E. Cerebrospinal fluid beta-amyloid 1-42 correlates with rate of progression in Alzheimer's disease. *Journal of Neural Transmission*. 2012;119(7):799-804. 배제사유: 알츠하이머 치매 의심환자를 대상으로 수행되지 않은 연구
624. Vos SvR, I. Burns, L. Knol, D. Scheltens, P. Soininen, H. Wahlund, L. O. Hampel, H. Tsolaki, M. Minthon, L. Handels, R. L'Italien, G. van der Flier, W. Aalten, P. Teunissen, C. Barkhof, F. Blennow, K. Wolz, R. Rueckert, D. Verhey, F. Visser, P. J. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. *Neurobiology of Aging*. 2012;33(10):2272-81. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
625. Wang LF, A. M. Shah, A. R. Beg, M. F. Csernansky, J. G. Morris, J. C. Holtzman, D. M. Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. *Alzheimer Disease & Associated Disorders*. 2012;26(4):314-21. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
626. Watt ADP, K. A. Rembach, A. R. Masters, C. L. Villemagne, V. L. Barnham, K. J. Variability in blood-based amyloid-beta assays: The need for consensus on pre-analytical processing. *Journal of Alzheimer's Disease*. 2012;30(2):323-36. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구

627. Wennstrom ML, E. Minthon, L. Nielsen, H. M. Altered CSF orexin and alpha-synuclein levels in dementia patients. *Journal of Alzheimer's Disease*. 2012;29(1):125-32. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
628. Wu GS, S. Wong, J. Tugusheva, K. Michener, M. S. Shi, X. Cook, J. J. Simon, A. J. Savage, M. J. Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. *Journal of Neuroscience Research*. 2012;90(12):2247-58. 배제사유: 인산화타우단백 [효소면역검사]를 수행하지 않은 연구
629. Abraham JDC-P, S. Cobo, S. Salvetat, N. Vicat, G. Molina, L. Touchon, J. Michel, B. F. Molina, F. Verdier, J. M. Fareh, J. Mourton-Gilles, C. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias. *Biomarkers*. 2011;16(2):161-71. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
630. Andersson MZ, H. Minthon, L. Blennow, K. Londos, E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. *International Journal of Geriatric Psychiatry*. 2011;26(1):100-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
631. Antonell AF, J. Rami, L. Bosch, B. Balasa, M. Sanchez-Valle, R. Iranzo, A. Molinuevo, J. L. Llado, A. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. *Journal of Neural Transmission*. 2011;118(2):259-62. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
632. Barten DMC, G. W. Hoque, N. DeCarr, L. B. Guss, V. L. Yang, L. Sankaranarayanan, S. Wes, P. D. Flynn, M. E. Meredith, J. E. Ahlijanian, M. K. Albright, C. F. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. *Journal of Alzheimer's Disease*. 2011;24 Suppl 2:127-41. 배제사유: 동물연구 또는 전임상연구
633. Bibl MM, B. Lewczuk, P. Esselmann, H. Wolf, S. Otto, M. Kornhuber, J. Ruther, E. Wiltfang, J. Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasia. *Dementia & Geriatric Cognitive Disorders*. 2011;31(1):37-44. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
634. Bjerke MZ, H. Edman, A. Blennow, K. Wallin, A. Andreasson, U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. *Journal of Alzheimer's Disease*. 2011;27(3):665-76. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
635. Bjornstal OR, K. Zhang, W. Delhaye, R. Malone, M. Unger, S. Nowatzke, W. The impact of decreased bead count to determine concentrations of amyloid beta1-42, total-tau, and phosphorylated-tau181 in human cerebrospinal fluid using xMAP technology. *Journal of Pharmaceutical Sciences*. 2011;100(11):4655-63. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

636. Blennow K. Dementia in 2010: Paving the way for Alzheimer disease drug development. *Nature Reviews Neurology*. 2011;7(2):65-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
637. Compta YE, M. Munoz, E. Tolosa, E. Valldeoriola, F. Rios, J. Camara, A. Fernandez, M. Buongiorno, M. T. Marti, M. J. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal beta-amyloid in Parkinson disease. *Neuroscience Letters*. 2011;487(2):169-73. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
638. Coulthart MBJ, G. H. Olsen, E. Godal, D. L. Connolly, T. Choi, B. C. Wang, Z. Cashman, N. R. Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. *BMC Neurology*. 2011;11:133. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
639. Craig-Schapiro RK, M. Xiong, C. Pickering, E. H. Liu, J. Misko, T. P. Perrin, R. J. Bales, K. R. Soares, H. Fagan, A. M. Holtzman, D. M. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. *PLoS ONE [Electronic Resource]*. 2011;6(4):e18850. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
640. Davinelli SI, M. Russo, C. Di Costanzo, A. Zella, D. Bosco, P. Scapagnini, G. The "Alzheimer's disease signature": Potential perspectives for novel biomarkers. *Immunity and Ageing*. 2011;8 (no pagination)(7). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
641. de Souza LCC, F. Habert, M. O. Uspenskaya, O. Maroy, R. Lamari, F. Chupin, M. Lehericy, S. Colliot, O. Hahn-Barma, V. Samri, D. Dubois, B. Bottlaender, M. Sarazin, M. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. *Brain*. 2011;134(Pt 7):2036-43. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
642. Fagan AMS, L. M. Xiong, C. Vanderstichele, H. Mintun, M. A. Trojanowski, J. Q. Coart, E. Morris, J. C. Holtzman, D. M. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. *Archives of Neurology*. 2011;68(9):1137-44. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
643. Fahnstock M. Brain-derived neurotrophic factor: The link between amyloid-beta and memory loss. *Future Neurology*. 2011;6(5):627-39. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
644. Fortea JL, A. Bosch, B. Antonell, A. Oliva, R. Molinuevo, J. L. Sanchez-Valle, R. Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. *Neurodegenerative Diseases*. 2011;8(4):202-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
645. Fronek KL, P. Spreer, A. Eiffert, H. Nau, R. Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of beta-Amyloid and Tau protein as determined by enzyme immunoassay. *Dementia & Geriatric Cognitive Disorders*.

- 2011;32(2):126-34. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
646. Funke SAW, D. Quantitation of amyloid-beta oligomers in human body fluids for alzheimer's disease: Early diagnosis or therapy monitoring? *Alzheimer's Disease Research Journal*. 2011;4(3):315-34. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
647. Gabelle AR, S. Geny, C. Bennys, K. Labauge, P. Tholance, Y. Quadrio, I. Tiers, L. Gor, B. Boulanghien, J. Chaulet, C. Vighetto, A. Croisile, B. Krolak-Salmon, P. Perret-Liaudet, A. Touchon, J. Lehmann, S. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. *Journal of Alzheimer's Disease*. 2011;26(3):553-63. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
648. Giovannoni GN, A. Editorial: After the storm: Neurofilament levels as a surrogate endpoint for neuroaxonal damage. *Neurology*. 2011;76(14):1200-1. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
649. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. *Trends in Biotechnology*. 2011;29(1):26-32. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
650. Jesse SB, J. Sussmuth, S. D. Landwehrmeyer, B. G. von Arnim, C. A. Ludolph, A. C. Tumani, H. Otto, M. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. *Journal of Neurology*. 2011;258(6):1034-41. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
651. Kandimalla RJP, S. Binukumar, B. K. Wani, W. Y. Gupta, N. Sharma, D. R. Sunkaria, A. Grover, V. K. Bhardwaj, N. Jain, K. Gill, K. D. Apo-Eepsilon4 allele in conjunction with Abeta42 and tau in CSF: biomarker for Alzheimer's disease. *Current Alzheimer Research*. 2011;8(2):187-96. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
652. Kandimalla RJS, P. Bk, B. Wani, W. Y. Sharma, D. R. Grover, V. K. Bhardwaj, N. Jain, K. Gill, K. D. Cerebrospinal fluid profile of amyloid beta42 (Abeta42), hTau and ubiquitin in North Indian Alzheimer's disease patients. *Neuroscience Letters*. 2011;487(2):134-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
653. Koric LF, O. Ceccaldi, M. [Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice]. *Revue Neurologique*. 2011;167(6-7):474-84. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
654. Lachno DRR, M. J. Siemers, E. R. Vanderstichele, H. Coart, E. Konrad, R. J. Zajac, J. J. Talbot, J. A. Jensen, H. F. Sethuraman, G. Demattos, R. B. May, P. C. Dean, R. A. Validation of ELISA methods for quantification of total tau and phosphorylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies. *Journal of Alzheimer's Disease*. 2011;26(3):531-41. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
655. Leinonen VM, L. G. Carroll, R. S. Dello Iacono, D. Grevet, J. Jaaskelainen, J. E. Black, P. M. Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. *International journal of Alzheimer's disease*. 2011;2011:312526. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

656. Maetzler WB, D. Synofzik, M. Brockmann, K. Godau, J. Melms, A. Gasser, T. Hornig, S. Langkamp, M. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. *Journal of Alzheimer's Disease*. 2011;26(1):171-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
657. Matsui YS, K. Miyazaki, T. Shirabe, S. Atarashi, R. Mutsukura, K. Satoh, A. Kataoka, Y. Nishida, N. High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease. *BMC Neurology*. 2011;11:120. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
658. Mattsson NA, U. Persson, S. Arai, H. Batish, S. D. Bernardini, S. Bocchio-Chiavetto, L. Blankenstein, M. A. Carrillo, et al., The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. *Alzheimer's & Dementia*. 2011;7(4):386-95. e6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
659. Meiner ZK, E. Baitcher, F. Korczyn, A. D. Chapman, J. Cohen, O. S. Milo, R. Aharon-Perez, J. Abramsky, O. Gabizon, R. Rosenmann, H. Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. *Journal of Neurology*. 2011;258(2):255-62. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
660. Mollenhauer BL, J. J. Schulz-Schaeffer, W. Sixel-Doring, F. Trenkwalder, C. Schlossmacher, M. G. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. *Lancet Neurology*. 2011;10(3):230-40. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
661. Montine TJ. PD biomarkersg-use of alpha-synuclein reaches new levels. *Nature Reviews Neurology*. 2011;7(6):308-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
662. Mulugeta EL, E. Ballard, C. Alves, G. Zetterberg, H. Blennow, K. Skogseth, R. Minthon, L. Aarsland, D. CSF amyloid beta38 as a novel diagnostic marker for dementia with Lewy bodies. *Journal of Neurology, Neurosurgery & Psychiatry*. 2011;82(2):160-4. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
663. Nakajima MM, M. Ogino, I. Watanabe, M. Miyata, H. Karagiozov, K. L. Arai, H. Hagiwara, Y. Segawa, T. Kobayashi, K. Hashimoto, Y. Leucine-rich alpha-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus. *Acta Neurochirurgica*. 2011;153(6):1339-46. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
664. Noelker CH, H. Dodel, R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: Current progress and clinical potential. *Molecular Diagnosis and Therapy*. 2011;15(2):83-102. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
665. Noguchi-Shinohara MH, T. Nozaki, I. Sakai, K. Yamada, M. Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. *Journal of Neurology*. 2011;258(8):1464-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
666. Okonkwo OCM, M. M. Griffith, H. R. Moghekar, A. R. O'Brien, R. J. Shaw, L. M.

- Trojanowski, J. Q. Albert, M. S. Alzheimer's Disease Neuroimaging, Initiative. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnesic mild cognitive impairment. *Archives of Neurology*. 2011;68(1):113-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
667. Parnetti LC, D. Bellomo, G. Giannandrea, D. De Carlo, C. Qureshi, M. M. Ardah, M. T. Varghese, S. Bonanni, L. Borroni, B. Tambasco, N. Eusebi, P. Rossi, A. Onofri, M. Padovani, A. Calabresi, P. El-Agnaf, O. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. *Movement Disorders*. 2011;26(8):1428-35. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
668. Perneczky RT, A. Arnold, A. Diehl-Schmid, J. Grimmer, T. Forstl, H. Kurz, A. Alexopoulos, P. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. *Neurology*. 2011;77(1):35-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
669. Perrin RJC-S, R. Malone, J. P. Shah, A. R. Gilmore, P. Davis, A. E. Roe, C. M. Peskind, E. R. Li, G. Galasko, D. R. Clark, C. M. Quinn, J. F. Kaye, J. A. Morris, J. C. Holtzman, D. M. Townsend, R. R. Fagan, A. M. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. *PLoS ONE [Electronic Resource]*. 2011;6(1):e16032. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
670. Rami LF, J. Bosch, B. Sole-Padulles, C. Llado, A. Iranzo, A. Sanchez-Valle, R. Molinuevo, J. L. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. *Journal of Alzheimer's Disease*. 2011;23(2):319-26. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
671. Ray BR, P. F. Lahiri, D. K. Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Abeta) peptide and phospho-tau. *Journal of Psychiatric Research*. 2011;45(4):539-47. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
672. Ray SR, P. J. Choudhary, S. Raghu, D. Srivastava, S. Emerging nanoproteomics approaches for disease biomarker detection: A current perspective. *Journal of Proteomics*. 2011;74(12):2660-81. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
673. Schipke CGJ, F. Teipel, S. Luckhaus, C. Wiltfang, J. Esselmann, H. Frolich, L. Maier, W. Ruther, E. Heppner, F. L. Prokop, S. Heuser, I. Peters, O. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. *Journal of Alzheimer's Disease*. 2011;26(2):255-62. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
674. Schipke CGP, S. Heppner, F. L. Heuser, I. Peters, O. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. *Dementia & Geriatric Cognitive Disorders*. 2011;31(2):139-45. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
675. Seppala TTK, A. M. Hartikainen, P. Helisalmi, S. Soininen, H. Herukka, S. K. Longitudinal changes of CSF biomarkers in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2011;25(4):583-94. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구



676. Shaw LMV, H. Knapik-Czajka, M. Figurski, M. Coart, E. Blennow, K. Soares, H. Simon, A. J. Lewczuk, P. Dean, R. A. Siemers, E. Potter, W. Lee, V. M. Trojanowski, J. Q. Alzheimer's Disease Neuroimaging, Initiative. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. *Acta Neuropathologica*. 2011;121(5):597-609. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
677. Spitzer PS, H. Kamrowski-Kruck, H. Otto, M. Chiasserini, D. Parnetti, L. Herukka, S. K. Schuchhardt, J. Wiltfang, J. Klafki, H. W. Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. *International journal of Alzheimer's disease*. 2011;2011:739847. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
678. Tang JXB, D. Hammond, M. Shaw, L. M. Eckenhoff, M. F. Eckenhoff, R. G. Human Alzheimer and inflammation biomarkers after anesthesia and surgery. *Anesthesiology*. 2011;115(4):727-32. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
679. Wu GS, S. Hsieh, S. H. Simon, A. J. Savage, M. J. Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer's disease cortex. *Journal of Neuroscience Research*. 2011;89(6):822-32. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
680. Alves GB, K. Aarsland, D. Blennow, K. Zetterberg, H. Ballard, C. Kurz, M. W. Andreasson, U. Tysnes, O. B. Larsen, J. P. Mulugeta, E. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. *Journal of Neurology, Neurosurgery & Psychiatry*. 2010;81(10):1080-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
681. Baumann TPD, H. Sollberger, M. Kuhle, J. Regeniter, A. Gomez-Mancilla, B. Schmidtke, K. Monsch, A. U. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy. *Dementia & Geriatric Cognitive Disorders*. 2010;29(6):530-3. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
682. Bibl ME, H. Lewczuk, P. Trenkwalder, C. Otto, M. Kornhuber, J. Wiltfang, J. Mollenhauer, B. Combined analysis of CSF Tau, A 42, A 142 and A 1 40 ox in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. *International Journal of Alzheimer's Disease*. 2010;(no pagination)(761571). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
683. Blennow KH, H. Weiner, M. Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nature Reviews Neurology*. 2010;6(3):131-44. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
684. Boban MS, H. Mimica, N. Mladinov, M. Susmair, C. Ackl, N. Bader, B. Huzak, M. Danek, A. Hof, P. R. Simic, G. CSF TAU proteins in differential diagnosis of dementia. *Translational Neuroscience*. 2010;1(1):43-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
685. Chen CCE, S. Dewaele, S. Le Bastard, N. Martin, J. J. Vanhooren, V. Libert, C. De Deyn, P. P. Altered serum glycomics in Alzheimer disease: a potential blood biomarker? *Rejuvenation Research*. 2010;13(4):439-44. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

686. Chen CS, Q. Zhang, B. Y. Wang, G. R. Zhou, W. Gao, C. Tian, C. Mei, G. Y. Han, Y. L. Han, J. Dong, X. P. The prepared tau exon-specific antibodies revealed distinct profiles of tau in CSF of the patients with Creutzfeldt-Jakob disease. PLoS ONE [Electronic Resource]. 2010;5(7):e11886. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
687. Comi CC, M. Chiocchetti, A. Nicola, S. Galimberti, D. Fenoglio, C. Cappellano, G. Monaco, F. Scarpini, E. Dianzani, U. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. Journal of Alzheimer's Disease. 2010;19(4):1143-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
688. Craig-Schapiro RP, R. J. Roe, C. M. Xiong, C. Carter, D. Cairns, N. J. Mintun, M. A. Peskind, E. R. Li, G. Galasko, D. R. Clark, C. M. Quinn, J. F. D'Angelo, G. Malone, J. P. Townsend, R. R. Morris, J. C. Fagan, A. M. Holtzman, D. M. YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry. 2010;68(10):903-12. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
689. Eckerstrom CA, U. Olsson, E. Rolstad, S. Blennow, K. Zetterberg, H. Malmgren, H. Edman, A. Wallin, A. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Dementia & Geriatric Cognitive Disorders. 2010;29(4):294-300. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
690. Formichi PP, L. Radi, E. Cevenini, G. Dotti, M. T. Federico, A. CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder. International journal of Alzheimer's disease. 2010;18:18. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
691. Forsberg AA, O. Engler, H. Wall, A. Langstrom, B. Nordberg, A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Current Alzheimer Research. 2010;7(1):56-66. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
692. Frisoni GBG, S. Signorini, M. Garibotto, V. Paghera, B. Binetti, G. Canu, E. Geroldi, C. Perani, D. Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases. Alzheimer Disease & Associated Disorders. 2010;24(1):108-14. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
693. Gabelle AR, S. Geny, C. Bennys, K. Labauge, P. Tholance, Y. Quadrio, I. Tiers, L. Gor, B. Chaulet, C. Vighetto, A. Croisile, B. Krolak-Salmon, P. Touchon, J. Perret-Liaudet, A. Lehmann, S. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Research. 2010;1357:175-83. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
694. Gazova ZA, A. Kristofikova, Z. Bartos, A. Ricny, J. Cechova, L. Klaschka, J. Ripova, D. Attenuated antiaggregation effects of magnetite nanoparticles in cerebrospinal fluid of people with Alzheimer's disease. Molecular Biosystems. 2010;6(11):2200-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

695. Gil-Bea FJS, M. Solomon, A. Mugueta, C. Winblad, B. Kivipelto, M. Ramirez, M. J. Cedazo-Minguez, A. Insulin levels are decreased in the cerebrospinal fluid of women with prodromal Alzheimer's disease. *Journal of Alzheimer's Disease*. 2010;22(2):405-13. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
696. Hampel HB, K. Shaw, L. M. Hoessler, Y. C. Zetterberg, H. Trojanowski, J. Q. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. *Experimental Gerontology*. 2010;45(1):30-40. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
697. Hanisch KS, H. Alafuzoff, I. Hoffmann, R. Analysis of human tau in cerebrospinal fluid. *Journal of Proteome Research*. 2010;9(3):1476-82. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
698. Hort JB, A. Pirtila, T. Scheltens, P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. *European Journal of Neurology*. 2010;17(1):90-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
699. Hu WTC-P, A. Arnold, S. E. Grossman, M. Clark, C. M. Shaw, L. M. McCluskey, L. Elman, L. Karlawish, J. Hurtig, H. I. Siderowf, A. Lee, V. M. Y. Soares, H. Trojanowski, J. Q. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. *Acta Neuropathologica*. 2010;120(3):385-99. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
700. Ikeuchi TH, S. Miida, T. Fukamachi, I. Tokutake, T. Ebinuma, H. Takubo, K. Kaneko, H. Kasuga, K. Kakita, A. Takahashi, H. Bujo, H. Saito, Y. Nishizawa, M. Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease. *Dementia & Geriatric Cognitive Disorders*. 2010;30(1):28-32. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
701. Jellinger KA. Neurochemical biomarkers in the differential diagnosis of movement disorders. *Movement Disorders*. 2010;25(4):500. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
702. Kamali-Moghaddam MP, F. E. Wu, D. Englund, H. Darmanis, S. Lord, A. Tavoosidana, G. Sehlin, D. Gustafsdottir, S. Nilsson, L. N. Lannfelt, L. Landegren, U. Sensitive detection of Abeta protofibrils by proximity ligation--relevance for Alzheimer's disease. *BMC Neuroscience*. 2010;11:124. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
703. Kasuga KT, T. Ishikawa, A. Uchiyama, T. Tokuda, T. Onodera, O. Nishizawa, M. Ikeuchi, T. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2010;81(6):608-10. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
704. Koric LF, O. Guedj, E. Hubert, A. M. Mancini, J. Boucraut, J. Ceccaldi, M. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? *Alzheimer Disease & Associated Disorders*. 2010;24(3):278-83. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

705. Matsubara E. Biological marker for Alzheimer disease. [Japanese]. *Brain and Nerve*. 2010;62(7):769-75. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
706. Matsui YS, K. Mutsukura, K. Watanabe, T. Nishida, N. Matsuda, H. Sugino, M. Shirabe, S. Eguchi, K. Kataoka, Y. Development of an ultra-rapid diagnostic method based on heart-type fatty acid binding protein levels in the CSF of CJD patients. *Cellular & Molecular Neurobiology*. 2010;30(7):991-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
707. Mukaetova-Ladinska EBM, R. Perry, E. K. Cerebrospinal fluid biomarkers for Dementia with Lewy Bodies. *International Journal of Alzheimer's Disease*. 2010;(no pagination)(536538). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
708. Mulder SDH, C. E. van der Flier, W. M. Scheltens, P. Blankenstein, M. A. Veerhuis, R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. *Journal of Alzheimer's Disease*. 2010;22(4):1073-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
709. Mulder SDvdF, W. M. Verheijen, J. H. Mulder, C. Scheltens, P. Blankenstein, M. A. Hack, C. E. Veerhuis, R. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. *Journal of Alzheimer's Disease*. 2010;20(1):253-60. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
710. Nakajima MA, H. Miyajima, M. [Diagnostic value of CSF biomarker profile in idiopathic normal pressure hydrocephalus; leucine-rich alpha-2-glycoprotein is a potential biological marker]. *Rinsho Shinkeigaku - Clinical Neurology*. 2010;50(11):973-6. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
711. Okamura NY, K. Furukawa, K. Arai, H. Kudo, Y. Biomarkers of neurological disease. [Japanese]. *Japanese Journal of Clinical Pharmacology and Therapeutics*. 2010;41(3):101-6. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
712. Okonkwo OCA, M. L. Griffith, H. R. Mielke, M. M. Shaw, L. M. Trojanowski, J. Q. Tremont, G. Alzheimer's Disease Neuroimaging, Initiative. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. *Archives of Neurology*. 2010;67(6):688-96. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
713. Petzold AV, N. A. van Uffelen, K. Blankenstein, M. A. Teunissen, C. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. *Journal of Neuroscience Methods*. 2010;193(2):296-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
714. Rolstad SN, A. Eckerstrom, C. Gustavsson, M. H. Blennow, K. Olesen, P. J. Zetterberg, H. Wallin, A. High education may offer protection against tauopathy in patients with mild cognitive impairment. *Journal of Alzheimer's Disease*. 2010;21(1):221-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
715. Sancesario GME, Z. Nuccetelli, M. Bernardini, S. Sorge, R. Martorana, A. Federici, G.

- Bernardi, G. Sancesario, G. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation? *Experimental Neurology*. 2010;223(2):371-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
716. Serrano-Pozo AV, G. L. Lutjohann, D. Locascio, J. J. Tennis, M. K. Deng, A. Atri, A. Hyman, B. T. Irizarry, M. C. Growdon, J. H. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. *Alzheimer Disease and Associated Disorders*. 2010;24(3):220-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
717. Sundelof JS, J. Hansson, O. Eriksdotter-Jonhagen, M. Giedraitis, V. Larsson, A. Degerman-Gunnarsson, M. Ingelsson, M. Minthon, L. Blennow, K. Kilander, L. Basun, H. Lannfelt, L. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. *Journal of Alzheimer's Disease*. 2010;22(4):1223-30. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
718. Tolboom NK, E. L. G. E. Schott, J. M. Yaqub, M. Blankenstein, M. A. Barkhof, F. Pijnenburg, Y. A. L. Lammertsma, A. A. Scheltens, P. Van Berckel, B. N. M. Dementia mimicking Alzheimer s disease owing to a Tau mutation: CSF and PET findings. *Alzheimer Disease and Associated Disorders*. 2010;24(3):303-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
719. Urakami K. Diagnostic biomarker for early stage of Alzheimer's disease: current state and view in the future. *Psychogeriatrics:The Official Journal of the Japanese Psychogeriatric Society*. 2010;10(2):49-52. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
720. Verbeek MMS, J. M. The use of indexes in the interpretation of cerebrospinal fluid analyses. *Neurobiology of Aging*. 2010;31(9):1654; discussion 5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
721. Verwey NAK, M. I. van der Flier, W. M. Veerhuis, R. Berkhof, H. Twaalfhoven, H. Blankenstein, M. A. Scheltens, Pijnenburg, Y. A. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. *Journal of Alzheimer's Disease*. 2010;20(2):445-52. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
722. Wang GRG, C. Shi, Q. Zhou, W. Chen, J. M. Dong, C. F. Shi, S. Wang, X. Wei, Y. Jiang, H. Y. Han, J. Dong, X. P. Elevated levels of tau protein in cerebrospinal fluid of patients with probable Creutzfeldt-Jakob disease. *American Journal of the Medical Sciences*. 2010;340(4):291-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
723. Wattamwar PRM, P. S. An overview of biomarkers in Alzheimer's disease. *Annals of Indian Academy of Neurology*. 2010;13(SUPPL. 2):S116-S23. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
724. Alexopoulos PG, F. Popp, J. Jessen, F. Peters, O. Wolf, S. Kneib, T. Kurz, A. Richter-Schmidinger, T. Lewczuk, P. Bleich, S. Wiltfang, J. Kornhuber, J. Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia. *Journal of the American Geriatrics Society*. 2009;57(4):737-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

725. Bjerke MA, U. Rolstad, S. Nordlund, A. Lind, K. Zetterberg, H. Edman, A. Blennow, K. Wallin, A. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. *Dementia & Geriatric Cognitive Disorders*. 2009;28(4):348-56. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
726. Blennow KdM, G. Hansson, O. Minthon, L. Wallin, A. Zetterberg, H. Lewczuk, P. Vanderstichele, H. Vanmechelen, E. Kornhuber, J. Wiltfang, J. Heuser, I. Maier, W. Luckhaus, C. Ruther, E. Hull, M. Jahn, H. Gertz, H. J. Frolich, L. Hampel, H. Pernetzki, R. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. *Journal of Nutrition, Health and Aging*. 2009;13(3):205-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
727. Blom ESG, V. Zetterberg, H. Fukumoto, H. Blennow, K. Hyman, B. T. Irizarry, M. C. Wahlund, L. O. Lannfelt, L. Ingelsson, M. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. *Dementia & Geriatric Cognitive Disorders*. 2009;27(5):458-64. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
728. Compta YM, M. J. Ibarretxe-Bilbao, N. Junque, C. Valdeoriola, F. Munoz, E. Ezquerra, M. Rios, J. Tolosa, E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. *Movement Disorders*. 2009;24(15):2203-10. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
729. Frost BJ, R. L. Diamond, M. I. Propagation of tau misfolding from the outside to the inside of a cell. *Journal of Biological Chemistry*. 2009;284(19):12845-52. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
730. Gabelle AR, S. Lehmann, S. CSF biomarkers: Proteomics investigations and clinical applications in neurodegenerative disorders. [French]. *Revue Neurologique*. 2009;165(3):213-22. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
731. Hampel HS, Y. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2009;69(1):8-12. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
732. Jesse SS, P. Cepek, L. von Arnim, C. A. Tumani, H. Lehnert, S. Kretzschmar, H. A. Baier, M. Otto, M. Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. *Journal of Alzheimer's Disease*. 2009;17(3):541-51. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
733. Klafki HWL, P. Kamrowski-Kruck, H. Maler, J. M. Muller, K. Peters, O. Heuser, I. Jessen, F. Popp, J. Frolich, L. Wolf, S. Prinz, B. Luckhaus, C. Schroder, J. Pantel, J. Gertz, H. J. Kolsch, H. Muller, B. W. Esselmann, H. Bibl, M. Kornhuber, J. Wiltfang, J. Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. *Journal of Alzheimer's Disease*. 2009;18(3):613-22. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

734. Korolainen MAP, T. Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease. *Acta Neurologica Scandinavica*. 2009;119(1):32-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
735. Laske CS, E. Fritsche, A. Eschweiler, G. W. Leyhe, T. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. *European Archives of Psychiatry & Clinical Neuroscience*. 2009;259(2):80-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
736. Laske CS, K. Stransky, E. Leyhe, T. Gawaz, M. Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early alzheimer's disease. *Journal of Alzheimer's Disease*. 2009;17(1):115-23. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
737. Lin YTC, J. T. Yao, Y. C. Juo, Lo, Y. K. Lin, C. H. Ger, L. P. Lu, P. J. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2009;18(4):907-18. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
738. Mares JK, P. Herzig, R. Stejskal, D. Vavrouskova, J. Hlustik, P. Vranova, H. Burval, S. Zapletalova, J. Pidrman, V. Obereigneru, R. Suchy, A. Vesely, J. Podivinsky, J. Urbanek, K. New laboratory markers in diagnosis of alzheimer dementia. *Neurological Research*. 2009;31(10):1056-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
739. Mattsson NZ, H. Alzheimer's disease and CSF biomarkers: Key challenges for broad clinical applications. *Biomarkers in Medicine*. 2009;3(6):735-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
740. Meyne FG, S. F. Ciesielczyk, B. Heinemann, U. Krasnianski, A. Meissner, B. Zerr, I. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. *Journal of Alzheimer's Disease*. 2009;17(4):863-73. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
741. Mollenhauer BT, C. Neurochemical biomarkers in the differential diagnosis of movement disorders. *Movement Disorders*. 2009;24(10):1411-26. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
742. Mutsukura KS, K. Shirabe, S. Tomita, I. Fukutome, T. Morikawa, M. Iseki, M. Sasaki, K. Shiaga, Y. Kitamoto, T. Eguchi, K. Familial Creutzfeldt-Jakob disease with a V180I mutation: comparative analysis with pathological findings and diffusion-weighted images. *Dementia & Geriatric Cognitive Disorders*. 2009;28(6):550-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
743. Ohrfelt AG, P. Andreasen, N. Wallin, A. Vanmechelen, E. Blennow, K. Zetterberg, H. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-A marker of synapse loss? *Neuroscience Letters*. 2009;450(3):332-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

744. Roher AEM, C. L. Sue, L. I. Hu, Y. Wilson, J. Beach, T. G. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. *Biomarkers*. 2009;14(7):493-501. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
745. Schuitemaker AD, M. G. Veerhuis, R. Scheltens, P. Schoonenboom, N. S. Hack, C. E. Blankenstein, M. A. Jonker, C. Inflammatory markers in AD and MCI patients with different biomarker profiles. *Neurobiology of Aging*. 2009;30(11):1885-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
746. Schultz KW, S. Nilsson, K. Nielsen, J. E. Lindquist, S. G. Hjermind, L. E. Andersen, B. B. Wallin, A. Nilsson, C. Petersen, A. Reduced CSF CART in dementia with Lewy bodies. *Neuroscience Letters*. 2009;453(2):104-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
747. Singer DS, H. Alafuzoff, I. Hoffmann, R. Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease. *Analytical & Bioanalytical Chemistry*. 2009;395(7):2263-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
748. Smach MAC, B. Ben Othman, L. Lammouchi, T. Dridi, H. Nafati, S. Ltaief, A. Bennamou, S. Limem, K. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. *European Neurology*. 2009;62(6):349-55. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
749. Straten GE, G. W. Maetzler, W. Laske, C. Leyhe, T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. *Journal of Alzheimer's Disease*. 2009;18(2):331-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
750. Talab RM, J. Andrys, C. Stourae, P. Hort, J. Valis, M. Tau protein, phosphorylated tau protein, and beta-amyloid 42 levels in patients with neurodegenerative diseases complicated by cognitive deficits: A non-randomized, concurrent, case-control investigation. *Neural Regeneration Research*. 2009;4(11):951-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
751. Tapiola TA, I. Herukka, S. K. Parkkinen, L. Hartikainen, P. Soininen, H. Pirtila, T. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. *Archives of Neurology*. 2009;66(3):382-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
752. Tarnaris AT, A. K. Kitchen, N. D. Watkins, L. D. Ongoing search for diagnostic biomarkers in idiopathic normal pressure hydrocephalus. *Biomarkers in Medicine*. 2009;3(6):787-805. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
753. Thompson PWL, A. Monitoring the amyloid beta-peptide in vivo - caveat emptor. *Drug Discovery Today*. 2009;14(5-6):241-51. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
754. Verwey NAvdF, W. M. Blennow, K. Clark, C. Sokolow, S. De Deyn, P. P. Galasko, D. Hampel, H. Hartmann, T. Kapaki, E. Lannfelt, L. Mehta, P. D. Parnetti, L. Petzold, A.



- Pirttila, T. Saleh, L. Skinningsrud, A. Swieten, J. C. Verbeek, M. M. Wiltfang, J. Younkin, S. Scheltens, P. Blankenstein, M. A. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. *Annals of Clinical Biochemistry*. 2009;46(Pt 3):235-40. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
755. Wiltfang JL, P. Riederer, P. Grunblatt, E. Hock, C. Scheltens, P. Hampel, H. Vanderstichele, H. Iqbal, K. Galasko, D. Lannfelt, L. Otto, M. Esselman, H. Henkel, A. W. Kornhuber, J. Blennow, K. Consensus paper of the WFSBP task force on biological markers of dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. [Portuguese]. *Revista de Psiquiatria Clinica*. 2009;36(SUPPL. 1):1-16. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
756. Yaka EE, M. Y. Keskinoglu, P. Cavdar, Z. Genc, S. Genc, K. Iyilikci, L. Yener, G. G. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease. *Cell Biochemistry & Function*. 2009;27(6):395-401. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
757. Zenzmaier CM, J. Kiefer, A. Berger, P. Humpel, C. Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients. *Journal of Neurochemistry*. 2009;110(2):653-61. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
758. Zhang YL, E. Minthon, L. Wattmo, C. Blennow, K. Liu, H. J. Bronge, L. Aspelin, P. Wahlund, L. O. Medial temporal lobe atrophy increases the specificity of cerebrospinal fluid biomarkers in Alzheimer disease with minor cerebrovascular changes. *Acta Radiologica*. 2009;50(6):674-81. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
759. Bibl MM, B. Esselmann, H. Schneider, M. Lewczuk, P. Welge, V. Gross, M. Falkai, P. Kornhuber, J. Wiltfang, J. Cerebrospinal fluid neurochemical phenotypes in vascular dementias: Original data and mini-review. *Dementia and Geriatric Cognitive Disorders*. 2008;25(3):256-65. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
760. Boban MG, K. Mladinov, M. Hof, P. R. Sussmair, C. Ackl, N. Stanic, G. Bader, B. Danek, A. Simic, G. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia. *Collegium Antropologicum*. 2008;32 Suppl 1:31-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
761. Formichi PP, L. Radi, E. Cevenini, G. Dotti, M. T. Federico, A. CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. *European Journal of Neurology*. 2008;15(11):1252-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
762. Frankfort SVT, L. R. van Campen, J. P. C. M. Verbeek, M. M. Jansen, R. W. M. M. Beijnen, J. H. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: A review of recent literature. *Current Clinical Pharmacology*. 2008;3(2):123-31. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
763. Ghidoni RB, L. Glionna, M. Franzoni, M. Binetti, G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. *Neurology*. 2008;71(16):1235-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
764. Hort JV, M. Waberzinek, G. Talab, R. Glossova, L. Bojar, M. Vyhnaek, M. Skoda, D.

- Masopust, J. St'ourac, P. Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia. [German]. *Nervenarzt*. 2008;79(8):891-8. 배제 사유: 한국어 또는 영어로 출판되지 않은 연구
765. Jellinger KAJ, B. Attems, J. Kienzl, E. Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? *Journal of Cellular & Molecular Medicine*. 2008;12(4):1094-117. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
766. Kaiser ES, P. Hunt, A. Thomann, P. A. Pantel, J. Schroder, J. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease]. *Zeitschrift fur Gerontologie und Geriatrie*. 2008;41(6):497-501. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
767. Lanz TAS, C. T. Semproni, A. R. Marconi, M. Brown, T. M. Richter, K. E. G. Schmidt, K. Nelson, F. R. Schachter, J. B. Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. *Biochemical Pharmacology*. 2008;75(5):1093-103. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
768. Laske CS, K. Eschweiler, G. W. Leyhe, T. Gawaz, M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? *Journal of Alzheimer's Disease*. 2008;15(1):83-95. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
769. Lee JMB, K. Andreasen, N. Laterza, O. Modur, V. Olander, J. Gao, F. Ohlendorf, M. Ladenson, J. H. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. *Clinical Chemistry*. 2008;54(10):1617-23. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
770. Liu LD, K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. *Journal of Visualized Experiments*. 2008;21:10. 배제사유: 동물연구 또는 전임상연구
771. Mandic GM, I. Ostojic, M. Stojkovic, T. Misirlic-Dencic, S. Zivanovic-Radnic, T. Stefanovic, R. Bumbasirevic, M. Stefanova, E. Kostic, V. [Cerebrospinal fluid amyloid beta and tau protein: biomarkers for Alzheimer's disease]. *Vojnosanitetski Pregled*. 2008;65(12):901-5. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
772. Marksteiner JP, M. Ullrich, C. Oberbauer, H. Blasko, I. Lederer, W. Hinterhuber, H. Humpel, C. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties. *Pharmacology*. 2008;82(3):214-20. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
773. Palumbo BS, D. Sabalich, I. Tranfaglia, C. Parnetti, L. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? *Functional Neurology*. 2008;23(2):93-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
774. Roche SG, A. Lehmann, S. Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. *Proteomics - Clinical Applications*. 2008;2(3):428-36. 배제 사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

775. Salehi ZM, F. Naji, M. Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. *Biofactors*. 2008;33(2):99-106. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
776. Sarac HH, S. Basic, S. Henigsberg, N. Rados, M. Simic, G. Magnetic resonance spectroscopy and measurement of tau epitopes of autopsy proven sporadic Creutzfeldt-Jakob disease in a patient with non-specific initial EEG, MRI and negative 14-3-3 immunoblot. *Collegium Antropologicum*. 2008;32 Suppl 1:199-204. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
777. Simic GB, M. Hof, P. R. Cerebrospinal fluid phosphorylated tau proteins as predictors of Alzheimer's disease in subjects with mild cognitive impairment. *Periodicum Biologorum*. 2008;110(1):27-30. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
778. Skogseth RM, E. Ballard, C. Rongve, A. Nore, S. Alves, G. Aarsland, D. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2008;25(6):559-63. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
779. Smach MAC, B. Lammouchi, T. Harrabi, I. Ben Othman, L. Dridi, H. Bennamou, S. Limem, K. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. *Neuroscience Letters*. 2008;440(2):145-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
780. Steinacker PH, C. Sperfeld, A. D. Jesse, S. von Arnim, C. A. Lehnert, S. Pabst, A. Uttner, I. Tumani, H. Lee, V. M. Trojanowski, J. Q. Kretzschmar, H. A. Ludolph, A. Neumann, M. Otto, M. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Archives of Neurology*. 2008;65(11):1481-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
781. Verwey NAB, F. H. Van Der Flier, W. M. Veerhuis, R. Scheltens, P. Blankenstein, M. A. Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. *Clinical Chemistry and Laboratory Medicine*. 2008;46(9):1300-4. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
782. Wan HID, M. Hurko, O. Rutkowski, J. L. Biomarkers for alzheimer's disease: Translational medicine approaches in development of disease modifying therapeutics. *American Pharmaceutical Review*. 2008;11(6). 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
783. Zabeo MDR, F. Rispoli, F. Somalvico, F. Longhi, E. Franceschi, M. Tau, p-Tau and beta amiloid 1-42 concentrations in Alzheimer and frontotemporal dementia patients. [Italian]. *Rivista Italiana della Medicina di Laboratorio*. 2008;4(4):259-63. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
784. Bibl MM, B. Wolf, S. Esselmann, H. Lewczuk, P. Kornhuber, J. Wiltfang, J. Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations. *Journal of Neural Transmission*. 2007;114(5):621-8. 배제사유: 적절한 의료결과를 하나 이상 보

고하지 않은 연구

785. Blennow KZ, H. Minthon, L. Lannfelt, L. Strid, S. Annas, P. Basun, H. Andreasen, N. Longitudinal stability of CSF biomarkers in Alzheimer's disease. *Neuroscience Letters*. 2007;419(1):18-22. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
786. Engelborghs SS, K. Cras, P. Brouwers, N. Serneels, S. De Leenheir, E. Martin, J. J. Vanmechelen, E. Van Broeckhoven, C. De Deyn, P. P. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. *Brain*. 2007;130(Pt 9):2320-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
787. Fiorini MZ, G. Benedetti, M. D. Righetti, P. G. Monaco, S. Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. *Proteomics - Clinical Applications*. 2007;1(9):963-71. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
788. Haass CS, D. J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. *Nature Reviews Molecular Cell Biology*. 2007;8(2):101-12. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
789. Herukka SKH, S. Hallikainen, M. Tervo, S. Soininen, H. Pirttila, T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. *Neurobiology of Aging*. 2007;28(4):507-14. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
790. Hu YH, A. Kauwe, J. S. K. Gross, J. Cairns, N. J. Goate, A. M. Fagan, A. M. Townsend, R. R. Holtzman, D. M. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. *Proteomics - Clinical Applications*. 2007;1(11):1373-84. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
791. Iqbal KG-I, I. Alzheimer subgroups: Towards effective drug development. *Future Neurology*. 2007;2(1):3-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
792. Jellinger KA. New possibilities for early diagnosis of Alzheimer disease: "Alzheimer associated gene" and blood biomarkers. *Psychogeriatrics Polska*. 2007;4(4):159-77. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
793. Kapaki EP, G. P. Theotoka, I. Liappas, I. Neurochemical profile of elderly alcoholic patients with cognitive decline compared with patients with other dementias. *International Journal on Disability and Human Development*. 2007;6(2):215-23. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
794. Le Bastard NVB, M. De Leenheir, E. Martin, J. J. De Deyn, P. P. Engelborghs, S. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2007;62(8):923-4; author reply 4-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
795. Marksteiner JH, H. Humpel, C. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. *Drugs of Today*. 2007;43(6):423-31. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

796. Mollenhauer BS, P. Bahn, E. Bibl, M. Brechlin, P. Schlossmacher, M. G. Locascio, J. J. Wiltfang, J. Kretzschmar, H. A. Poser, S. Trenkwalder, C. Otto, M. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: Marker candidates for dementia with Lewy bodies. *Neurodegenerative Diseases*. 2007;4(5):366-75. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
797. Nielsen HMM, L. Londos, E. Blennow, K. Miranda, E. Perez, J. Crowther, D. C. Lomas, D. A. Janciauskiene, S. M. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. *Neurology*. 2007;69(16):1569-79. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
798. Paraskevas GPK, E. Kararizou, E. Mitsonis, C. Sfagos, C. Vassilopoulos, D. Cerebrospinal fluid tau protein is increased in neurosyphilis: a discrimination from syphilis without nervous system involvement? *Sexually Transmitted Diseases*. 2007;34(4):220-3. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
799. Petzold A. CSF biomarkers for improved prognostic accuracy in acute CNS disease. *Neurological Research*. 2007;29(7):691-708. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
800. Robert MM, P. Tau and tauopathies. *Neurology India*. 2007;55(1):11-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
801. Satoh KS, S. Eguchi, K. [Clinical typing and diagnosis of sporadic human prion diseases (classic sporadic CJD, MM2-cortical form CJD, MM2-thalamic form CJD)]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*. 2007;65(8):1423-32. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
802. Schipper HM. The role of biologic markers in the diagnosis of Alzheimer's disease. *Alzheimer's and Dementia*. 2007;3(4):325-32. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
803. Schonknecht PP, J. Kaiser, E. Thomann, P. Schroder, J. Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. *Neuroscience Letters*. 2007;416(1):39-42. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
804. Shaw LMK, M. Clark, C. M. Lee, V. M. Y. Trojanowski, J. Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. *Nature Reviews Drug Discovery*. 2007;6(4):295-303. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
805. Shipp G. Ultra-sensitive measurement of protein and nucleic acid biomarkers may enable earlier disease detection and more effective therapies. *Drug Discovery World*. 2007;8(1):79-82. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
806. Skoda DH, J. Vyhnaek, M. Glosova, L. Minarikova, M. Jinoch, P. Kranda, K. Bojar, M. Specific anti-beta tubulin antibodies in differential diagnosis of dementias. [Czech]. *Ceska a Slovenska Neurologie a Neurochirurgie*. 2007;70(2):152-7. 배제사유: 한국어 또는 영어로 출판되지 않은 연구

807. Steinerman JRH, L. S. Laboratory biomarkers in Alzheimer's disease. *Current Neurology and Neuroscience Reports*. 2007;7(5):381-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
808. Wada-Isoe KK, M. Nakaso, K. Nakashima, K. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. *Journal of the Neurological Sciences*. 2007;260(1-2):33-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
809. Wiltfang JB, M. Maler, M. Klafki, M. W. Esselmann, H. Kornhuber, J. Lewczuk, R. Neurochemical diagnostic of dementia - Quo vadis?. [German]. *Nervenheilkunde*. 2007;26(10):861-6. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
810. Wiltfang JE, H. Bibl, M. Hull, M. Hampel, H. Kessler, H. Frolich, L. Schroder, J. Peters, O. Jessen, F. Luckhaus, C. Perneczky, R. Jahn, H. Fiszer, M. Maler, J. M. Zimmermann, R. Bruckmoser, R. Kornhuber, J. Lewczuk, P. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. *Journal of Neurochemistry*. 2007;101(4):1053-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
811. Yamamori HK, S. Grundke-Iqbal, I. Blennow, K. Ewers, M. Hampel, H. Iqbal, K. Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. *Neuroscience Letters*. 2007;418(2):186-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
812. Zhong ZE, M. Teipel, S. Burger, K. Wallin, A. Blennow, K. He, P. McAllister, C. Hampel, H. Shen, Y. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. *Archives of General Psychiatry*. 2007;64(6):718-26. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
813. Bibl MM, B. Esselmann, H. Lewczuk, P. Trenkwalder, C. Brechlin, P. Ruther, E. Kornhuber, J. Otto, M. Wiltfang, J. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. *Journal of Neural Transmission*. 2006;113(11):1771-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
814. Botella-Lopez AB, F. Gavin, R. Garcia-Ayllon, M. S. Gomez-Tortosa, E. Pena-Casanova, J. Urena, J. M. Del Rio, J. A. Blesa, R. Soriano, E. Saez-Valero, J. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(14):5573-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
815. Brettschneider JP, A. Sussmuth, S. D. Ludolph, A. C. Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. *Neurology*. 2006;66(6):852-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
816. Brettschneider JW, K. Ehrenreich, H. Riepe, M. Tumani, H. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. *Neuroscience Letters*. 2006;404(3):347-51. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

817. Carro ET, J. L. Spuch, C. Bohl, D. Heard, J. M. Torres-Aleman, I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? *Neurobiology of Aging*. 2006;27(11):1618-31. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
818. Clark CMP, D. Shaw, L. M. Leight, S. Xie, S. X. Gu, A. Lee, V. M. Y. Trojanowski, J. Q. Commentary on "Optimal design of clinical trials for drugs designed to slow the course of AlzheimerdeegreeFs disease. " *Biochemical biomarkers of late-life dementia. Alzheimer's and Dementia*. 2006;2(4):287-93. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
819. Engelborghs SM, K. Vloeberghs, E. Aerts, T. Somers, N. Marien, P. De Deyn, P. P. Neuropsychological and behavioural correlates of CSF biomarkers in dementia. *Neurochemistry International*. 2006;48(4):286-95. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
820. Fagan AMM, M. A. Mach, R. H. Lee, S. Y. Dence, C. S. Shah, A. R. LaRossa, G. N. Spinner, M. L. Klunk, W. E. Mathis, C. A. DeKosky, S. T. Morris, J. C. Holtzman, D. M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta;<sup>42</sup> in humans. *Annals of Neurology*. 2006;59(3):512-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
821. Formichi PB, C. Radi, E. Federico, A. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. *Journal of Cellular Physiology*. 2006;208(1):39-46. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
822. Goodall CAH, M. W. Everington, D. Ironside, J. W. Knight, R. S. Green, A. J. Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications. *Journal of Neurology, Neurosurgery & Psychiatry*. 2006;77(1):89-91. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
823. Hunt AS, P. Henze, M. Toro, P. Haberkorn, U. Schroder, J. CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer's disease. *Neuropsychiatric Disease and Treatment*. 2006;2(2):207-12. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
824. Leoni VS, M. Salomon, A. Kivipelto, M. Bjorkhem, I. Wahlund, L. O. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? *Neuroscience Letters*. 2006;397(1-2):83-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
825. Lewczuk PB, G. Esselmann, H. Bruckmoser, R. Zimmermann, R. Fiszer, M. Bibl, M. Maler, J. M. Kornhuber, J. Wiltfang, J. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides [4]. *Clinical Chemistry*. 2006;52(2):332-4. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
826. Maccioni RBL, M. Guillon, M. Mujica, C. Bosch, R. Farias, G. Fuentes, P. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. *Neurobiology of Aging*. 2006;27(2):237-44. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

나 이상 보고하지 않은 연구

827. Merrill CAJ, M. A. Minthon, L. Ejnell, H. C. son Silander HBlennow, K. Karlsson, M. Nordlund, A. Rolstad, S. Warkentin, S. Ben-Menachem, E. Sjogren, M. J. Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year. *Journal of Clinical Psychiatry*. 2006;67(8):1171-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
828. Mollenhauer BT, C. von Ahsen, N. Bibl, M. Steinacker, P. Brechlin, P. Schindehuetter, J. Poser, S. Wiltfang, J. Otto, M. Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. *Dementia & Geriatric Cognitive Disorders*. 2006;22(3):200-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
829. Padmanabhan JL, M. Dickson, D. W. Potter, H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. *Brain*. 2006;129(Pt 11):3020-34. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
830. Peoc'h KH, M. Chasseigneaux, S. Leandre, S. Lenne, M. Beaudry, P. Launay, J. M. Laplanche, J. L. Clinical biology and human prion diseases. [French]. *Immuno-Analyse et Biologie Specialisee*. 2006;21(6):369-74. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
831. Rentzos MP, G. P. Kapaki, E. Nikolaou, C. Zoga, M. Rombos, A. Tsoutsou, A. Vassilopoulos, D. D. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. *Journal of the Neurological Sciences*. 2006;249(2):110-4. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
832. Sengupta AG-I, I. Iqbal, K. Regulation of phosphorylation of tau by protein kinases in rat brain. *Neurochemical Research*. 2006;31(12):1473-80. 배제사유: 동물연구 또는 전임상연구
833. Shiga YW, H. Miyazawa, K. Kido, H. Itoyama, Y. 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages. *Journal of Clinical Neuroscience*. 2006;13(6):661-5. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
834. Siemers ERD, R. A. Demattos, R. May, P. C. New pathways in drug discovery for Alzheimer's disease. *Current Neurology and Neuroscience Reports*. 2006;6(5):372-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
835. Stefani AM, A. Bernardini, S. Panella, M. Mercati, F. Orlacchio, A. Pierantozzi, M. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. *Journal of the Neurological Sciences*. 2006;251(1-2):124-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
836. Urakami K. Mild cognitive impairment: Biological diagnostic markers for early stages of Alzheimer's disease. *Psychogeriatrics*. 2006;6(SUPPL. 1):S26-S9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
837. Van Everbroeck BM, A. Sciot, R. Godfraind, C. Deprez, M. Quoilin, S. Martin, J. J. Cras,



- P. Increased incidence of sporadic Creutzfeldt-Jakob disease in the age groups between 70 and 90 years in Belgium. *European Journal of Epidemiology*. 2006;21(6):443-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
838. Wolozin BB, M. M. Interventions for heart disease and their effects on Alzheimer's disease. *Neurological Research*. 2006;28(6):630-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
839. Yaka EYE, M. Keskinoglu, P. Cavdar, Z. Genc, S. Genc, K. Iyilikci, L. Yener, G. G. Biochemical markers in cerebrospinal fluid (CSF) and evaluation of the effect of CSF on PC12 cell line viability in Alzheimer's disease. [Turkish]. *Turk Geriatri Dergisi*. 2006;9(1):1-7. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
840. Andreasen NB, K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. *Clinical Neurology and Neurosurgery*. 2005;107(3):165-73. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
841. Blennow K. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. *Expert Review of Molecular Diagnostics*. 2005;5(5):661-72. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
842. Blennow KJ, A. Zetterberg, H. Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. *International Journal of Molecular Medicine*. 2005;16(6):1147-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
843. Davidsson PS, M. The use of proteomics in biomarker discovery in neurodegenerative diseases. *Disease Markers*. 2005;21(2):81-92. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
844. El Mouedden MV, M. Meert, T. Mercken, M. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides. *Journal of Neuroscience Methods*. 2005;145(1-2):97-105. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
845. Fu XJ. Determination of tau protein and beta-amyloid 42 in cerebrospinal fluid of cognitive handicap patients with cerebral infarction and diabetes mellitus. [Chinese]. *Chinese Journal of Clinical Rehabilitation*. 2005;9(9):92-4. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
846. Hampel HB, K. Pruessner, J. C. Zinkowski, R. DeBernardis, J. Kerkman, D. Leinsinger, G. Evans, A. C. Davies, P. Moller, H. J. Teipel, S. J. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. *Archives of Neurology*. 2005;62(5):770-3. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
847. Ibach BH, E. Marienhagen, J. Hajak, G. Clioquinol treatment in familiar early onset of Alzheimer's disease: A case report. *Pharmacopsychiatry*. 2005;38(4):178-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구

848. Iqbal KF, M. Khatoon, S. Soininen, H. Pirttila, T. Lehtovirta, M. Alafuzoff, I. Blennow, K. Andreasen, N. Vanmechelen, E. Grundke-Iqbal, I. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. *Annals of Neurology*. 2005;58(5):748-57. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
849. Jia JPM, R. Sun, Y. X. Sun, W. J. Ji, X. M. Jia, L. F. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. *Neuroscience Letters*. 2005;383(1-2):12-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
850. Kapaki EL, I. Paraskevas, G. P. Theotoka, I. Rabavilas, A. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages. *International Journal of Geriatric Psychiatry*. 2005;20(8):722-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
851. Kawarabayashi TS, M. [Biomarker and imaging of Alzheimer's disease]. *No to Shinkei - Brain & Nerve*. 2005;57(10):839-52. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
852. Lavados MF, G. Rothhammer, F. Guillon, M. Mujica, M. C. Maccioni, C. Maccioni, R. B. ApoE alleles and tau markers in patients with different levels of cognitive impairment. *Archives of Medical Research*. 2005;36(5):474-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
853. Leszek JM, K. Janicka, B. Kiejna, A. Wiak, A. Usefulness of cerebrospinalis fluid total tau concentration as biomarker for Alzheimer's disease. *Advances in Clinical and Experimental Medicine*. 2005;14(3):505-9. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
854. Matsui TN, M. Maruyama, M. Yuzuriha, T. Yao, H. Tanji, H. Ootsuki, M. Tomita, N. Matsushita, S. Higuchi, S. Yoshida, Y. Seki, T. Iwasaki, K. Furukawa, K. Arai, H. Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease. *Neurodegenerative Diseases*. 2005;2(6):299-304. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
855. Miller BBM, J. W. Multiplex method for measuring biomarkers of Alzheimer disease in cerebrospinal fluid. *Clinical Chemistry*. 2005;51(2):289-90. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
856. Paraskevas GPK, E. Liappas, I. Theotoka, I. Mamali, I. Zournas, C. Lykouras, L. The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. *Journal of Geriatric Psychiatry and Neurology*. 2005;18(3):163-73. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
857. Peoc'h K. [The mystery of prion proteins: from neurodegenerative diseases to the biology of reproduction]. *Annales de Biologie Clinique*. 2005;63(2):121-6. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
858. Qiu XY. Levels of tau protein and beta-amyloid 42 protein in cerebrospinal fluid and

- the levels of beta-amyloid 42 protein and transforming growth factor-alpha in serum of patients with vascular dementia. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9(16):122-4. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
859. Romeo MJE, V. Lowenthal, M. Espina, B. H. Petricoin, Iii E. F. Liotta, L. A. CSF proteome: A protein repository for potential biomarker identification. Expert Review of Proteomics. 2005;2(1):57-70. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
860. Ruetschi UZ, H. Podust, V. N. Gottfries, J. Li, S. Hviid Simonsen, A. McGuire, J. Karlsson, M. Rymo, L. Davies, H. Minthon, L. Blennow, K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Experimental Neurology. 2005;196(2):273-81. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
861. Stefani AB, S. Panella, M. Pierantozzi, M. Nuccetelli, M. Koch, G. Urbani, A. Giordano, A. Martorana, A. Orlacchio, A. Federici, G. Bernardi, G. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. Journal of the Neurological Sciences. 2005;237(1-2):83-8. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
862. Urakami KT, M. Inoue, M. Wada-Isoe, K. Wakutani, Y. Nakashima, K. Studies on diagnostic markers for Alzheimer's disease. Psychogeriatrics. 2005;5(3):99-102. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
863. Vanderstichele HDM, G. Andreasen, N. Kostanjevecki, V. Wallin, A. Olsson, A. Blennow, K. Vanmechelen, E. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clinical Chemistry. 2005;51(9):1650-60. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
864. Verbeek MMP, Y. A. Schoonenboom, N. S. Kremer, B. P. H. Scheltens, P. Grossman, M. Lee, V. M. Y. Farmer, J. Leight, S. Trojanowski, J. Q. Cerebrospinal fluid tau levels in frontotemporal dementia [4] (multiple letters). Annals of Neurology. 2005;58(4):656-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
865. Wang SH. Level of related factors in cerebrospinal fluid for evaluating Alzheimer disease patients' condition. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2005;9(9):48-9+69. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
866. Wiltfang JL, P. Riederer, P. Grunblatt, E. Hock, C. Scheltens, P. Hampel, H. Vanderstichele, H. Iqbal, K. Galasko, D. Lannfelt, L. Otto, M. Esselmann, H. Henkel, A. W. Kornhuber, J. Blennow, K. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World Journal of Biological Psychiatry. 2005;6(2):69-84. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
867. Yao YC, C. M. Trojanowski, J. Q. Lee, V. M. Pratico, D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Annals of Neurology. 2005;58(4):623-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
868. Zetterberg HH, A. L. Nilsson, P. Andersson, E. Lind, B. Blennow, K. New possibilities to analyse suspected Creutzfeldt-Jakob disease. Safer diagnosis with cerebrospinal fluid

- analysis of 14-3-3 proteins and T-tau/P-tau levels. [Swedish]. *Lakartidningen*. 2005;102(12-13):956-61. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
869. Burkhard PEF, R. Mermillod, B. Krause, K. H. Bouras, C. Irminger, I. Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: Delineation of reference intervals and their limitations. *Clinical Chemistry and Laboratory Medicine*. 2004;42(4):396-407. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
870. Glosova LH, J. Bojar, M. Skoda, D. Assessment of total tau protein, phospho-tau and beta amyloid in cerebrospinal fluid: The first experience of our laboratory. [Czech]. *Klinicka Biochemie a Metabolismus*. 2004;12(2):113-6. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
871. Golab JB, T. M. Daniel, V. Naujokat, C. Role of the ubiquitin-proteasome pathway in the diagnosis of human diseases. *Clinica Chimica Acta*. 2004;340(1-2):27-40. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
872. Guo HZL, L. P. Qu, C. Q. Sensitivity and specificity of proteins in cerebrospinal fluid for diagnosis of Alzheimer's disease. *Chinese Journal of Clinical Rehabilitation*. 2004;8(10):1982-3. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
873. Hampel HB, K. Zinkowski, R. Teipel, S. J. Goernitz, A. Andreasen, N. Sjoegren, M. DeBernardis, J. Kerkman, D. Ishiguro, K. Ohno, H. Vanmechelen, E. Vanderstichele, H. McCulloch, C. Moller, H. J. Davies, P. Blennow, K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. *Archives of General Psychiatry*. 2004;61(1):95-102. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
874. Hampel HT, S. J. Fuchsberger, T. Andreasen, N. Wiltfang, J. Otto, M. Shen, Y. Dodel, R. Du, Y. Farlow, M. Moller, H. J. Blennow, K. Buerger, K. Value of CSF beta-amyloid $\langle\text{inf}\rangle$ 1-42 $\langle\text{/inf}\rangle$  and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. *Molecular Psychiatry*. 2004;9(7):705-10. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
875. Hampel HT, S. J. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. *Dementia & Geriatric Cognitive Disorders*. 2004;17(4):350-4. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
876. Ingelsson MJ, J. Irizarry, M. C. Hyman, B. T. Rebeck, G. W. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. *Neuroscience Letters*. 2004;367(2):228-31. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
877. Johansson AK, H. Zetterberg, H. Feuk, L. Johansson, B. Bogdanovic, N. Andreasen, N. Lenhard, B. Brookes, A. J. Pedersen, N. L. Blennow, K. Prince, J. A. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. *Human Genetics*. 2004;114(6):581-7. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
878. Lewczuk PE, H. Bibl, M. Beck, G. Maler, J. M. Otto, M. Kornhuber, J. Wiltfang, J. Tau

- protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. *Journal of Molecular Neuroscience*. 2004;23(1-2):115-22. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
879. Lewczuk PE, H. Otto, M. Maler, J. M. Henkel, A. W. Henkel, M. K. Eikenberg, O. Antz, C. Krause, W. R. Reulbach, U. Kornhuber, J. Wiltfang, J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. *Neurobiology of Aging*. 2004;25(3):273-81. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
880. Lins HW, I. Bancher, C. Wallesch, C. W. Jellinger, K. A. Rosler, N. Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. *Journal of Neural Transmission*. 2004;111(3):273-80. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
881. Maccioni RBL, M. Maccioni, C. B. Mendoza-Naranjo, A. Biological markers of Alzheimer's disease and mild cognitive impairment. *Current Alzheimer Research*. 2004;1(4):307-14. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
882. Sunderland TM, N. Putnam, K. T. Linker, G. Bhupali, D. Durham, R. Soares, H. Kimmel, L. Friedman, D. Bergeson, J. Csako, G. Levy, J. A. Bartko, J. J. Cohen, R. M. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. *Biological Psychiatry*. 2004;56(9):670-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
883. Takeda MT, T. Kudo, T. Okochi, M. Kamino, A. Tagami, S. [Biological markers for diagnosis of Alzheimer's disease]. *Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica*. 2004;106(12):1610-4. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
884. Zetterberg HA, N. Blennow, K. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. *Neuroscience Letters*. 2004;367(2):194-6. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
885. Zetterberg HB, K. Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results. *Neurological Sciences*. 2004;25(5):301-2. 배제사유: 적절한 의료결과를 하나 이상 보고하지 않은 연구
886. Buerger KZ, R. Teipel, S. J. Arai, H. DeBernardis, J. Kerkman, D. McCulloch, C. Padberg, F. Faltraco, F. Goernitz, A. Tapiola, T. Rapoport, S. I. Pirttila, T. Moller, H. J. Hampel, H. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. *American Journal of Psychiatry*. 2003;160(2):376-9. 배제사유: 2004년 이전 문헌
887. Frank RAG, D. Hampel, H. Hardy, J. De Leon, M. J. Mehta, P. D. Rogers, J. Siemers, E. Trojanowski, J. Q. Biological markers for therapeutic trials in Alzheimer's disease: Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. *Neurobiology of Aging*. 2003;24(4):521-36. 배제사유: 2004년 이전 문헌
888. Franz GB, R. Kampfl, A. Engelhardt, K. Schmutzhard, E. Ulmer, H. Deisenhammer, F. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.

- Neurology. 2003;60(9):1457-61. 배제사유: 2004년 이전 문헌
889. Galasko D. Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement? Archives of Neurology. 2003;60(9):1195-6. 배제사유: 2004년 이전 문헌
890. Gomez Tortosa EG, I. Fanjul, S. Cantarero, S. Cuadrado, N. Garcia Yebenes, J. Cemillan, C. Del Ser, T. Tau protein and beta-amyloid levels in dementia with Lewy bodies compared to Alzheimer's disease. [Spanish]. Mapfre Medicina. 2003;14(2):118-24. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
891. Gomez-Tortosa EG, I. Fanjul, S. Sainz, M. J. Cantarero, S. Cemillan, C. Garcia Yebenes, J. Del Ser, T. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Archives of Neurology. 2003;60(9):1218-22. 배제사유: 2004년 이전 문헌
892. Hampel HG, A. Buerger, K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Research Bulletin. 2003;61(3):243-53. 배제사유: 2004년 이전 문헌
893. Han XF, A. M. Cheng, H. Morris, J. C. Xiong, C. Holtzman, D. M. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Annals of Neurology. 2003;54(1):115-9. 배제사유: 2004년 이전 문헌
894. Leszek JM, K. Janicka, B. Kiejna, A. Wiak, A. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. Medical Science Monitor. 2003;9(11):CR484-8. 배제사유: 2004년 이전 문헌
895. Lolli FM, B. Rovero, P. Papini, A. M. Synthetic peptides in the diagnosis of neurological diseases. Current Protein and Peptide Science. 2003;4(4):277-84. 배제사유: 2004년 이전 문헌
896. Maddalena AP, A. Muller-Tillmanns, B. Jung, H. H. Hegi, T. Nitsch, R. M. Hock, C. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Archives of Neurology. 2003;60(9):1202-6. 배제사유: 2004년 이전 문헌
897. Pietrini VP, G. Limido, L. Rossi, G. Di Fede, G. Giaccone, G. Mangieri, M. Tedeschi, F. Bondavalli, A. Mancina, D. Bugiani, O. Tagliavini, F. Creutzfeldt-Jakob disease with a novel extra-repeat insertional mutation in the PRNP gene. Neurology. 2003;61(9):1288-91. 배제사유: 2004년 이전 문헌
898. Prince JAF, L. Gu, H. F. Johansson, B. Gatz, M. Blennow, K. Brookes, A. J. Genetic Variation in a Haplotype Block Spanning IDE Influences Alzheimer Disease. Human Mutation. 2003;22(5):363-71. 배제사유: 2004년 이전 문헌
899. Rosso SMvH, E. Pijnenburg, Y. A. Schoonenboom, N. S. Scheltens, P. Heutink, P. van Swieten, J. C. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Archives of Neurology. 2003;60(9):1209-13. 배제사유: 2004년 이전 문헌
900. Schonknecht PP, J. Hunt, A. Volkmann, M. Buerger, K. Hampel, H. Schroder, J. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient

- and manifest Alzheimer's disease. *Neuroscience Letters*. 2003;339(2):172-4. 배제사유: 2004년 이전 문헌
901. Sjogren MA, N. Blennow, K. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. *Clinica Chimica Acta*. 2003;332(1-2):1-10. 배제사유: 2004년 이전 문헌
902. Sunderland TL, G. Mirza, N. Putnam, K. T. Friedman, D. L. Kimmel, L. H. Bergeson, J. Manetti, G. J. Zimmermann, M. Tang, B. Bartko, J. J. Cohen, R. M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. *JAMA*. 2003;289(16):2094-103. 배제사유: 2004년 이전 문헌
903. Tarkowski EA, N. Tarkowski, A. Blennow, K. Intrathecal inflammation precedes development of Alzheimer's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003;74(9):1200-5. 배제사유: 2004년 이전 문헌
904. Urakami KI, N. Arai, H. Ishiguro, K. Ohno, H. Nakashima, K. [The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease]. *Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica*. 2003;105(4):393-7. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
905. Wallin AS, M. Blennow, K. Davidsson, P. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. *Dementia & Geriatric Cognitive Disorders*. 2003;16(4):200-7. 배제사유: 2004년 이전 문헌
906. Wan YK, K. Yamanouchi, H. Simultaneous assay of CSF levels of tau and Abeta1-42 to the diagnosis of Alzheimer's disease. *Chinese Journal of Neuroscience*. 2003;19(1):41-4. 배제사유: 2004년 이전 문헌
907. Wiltfang JE, H. Smirnov, A. Bibl, M. Cepek, L. Steinacker, P. Mollenhauer, B. Buerger, K. Hampel, H. Paul, S. Neumann, M. Maler, M. Zerr, I. Kornhuber, J. Kretschmar, H. A. Poser, S. Otto, M. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. *Annals of Neurology*. 2003;54(2):263-7. 배제사유: 2004년 이전 문헌
908. Bonelli RMA, A. Niederwieser, G. Heuberger, C. Jirikowski, G. Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease. *Neurobiology of Disease*. 2002;11(1):106-10. 배제사유: 2004년 이전 문헌
909. Briani CR, S. Naccarato, M. Cagnin, A. Ricchieri, G. L. Pasqui, L. Pizzolato, G. Battistin, L. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. *Journal of Neural Transmission*. 2002;109(3):393-8. 배제사유: 2004년 이전 문헌
910. Buerger KZ, R. Teipel, S. J. Tapiola, T. Arai, H. Blennow, K. Andreasen, N. Hofmann-Kiefer, K. DeBernardis, J. Kerkman, D. McCulloch, C. Kohnken, R. Padberg, F. Pirttila, T. Schapiro, M. B. Rapoport, S. I. Moller, H. J. Davies, P. Hampel, H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. *Archives of Neurology*. 2002;59(8):1267-72. 배제사유: 2004년 이전 문헌

911. de la Monte SMW, J. R. The AD7C-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. *Frontiers in Bioscience*. 2002;7:d989-96. 배제사유: 2004년 이전 문헌
912. de Leon MJS, S. Tarshish, C. Y. DeSanti, S. Zinkowski, R. Mehta, P. D. Convit, A. Caraos, C. Rusinek, H. Tsui, W. Saint Louis, L. A. DeBernardis, J. Kerkman, D. Qadri, F. Gary, A. Lesbre, P. Wisniewski, T. Poirier, J. Davies, P. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. *Neuroscience Letters*. 2002;333(3):183-6. 배제사유: 2004년 이전 문헌
913. Hattori HM, M. Iwai, K. Tsuchiya, H. Miyauchi, E. Takasaki, M. Kamino, K. Munehira, J. Kimura, Y. Kawanishi, K. Hoshino, T. Murai, H. Ogata, H. Maruyama, H. Yoshida, H. The tau protein of oral epithelium increases in Alzheimer's disease. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2002;57(1):M64-70. 배제사유: 2004년 이전 문헌
914. Hu YYH, S. S. Wang, X. C. Duan, Q. H. Khatoon, S. Iqbal, K. Grundke-Iqbal, I. Wang, J. Z. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. *Neuroscience Letters*. 2002;320(3):156-60. 배제사유: 2004년 이전 문헌
915. Hu YYH, S. S. Wang, X. Duan, Q. H. Grundke-Iqbal, I. Iqbal, K. Wang, J. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. *American Journal of Pathology*. 2002;160(4):1269-78. 배제사유: 2004년 이전 문헌
916. Matsuda KT, K. Hayashi, Y. Monji, A. Yoshida, I. Mitsuyama, Y. Measurement of laminins in the cerebrospinal fluid obtained from patients with Alzheimer's disease and vascular dementia using a modified enzyme-linked immunosorbent assay. *Dementia & Geriatric Cognitive Disorders*. 2002;14(3):113-22. 배제사유: 2004년 이전 문헌
917. Nagga KG, J. Blennow, K. Marcusson, J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. *Dementia & Geriatric Cognitive Disorders*. 2002;14(4):183-90. 배제사유: 2004년 이전 문헌
918. Otto MW, J. Cepek, L. Neumann, M. Mollenhauer, B. Steinacker, P. Ciesielczyk, B. Schulz-Schaeffer, W. Kretschmar, H. A. Poser, S. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. *Neurology*. 2002;58(2):192-7. 배제사유: 2004년 이전 문헌
919. Parnetti LA, S. Lanari, A. Romani, C. Antognelli, C. Andreasen, N. Minthon, L. Davidsson, P. Pottel, H. Blennow, K. Gallai, V. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. *Neurological Sciences*. 2002;23 Suppl 2:S95-6. 배제사유: 2004년 이전 문헌
920. Riemenschneider ML, N. Wagenpfeil, S. Diehl, J. Drzezga, A. Kurz, A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild



- cognitive impairment. Archives of Neurology. 2002;59(11):1729-34. 배제사유: 2004년 이전 문헌
921. Riemenschneider MW, S. Diehl, J. Lautenschlager, N. Thöml, T. Heldmann, B. Drzezga, A. Jahn, T. Forstl, H. Kurz, A. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology. 2002;58(11):1622-8. 배제사유: 2004년 이전 문헌
922. Rosenberg RN. Evolutionary time and human memory. Journal of the American Medical Association. 2002;288(23):3045-7. 배제사유: 2004년 이전 문헌
923. Sanchez-Valle RS, A. Graus, F. 14-3-3 Protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease. Neuroscience Letters. 2002;320(1-2):69-72. 배제사유: 2004년 이전 문헌
924. Shoji MM, E. Murakami, T. Manabe, Y. Abe, K. Kanai, M. Ikeda, M. Tomidokoro, Y. Shizuka, M. Watanabe, M. Amari, M. Ishiguro, K. Kawarabayashi, T. Harigaya, Y. Okamoto, K. Nishimura, T. Nakamura, Y. Takeda, M. Urakami, K. Adachi, Y. Nakashima, K. Arai, H. Sasaki, H. Kanemaru, K. Yamanouchi, H. Yoshida, Y. Ichise, K. Tanaka, K. Hamamoto, M. Yamamoto, H. Matsubayashi, T. Yoshida, H. Toji, H. Nakamura, S. Hirai, S. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiology of Aging. 2002;23(3):363-70. 배제사유: 2004년 이전 문헌
925. Sjogren MD, P. Wallin, A. Granerus, A. K. Grundstrom, E. Askmark, H. Vanmechelen, E. Blennow, K. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mistreatment of beta-amyloid induced by disparate mechanisms. Dementia & Geriatric Cognitive Disorders. 2002;13(2):112-8. 배제사유: 2004년 이전 문헌
926. Urakami KN, K. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker]. Rinsho Shinkeigaku - Clinical Neurology. 2002;42(11):1162-4. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
927. Van Everbroeck BG, A. J. E. Vanmechelen, E. Vanderstichele, H. Pals, P. Sanchez-Valle, R. Cuadrado Corrales, N. Martin, J. J. Cras, P. Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. Journal of Neurology Neurosurgery and Psychiatry. 2002;73(1):79-81. 배제사유: 2004년 이전 문헌
928. Wang KD, X. S. Cheng, H. Study on correlations between CSF-tau and clinical indexes in senile dementia patients. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2002;6(21):3174-5. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
929. Zhu XMZ, J. Wang, J. Cerebrospinal fluid level of tau-protein in diagnosing Alzheimer's disease. [Chinese]. Chinese Journal of Clinical Rehabilitation. 2002;6(13):1909-10. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
930. Blennow KL, B. Andersson, E. Andreasen, N. [CSF-analyses in clinical diagnosis of Creutzfeldt-Jakob disease. A literature review and three cases from routine clinical practice]. Lakartidningen. 2001;98(20):2446-51. 배제사유: 한국어 또는 영어로 출판되지 않은 연구

931. De la Monte SMW, J. R. The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. *Journal of Alzheimer's Disease*. 2001;3(3):345-53. 배제사유: 2004년 이전 문헌
932. Galasko D. Biological markers and the treatment of Alzheimer's disease. *Journal of Molecular Neuroscience*. 2001;17(2):119-25. 배제사유: 2004년 이전 문헌
933. Green AJT, E. J. Stewart, G. E. Zeidler, M. McKenzie, J. M. MacLeod, M. A. Ironside, J. W. Will, R. G. Knight, R. S. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2001;70(6):744-8. 배제사유: 2004년 이전 문헌
934. Hampel HB, K. Kohnken, R. Teipel, S. J. Zinkowski, R. Moeller, H. J. Rapoport, S. I. Davies, P. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 [3]. *Annals of Neurology*. 2001;49(4):545-6. 배제사유: 2004년 이전 문헌
935. Hu YH, S. Wang, J. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease]. *Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]*. 2001;81(22):1377-9. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
936. Itoh NA, H. Urakami, K. Ishiguro, K. Ohno, H. Hampel, H. Buerger, K. Wiltfang, J. Otto, M. Kretschmar, H. Moeller, H. J. Imagawa, M. Kohno, H. Nakashima, K. Kuzuhara, S. Sasaki, H. Imahori, K. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. *Annals of Neurology*. 2001;50(2):150-6. 배제사유: 2004년 이전 문헌
937. Kapaki EK, K. Paraskevas, G. P. Michalopoulou, M. Patsouris, E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? *Journal of Neurology, Neurosurgery & Psychiatry*. 2001;71(3):401-3. 배제사유: 2004년 이전 문헌
938. Maruyama MA, H. Sugita, M. Tanji, H. Higuchi, M. Okamura, N. Matsui, T. Higuchi, S. Matsushita, S. Yoshida, H. Sasaki, H. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. *Experimental Neurology*. 2001;172(2):433-6. 배제사유: 2004년 이전 문헌
939. McLean CAB, K. Masters, C. L. Amyloid Abeta levels in Alzheimer's disease - A diagnostic tool and the key to understanding the natural history of Abeta? *Journal of Alzheimer's Disease*. 2001;3(3):305-12. 배제사유: 2004년 이전 문헌
940. Parnetti LL, A. Amici, S. Gallai, V. Vanmechelen, E. Hulstaert, F. Phospho-Tau International Study, Group. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. *Neurological Sciences*. 2001;22(1):77-8. 배제사유: 2004년 이전 문헌
941. Rosler NW, I. Jellinger, K. A. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. *Journal of Neural*

- Transmission. 2001;108(2):231-46. 배제사유: 2004년 이전 문헌
942. Sjogren MD, P. Gottfries, J. Vanderstichele, H. Edman, A. Vanmechelen, E. Wallin, A. Blennow, K. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. *Dementia and Geriatric Cognitive Disorders*. 2001;12(4):257-64. 배제사유: 2004년 이전 문헌
943. Sjogren MD, P. Tullberg, M. Minthon, L. Wallin, A. Wikkelso, C. Granerus, A. K. Vanderstichele, H. Vanmechelen, E. Blennow, K. Both total and phosphorylated tau are increased in Alzheimer's disease. *Journal of Neurology Neurosurgery and Psychiatry*. 2001;70(5):624-30. 배제사유: 2004년 이전 문헌
944. Sjogren MV, H. Agren, H. Zachrisson, O. Edsbacke, M. Wikkelso, C. Skoog, I. Wallin, A. Wahlund, L. O. Marcusson, J. Nagga, K. Andreasen, N. Davidsson, P. Vanmechelen, E. Blennow, K. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. *Clinical Chemistry*. 2001;47(10):1776-81. 배제사유: 2004년 이전 문헌
945. Tarkowski EL, A. M. Nilsson, A. Minthon, L. Blennow, K. Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease. *Dementia & Geriatric Cognitive Disorders*. 2001;12(5):314-7. 배제사유: 2004년 이전 문헌
946. Arai HI, K. Ohno, H. Moriyama, M. Itoh, N. Okamura, N. Matsui, T. Morikawa, Y. Horikawa, E. Kohno, H. Sasaki, H. Imahori, K. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. *Experimental Neurology*. 2000;166(1):201-3. 배제사유: 2004년 이전 문헌
947. Diamandis EPY, G. M. Petraki, C. Soosaipillai, A. R. Human kallikrein 6 as a biomarker of alzheimer's disease. *Clinical Biochemistry*. 2000;33(8):663-7. 배제사유: 2004년 이전 문헌
948. Kahle PJJ, M. Teipel, S. J. Hampel, H. Petzinger, G. M. Di Monte, D. A. Silverberg, G. D. Moller, H. J. Yesavage, J. A. Tinklenberg, J. R. Shooter, E. M. Murphy, G. M. , Jr. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. *Neurology*. 2000;54(7):1498-504. 배제사유: 2004년 이전 문헌
949. Kohnken RB, K. Zinkowski, R. Miller, C. Kerkman, D. DeBernardis, J. Shen, J. Moller, H. J. Davies, P. Hampel, H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. *Neuroscience Letters*. 2000;287(3):187-90. 배제사유: 2004년 이전 문헌
950. Kudo TM, T. Hashimoto, R. Nakao, K. Morihara, T. Tanimukai, H. Tsujio, I. Koike, Y. Tagami, S. Mori, H. Nakamura, Y. Tanaka, T. Mori, K. Takeda, M. Tau protein is a potential biological marker for normal pressure hydrocephalus. *Psychiatry and Clinical Neurosciences*. 2000;54(2):199-202. 배제사유: 2004년 이전 문헌
951. Schonknecht PP, J. Werle, E. Hartmann, T. Essig, M. Baudendistel, K. Beyreuther, K. Schroder, J. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease]. *Fortschritte der Neurologie-Psychiatrie*. 2000;68(10):439-46. 배제사유: 한국어 또는 영어로 출판되지 않은 연구

952. Tapiola TP, T. Mehta, P. D. Alafuzoff, I. Lehtovirta, M. Soininen, H. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. *Neurobiology of Aging*. 2000;21(5):735-40. 배제사유: 2004년 이전 문헌
953. Tapiola TP, T. Mikkonen, M. Mehta, P. D. Alafuzoff, I. Koivisto, K. Soininen, H. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. *Neuroscience Letters*. 2000;280(2):119-22. 배제사유: 2004년 이전 문헌
954. Tarkowski EL, A. M. Nilsson, A. Ricksten, A. Davidsson, P. Minthon, L. Blennow, K. TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD. *Neurology*. 2000;54(11):2077-81. 배제사유: 2004년 이전 문헌
955. Vanmechelen EV, H. Davidsson, P. Van Kerschaver, E. Van Der Perre, B. Sjogren, M. Andreasen, N. Blennow, K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. *Neuroscience Letters*. 2000;285(1):49-52. 배제사유: 2004년 이전 문헌
956. Andreasen NM, L. Clarberg, A. Davidsson, P. Gottfries, J. Vanmechelen, E. Vanderstichele, H. Winblad, B. Blennow, K. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. *Neurology*. 1999;53(7):1488-94. 배제사유: 2004년 이전 문헌
957. Burger Nee Buch KP, F. Nolde, T. Teipel, S. J. Stubner, S. Haslinger, A. Schwarz, M. J. Sunderland, T. Arai, H. Rapoport, S. I. Moller, H. J. Hampel, H. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. *Neuroscience Letters*. 1999;277(1):21-4. 배제사유: 2004년 이전 문헌
958. de Almeida SMR, C. E. Tang, B. de Pereira, A. P. Rotta, I. Vaida, F. Letendre, S. Potter, M. Ellis, R. J. Neurocytoskeleton proteins in cerebrospinal fluid of people with HIV-1 subtypes B and C. *Journal of acquired immune deficiency syndromes*. 1999(pagination). 배제사유: 2004년 이전 문헌
959. Hampel HT, S. J. Padberg, F. Haslinger, A. Riemenschneider, M. Schwarz, M. J. Kotter, H. U. Scheloske, M. Buch, K. Stubner, S. Dukoff, R. Lasser, R. Muller, N. Sunderland, T. Rapoport, S. I. Moller, H. J. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. *Brain Research*. 1999;823(1-2):104-12. 배제사유: 2004년 이전 문헌
960. Hulstaert FB, K. Ivanoiu, A. Schoonderwaldt, H. C. Riemenschneider, M. De Deyn, P. P. Baner, C. Cras, P. Wilfang, J. Mehta, P. D. Iqbal, K. Pottel, H. Vanmechelen, E. Vanderstichele, H. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. *Neurology*. 1999;52(8):1555-62. 배제사유: 2004년 이전 문헌
961. Ingelson MB, M. Benedikz, E. Wahlund, L. O. Karlsson, E. Vanmechelen, E. Lannfelt, L. Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. *Dementia & Geriatric Cognitive Disorders*. 1999;10(6):442-5. 배제사유: 2004년 이전 문헌

962. Ishiguro KO, H. Arai, H. Yamaguchi, H. Urakami, K. Park, J. M. Sato, K. Kohno, H. Imahori, K. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. *Neuroscience Letters*. 1999;270(2):91-4. 배제사유: 2004년 이전 문헌
963. Li HW, K. Zhang, M. The concentration of CSF tau protein in patients with Alzheimer's disease. [Chinese]. *Chinese Journal of Psychiatry*. 1999;32(3):142-4. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
964. Sunderland TW, B. Galasko, D. Levy, J. Dukoff, R. Bahro, M. Lasser, R. Motter, R. Lehtimaki, T. Seubert, P. Longitudinal stability of CSF tau levels in Alzheimer patients. *Biological Psychiatry*. 1999;46(6):750-5. 배제사유: 2004년 이전 문헌
965. Urakami KM, M. Wada, K. Kowa, H. Takeshima, T. Arai, H. Sasaki, H. Kanai, M. Shoji, M. Ikemoto, K. Morimatsu, M. Hikasa, C. Nakashima, K. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. *Neuroscience Letters*. 1999;259(2):127-9. 배제사유: 2004년 이전 문헌
966. Van Everbroeck BG, A. J. E. Pals, PhMartin, J. J. Cras, P. Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. *Journal of Alzheimer's Disease*. 1999;1(6):419-24. 배제사유: 2004년 이전 문헌
967. Zemlan FPR, W. S. Luebke, P. A. Campbell, T. A. Dean, G. E. Weiner, N. E. Cohen, J. A. Rudick, R. A. Woo, D. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. *Journal of Neurochemistry*. 1999;72(2):741-50. 배제사유: 2004년 이전 문헌
968. Arai HC, C. M. Ewbank, D. C. Takase, S. Higuchi, S. Miura, M. Seki, H. Higuchi, M. Matsui, T. Lee, V. M. Trojanowski, J. Q. Sasaki, H. Cerebrospinal fluid tau protein as a potential diagnostic marker in Alzheimer's disease. *Neurobiology of Aging*. 1998;19(2):125-6. 배제사유: 2004년 이전 문헌
969. Ellis RJS, P. Motter, R. Galasko, D. Deutsch, R. Heaton, R. K. Heyes, M. P. McCutchan, J. A. Atkinson, J. H. Grant, I. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC). *Neuroscience Letters*. 1998;254(1):1-4. 배제사유: 2004년 이전 문헌
970. Franciotta DDP, E. Tinelli, C. d'Eril, G. M. Protein tau in cerebrospinal fluid of patients with Alzheimer disease. *Clinical Chemistry*. 1998;44(2):357-8. 배제사유: 2004년 이전 문헌
971. Galasko DC, L. Motter, R. Clark, C. M. Kaye, J. Knopman, D. Thomas, R. Kholodenko, D. Schenk, D. Lieberburg, I. Miller, B. Green, R. Basherad, R. Kertiles, L. Boss, M. A. Seubert, P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. *Archives of Neurology*. 1998;55(7):937-45. 배제사유: 2004년 이전 문헌
972. Jansen Steur EV, I. De Vos, R. A. I. Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease. *Lancet*. 1998;351(9109):1105-6. 배제사유: 2004년 이전 문헌
973. Kanai MM, E. Isoe, K. Urakami, K. Nakashima, K. Arai, H. Sasaki, H. Abe, K. Iwatsubo,

- T. Kosaka, T. Watanabe, M. Tomidokoro, Y. Shizuka, M. Mizushima, K. Nakamura, T. Igeta, Y. Ikeda, Y. Amari, M. Kawarabayashi, T. Ishiguro, K. Harigaya, Y. Wakabayashi, K. Okamoto, K. Hirai, S. Shoji, M. Longitudinal study of cerebrospinal fluid levels of tau, Abeta1-40, and Abeta1-42(43) in Alzheimer's disease: A study in Japan. *Annals of Neurology*. 1998;44(1):17-26. 배제사유: 2004년 이전 문헌
974. Mecocci PC, A. Bregnocchi, M. Chionne, F. Cecchetti, R. Lowenthal, D. T. Senin, U. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? *Alzheimer Disease & Associated Disorders*. 1998;12(3):211-4. 배제사유: 2004년 이전 문헌
975. Nishimura TT, M. Nakamura, Y. Yosbida, Y. Arai, H. Sasaki, H. Shouji, M. Hirai, S. Khise, K. Tanaka, K. Hamamoto, M. Yamamoto, H. Matsubayashi, T. Urakami, K. Adachi, Y. Nakashima, K. Toji, H. Nakamura, S. Yoshida, H. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. *Methods & Findings in Experimental & Clinical Pharmacology*. 1998;20(3):227-35. 배제사유: 2004년 이전 문헌
976. Shoji MM, E. Kanai, M. Watanabe, M. Nakamura, T. Tomidokoro, Y. Shizuka, M. Wakabayashi, K. Igeta, Y. Ikeda, Y. Mizushima, K. Amari, M. Ishiguro, K. Kawarabayashi, T. Harigaya, Y. Okamoto, K. Hirai, S. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. *Journal of the Neurological Sciences*. 1998;158(2):134-40. 배제사유: 2004년 이전 문헌
977. Tapiola TL, M. Ramberg, J. Helisalml, S. Linnaranta, K. Riekkinen, P. , Sr. Soininen, H. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. *Neurology*. 1998;50(1):169-74. 배제사유: 2004년 이전 문헌
978. Terryberry JWT, G. Peter, J. B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. *Neurobiology of Aging*. 1998;19(3):205-16. 배제사유: 2004년 이전 문헌
979. Vanmechelen EV, H. Towards an earlier diagnosis of Alzheimer's disease. *Journal of Biotechnology*. 1998;66(2-3):229-31. 배제사유: 2004년 이전 문헌
980. Hoffmann RL, V. M. Leight, S. Varga, I. Otvos, L. , Jr. Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. *Biochemistry*. 1997;36(26):8114-24. 배제사유: 2004년 이전 문헌
981. Johnson GVS, P. Cox, T. M. Motter, R. Brown, J. P. Galasko, D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. *Journal of Neurochemistry*. 1997;68(1):430-3. 배제사유: 2004년 이전 문헌
982. Otto MW, J. Tumani, H. Zerr, I. Lantsch, M. Kornhuber, J. Weber, T. Kretschmar, H. A. Poser, S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. *Neuroscience Letters*. 1997;225(3):210-2. 배제사유: 2004년 이전 문헌
983. Arai HS, K. Terajima, M. Nakagawa, T. Higuchi, M. Kosaka, Y. I. Zhu, C. Sasaki, H. Tau

- protein in cerebrospinal fluid - A potential marker of Alzheimer's disease. [Japanesel. Japanese Journal of Geriatrics. 1996;33(9):669-75. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
984. Arai HS, K. Terajima, M. Nakagawa, T. Higuchi, M. Kosaka, Y. Zhu, C. Sasaki, H. [Tau protein in cerebrospinal fluid--a potential marker of Alzheimer's disease]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics. 1996;33(9):669-75. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
985. Blomberg MJ, M. Basun, H. Lannfelt, L. Wahlund, L. O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neuroscience Letters. 1996;214(2-3):163-6. 배제사유: 2004년 이전 문헌
986. Boissier-Molina LT, J. Pau, B. Mourton-Gilles, C. Detection of tau protein in cerebrospinal fluid of patients with dementia of Alzheimer type. [French]. Immuno-Analyse et Biologie Specialisee. 1996;11(3):191-5. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
987. Riemenschneider MB, K. Schmolke, M. Kurz, A. Guder, W. G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neuroscience Letters. 1996;212(3):209-11. 배제사유: 2004년 이전 문헌
988. Rosler NW, I. Bancher, C. Jellinger, K. Immunoreactive total tau und total apolipoprotein E in cerebrospinal fluid of Alzheimer's disease. [German]. Neuropsychiatrie. 1996;10(2):84-6. 배제사유: 한국어 또는 영어로 출판되지 않은 연구
989. Rosler NW, I. Jellinger, K. A. Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry. 1996;60(4):452-4. 배제사유: 2004년 이전 문헌
990. Rosler NW, I. Jellinger, K. A. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease [8]. Journal of Neurology Neurosurgery and Psychiatry. 1996;60(2):237-8. 배제사유: 2004년 이전 문헌
991. Arai HT, M. Miura, M. Higuchi, S. Muramatsu, T. Machida, N. Seiki, H. Takase, S. Clark, C. M. Lee, V. M. et al. . Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Annals of Neurology. 1995;38(4):649-52. 배제사유: 2004년 이전 문헌
992. Blennow KW, A. Agren, H. Spenger, C. Siegfried, J. Vanmechelen, E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Molecular & Chemical Neuropathology. 1995;26(3):231-45. 배제사유: 2004년 이전 문헌
993. Hock CG, S. Naser, W. Muller-Spahn, F. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment. Annals of Neurology. 1995;37(3):414-5. 배제사유: 2004년 이전 문헌
994. Jensen MB, H. Lannfelt, L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neuroscience Letters. 1995;186(2-3):189-91. 배제사유: 2004년 이전 문헌

995. Mori HH, K. Matsubara, E. Nakamoto, T. Furiya, Y. Endoh, R. Usami, M. Shoji, M. Maruyama, S. Hirai, S. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. *Neuroscience Letters*. 1995;186(2-3):181-3. 배제사유: 2004년 이전 문헌
996. Motter RV-P, C. Kholodenko, D. Barbour, R. Johnson-Wood, K. Galasko, D. Chang, L. Miller, B. Clark, C. Green, R. et al. . Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. *Annals of Neurology*. 1995;38(4):643-8. 배제사유: 2004년 이전 문헌
997. Munroe WAS, P. C. Chang, L. Scharre, D. W. Echols, C. L. , Jr. Fu, P. C. Whaley, J. M. Wolfert, R. L. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. *Annals of Clinical & Laboratory Science*. 1995;25(3):207-17. 배제사유: 2004년 이전 문헌
998. Tato REF, A. Hernanz, A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. *Journal of Neurology, Neurosurgery & Psychiatry*. 1995;59(3):280-3. 배제사유: 2004년 이전 문헌
999. Vigo-Pelfrey CS, P. Barbour, R. Blomquist, C. Lee, M. Lee, D. Coria, F. Chang, L. Miller, B. Lieberburg, I. et al. . Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. *Neurology*. 1995;45(4):788-93. 배제사유: 2004년 이전 문헌
1000. Vandermeeren MM, M. Vanmechelen, E. Six, J. van de Voorde, A. Martin, J. J. Cras, P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. *Journal of Neurochemistry*. 1993;61(5):1828-34. 배제사유: 2004년 이전 문헌